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Chronic kidney disease (CKD) is a complex health related comorbidity with an 
enormous economic burden on any healthcare system globally. Clinical pharmacy 
services have potential to contribute significantly to the multidisciplinary team 
providing safe, effective and economic care for patients.  However, published 
literature shows there is a lack of robust evidence for the role of clinical 
pharmacists in providing care to patients with CKD.  
The overall aim of this doctoral research was to investigate the structures, 
processes and related outcomes of clinical pharmacy practice in the care of 
patients with CKD. 
This doctoral research was undertaken under two stages. Stage 1 was a 
systematic review to appraise, synthesize and present the available evidence on 
the structures, processes and related outcomes of clinical pharmacy practice in 
the care of patients with CKD. While there is some evidence of positive impact on 
clinical, humanistic and economic outcomes, this evidence is generally of low 
quality and insufficient volume. While the existing evidence is in favour of 
pharmacists’ involvement in the multidisciplinary team providing care to patients 
with CKD, more high-quality research is warranted. 
A sequential explanatory design underpinned by the Consolidated Framework of 
Implementation Research CFIR was employed in Stage 2 of this doctoral 
research. It was executed in two phases of data generation. The findings from 
the first phase informed the subsequent phase.  
In Phase 1, an online theoretically based cross-sectional survey was conducted 
on the behaviours and experiences of clinical pharmacists caring for patients with 
CKD. Seventy-one respondents completed the survey with a response rate of 
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50.0%. The majority of respondents provided general pharmaceutical care to 
dialysis and transplant patients, were confident in their abilities and tried new 
ways of working including independent prescribing. There was high level of 
agreement among the respondents in relation to CFIR items for clinical practice. 
Most respondents strongly agreed / agreed with CFIR items for prescribing 
practice yet 39.6% disagreed that they had sufficient cover for their prescribing 
duties when they are away. Many expressed that lack of resources was the main 
barrier to providing more advanced care. Further work is needed to explore these 
matters in more depth. 
Phase 2 of stage 2 involved a semi-structured qualitative interview with clinical 
pharmacist prescribers’ members of the UK Renal Pharmacy Group involved in 
the care of patients with CKD. Data saturation was confirmed after completing 
and analysing 14 interviews. The key findings of the interviews demonstrated 
positive views of prescribing practice for patients with CKD among the 
pharmacists. Underpinning the research with CFIR helped identify the key 
facilitators and barriers to the implementation of prescribing practice and 
facilitated identifying key areas for further developing the service. 
Overall, this doctoral research produced original contribution to knowledge in the 
area of clinical pharmacy services in the care for patients with CKD in the UK and 
with emphasis of prescribing practice. The rigorous and robust findings from 
stage 2 of the research can help further develop pharmacy practice and 
prescribing practice in the care for patients with CKD. More research is needed to 
explore the potential to implement such practices in a wider context. 
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This doctoral thesis describes work undertaken to fulfil the requirement of my 
PhD research exploring the structures, process and related outcomes of clinical 
pharmacy practice as part of the multidisciplinary care of patients with CKD. 
Before starting my PhD journey, I was working as a newly appointed academic 
staff at the Oman Pharmacy College. Prior to this, I had worked as a renal 
pharmacist for 15 years in a tertiary care hospital in Oman (The Royal Hospital).  
My background as a renal pharmacist kindled my passion for clinical pharmacy 
practice for patients with renal disease and to incorporate my experience in 
clinical practice into education to enable the develop students clinically from the 
start of their pharmacy education and so facilitate the development of the next 
generation of clinical pharmacists. My primary aim for pursuing a PhD is to be a 
competent academic practitioner and to gain the skills to be able to transfer the 
knowledge in the best way to my students. 
Through this I know I will enhance my research skills and satisfy my curiosity to 
advance knowledge, to stretch myself and explore my abilities. Another reason 
for my passion for pursuing a doctoral degree is to be able to make an original 
contribution to my study field. 
Since I started my PhD at the Robert Gordon University, I have learned a lot of 
research related knowledge and skills. This has included a strong grounding in 
research methodology encompassing; research paradigms, philosophies, 
research theories and different methods for research. I understand the 
importance of this to designing and executing a robust research programme. I 
have attended a wide range of courses and training sessions throughout the four 
years of my PhD journey. These training sessions have developed my skills as a 
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researcher and equipped me with wide range of tools to use while undertaking 
high-quality research. I have attended courses related to conducting systematic 
reviews, managing references, qualitative research, as well as courses relevant 
to my wider development as an academic including those related to teaching and 
demonstrating. 
I am very privileged to be supervised by such a great team of experienced 
supervisors for my PhD. Prof. Scott Cunningham, my principal supervisor, has 
been a great strength and support throughout these four years journey to 
undertake my PhD. Prof. Derek Stewart my second supervisor, who had to move 
to Qatar University to take a new post, has continued to offer dedicated support 
to me to the end of my journey. 
My supervisors also encourage me to take a lot of demonstrating roles and so 
involvement in the teaching of the MPharm undergraduate students. This has 
helped me develop other skills beyond my research to enhance my academic 
skills. I have also delivered some research-based modules to MSc students and 
also delivered pharmaceutical care in renal patients to a cohort of MSc students. 
The area of clinical pharmacy practice for renal patients was and will be always 
my passion and was my primary driver to conduct this research to show the 
importance of this practice. 
Towards the end of my PhD journey I am sure I will continue developing my 
skills though conducting more research and maybe consider undertaking a post-
doctoral position.  
I am confident that the findings of this doctoral research will have great impact 
on the advancement of clinical pharmacy practice for in renal medicine with 
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particular focus on the advancement of prescribing practice for patients with CKD 
in the UK and maybe extended to Oman.  
This doctoral research was undertaken by employing a mixed-method approach 
and followed two stages; stage 1 was a systematic review and stage 2 was in 
two phases for generating data with phase 1 using a quantitative survey 
approach and phase 2 using a qualitative semi-structured interview approach. 
The doctoral research is reported in six chapters as explained below: 
Chapter one: This chapter introduces the thesis with all relevant background of 
Chronic Kidney Disease and clinical pharmacy practice. The chapter also briefly 
provide information about the UK Renal Pharmacy group, nonmedical prescribing 
and Donabedian’s Framework for healthcare quality in terms of structure, 
process and outcome. The Chapter also defines the overall research aim and 
specific objectives.  
Chapter two: This chapter focuses on the research paradigms, philosophies, 
methodologies and methods in general and with the rationale of following specific 
methodologies for this doctoral research. The chapter also provide details about 
different types of reviews and the use of theoretical frameworks with specific 
justification for this programme. Towards the end of the chapter details about 
rigour and robustness as well as reflexivity as described. 
Chapter three: This chapter reports an original systematic review of clinical 
pharmacy practice in the care of Chronic Kidney Disease patients. The systematic 
review was initiated by developing a protocol and registered in the PROSPERO 
database with registration number CRD42017065258. The results of the review 
reported that there is some evidence that shows positive contributions of 
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pharmacists’ involvement in the multidisciplinary team to provide care to 
patients with CKD and more high-quality research in this topic is warranted. 
Chapter four: First phase of the second stage is a quantitative survey 
underpinned with a theoretical framework (Consolidated Framework of 
Implementation Research) CFIR. The survey targeted clinical pharmacist caring 
for patients with CKD and members of the UK renal pharmacy group to report 
the characteristics of models of clinical pharmacy practice in the care for patients 
with CKD. It also reported the positive and negative experiences on the 
development and implementation of these models. 
Chapter five: The second phase of the second stage is a qualitative semi-
structured interview with pharmacist prescribing for patients with CKD and took 
part in the previous stage (survey). This phase aimed to explore the 
development, implementation and evaluation of pharmacist prescribing for 
patients with Chronic Kidney Disease (CKD) in the UK. 
Chapter six: The final chapter of this doctoral thesis is an overall summary of key 
findings for each stage with highlights on the strengths and limitations of the 
research programme. The chapter also describes the originality of the work and 
the impact of the research in a wider context. The chapter also list some 
potential future research ideas as a follow-up from this doctoral research 
programme. Since my doctoral research programme was funded from the Omani 
government, my plan is to return to Oman after the completion of my doctoral 
programme with plans to continue further research in the area of my interest in 
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1.  Introduction to the chapter  
The aim of this doctoral research was to scope structures, processes and related 
outcomes of clinical pharmacy practice as part of the multidisciplinary care of 
patients with Chronic Kidney Disease. This introduction provides a brief 
background of CKD and highlights some important aspects of the disease 
complications, management options and the role of the pharmacist in managing 
CKD patients in a multidisciplinary care. The Chapter also provides an overview 
of clinical pharmacy practice in the care of patients with CKD including 
pharmacist prescribing practice and models of such practice. Towards the end 
the chapter focuses on Donabedian’s Framework for healthcare quality focusing 
on the structure, process and outcomes of a care provision (Donabedian 1990). 
Finally, the chapter ends with the research aim and objectives of each phase of 
this doctoral research. 
1.1. Chronic kidney disease 
1.1.1. Chronic Kidney Disease definition 
Chronic Kidney Disease (CKD) is defined by many international organisations as 
a progressive loss of kidney function over a period of time varying from weeks to 
months. The Kidney Diseases Improving Global Outcomes (KDIGO) group 
comprehensively defines CKD as abnormalities in either the structure or the 
function of the kidney which is present for more than three months, with health 
concerns requiring an intervention (KDIGO 2013). The National Kidney 
Foundation (NKF) defines kidney damage by any one of the following findings: 
a) Pathological abnormalities in the kidney 
b) Persistent proteinuria 
c) Urine abnormalities, such as renal haematuria 
d) Structural abnormalities (imaging) 
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e) eGFR <60 mL/min/1.73 m2 on two occasions separated by ≥90 days and that 
is not associated with a transient, reversible condition such as volume depletion 
(NKF 2012). Table 1.1 summarises the definition and categorisation of CKD in 
accordance with KDIGO guidance. 
1.1.2. Classification and Staging of Chronic Kidney Disease 
Table 1.1: Summary of the definition and categorisation of CKD by KDIGO 2012. 
Adapted from KDIGO guidelines 2012. 
CKD classification and Staging 
   Green: Low risk (LR) 
   Yellow: Moderate risk (MR) 
   Orange: High risk (HR) 
   Red: Very high risk (VHR) 
Kidney damage stage 
Urine albumin/creatinine ratio 
Description and range 

































































G1 Normal or high ≥90 LR MR HR 
G2 Mild decrease  60-89 LR MR HR 
G3a Mild to moderate decrease 45-59 MR HR VHR 
G3b Moderate to severe 
decrease 
30-44 HR VHR VHR 
G4 Severe decrease 15-29 VHR VHR VHR 
G5 Kidney failure <15 VHR VHR VHR 
  
The Kidney Disease Outcomes Quality Initiative (KDOQI) defines CKD as all 
individuals with Glomerular Filtration Rate (GFR) <60 mL/min/1.73 m2 for ≥ 3 
months, irrespective of the presence or absence of kidney damage. The 
justification for including patients with (GFR) <60 mL/min/1.73 m2 is that as 
kidney function declines to this level, there is a loss of 50% of the normal 
function of the kidneys, resulting in the patient being at risk of developing major 
complications (Stevens 2008). Table 1.2 shows the stages of CKD in accordance 





Table 1.2: Stages of CKD according to KDOQI guidelines. Adapted from KDOQI 2012. 
Stage Description GFR (ml/min/1.73 m2) 
1 Kidney damage with normal or ↑ 
GFR 
≥ 90 
2 Kidney damage with mild ↓ GFR 60-89 
3 Moderate ↓ GFR 30-59 
4 Severe ↓ GFR 15-29 
5 Kidney failure < 15 (require replacement 
therapy) 
 
Both guidelines are very similar and interchangeable concerning defining or 
classifying CKD. 
1.1.3. Aetiology of Chronic Kidney Disease 
The aetiology of CKD and resultant kidney damage can be classified in three 
main ways: pre-renal, renal and post-renal. Pre-renal CKD may be caused due to 
conditions like hypovolaemia arising from major bleeding episode, or stenosis in 
the renal arteries, which may lead to hypoperfusion leading to renal ischaemia 
and so resulting in CKD (Ashley and Morlidge 2008). Whereas, in renal CKD the 
most irreversible damages occur within the kidney due to causes such as 
diabetes, hypertension, vasculitis, nephritis and polycystic kidney disease. 
Causes of CKD in the post-renal classification are most commonly associated 
with the disruption of the urine flow, which might be due to an obstruction in the 
bladder, ureteric stones or fibrosis, leading to increased pressure within the 
kidneys and damage to the nephrons (Ashley and Morlidge 2008). Classification 

















Figure 1.1: Causes of CKD (Ralston 2018) 
1.1.4. Epidemiology of Chronic Kidney Disease 
A systematic review published in 2016 focused on the global prevalence of CKD 
and reported that CKD prevalence in stages 1-5 was 13·4% and 10·6% in stages 
3-5 (Hill 2016). 
The prevalence of CKD (stage 3-5) in Quality and Outcomes Framework (QOF) 
reports for England in 2016-17 was 4.1% in adults, compared to 3.19% in 
Scotland. The UK Renal Registry report data for the UK notes that the incidence 
rate in the UK increased from 120 per million population (pmp) in 2015 to 121 
pmp in 2017 (ScotPHO 2017).  
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1.1.5. Comorbidity and mortality 
Comorbidities associated with CKD result in higher rates of mortality. Most 
common comorbidities associated with CKD are diabetes and hypertension as 
shown in Figure 1.2 below. Patients with CKD are also at increased risk of 
developing cardiovascular diseases (CVD). It is evident that more patients with 
CKD die as a result of associated CVD related conditions than the progression of 
their CKD (Allan 2003). Mortality is inversely related to the stage of CKD as 
shown in Figure 1.3. 
 
Figure 1.2: Common comorbidities observed in patients with CKD 
(USRDS 2008).  




Stages of CKD 
Figure 1.3: All-cause mortality by stage of CKD (NKF 2012). 
1.1.6. Clinical manifestations and complications 
CKD patients experience various types of symptoms ranging from direct 
symptoms such as uraemia to other symptoms including electrolyte disturbance, 
hypertension, pruritis, anaemia and mineral bone disease (Arnold 2016). 
A) Electrolyte imbalance 
One of the major roles of the kidney is to maintain fluid and electrolyte balance, 
hence, any deterioration in the kidney functions leads to electrolyte imbalance 
such as: hypo or hyperkalaemia, hypo or hyperphosphataemia, hyper or 
hypocalcaemia, and bicarbonate deficiency (Chambers 1987) 
B) Mineral and Bone Disorder (MBD) 
Patients with CKD suffer from imbalance in hormone levels because the kidneys 
lose the ability to balance the mineral levels in the body causing imbalance in 
hormones and electrolytes such as calcium and phosphate (Dhondup and Qian 















raised phosphate levels which subsequently leads to a reduction in the calcium 
levels (Moe 2006). On the other hand, deficiency of active vitamin D results in 
reduced calcium absorption leading to low plasma calcium levels (Cheng 2016). 
The combined effect of hypocalcaemia, hyperphosphataemia and reduced vitamin 
D level leads to increased stimulation of parathyroid hormone secretion, which 
will stimulate calcium release from the bones causing renal bone diseases and 
fractures (Dhondup and Qian 2017). 
C) Anaemia 
Anaemia is one of the common consequences on CKD. It arises since patients 
suffer reduced production of erythropoietin from the damaged kidneys leading to 
reduction in red blood cell stimulation by the bone marrow. Not only that, 
patients with CKD also lose blood during the dialysis sessions and as a 
consequence they lose iron and folic acid (NICE 2015). 
D) Hypertension 
Chronic kidney disease and high blood pressure are associated together with an 
interlinked pathophysiological states. Up to 90% of patients with CKD might 
suffer from hypertension due to various causes. Uncontrolled hypertension could 
be a primary cause of CKD. On the other hand, patients with CKD have the 
tendency for sodium and fluid retention which could lead to hypertension as a 
CKD complication. This is due to volume expansions and rise in the systematic 
vascular resistance (Botdorf 2011). 
E) Other Complications of Chronic Kidney Disease 
Other symptoms include: pruritis due to raised phosphate levels, restless leg 
syndrome as a result of iron deficiency in CKD, nausea due to accumulation of 
toxins like urea in the circulation, oedema due to sodium and fluid retention, and 
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stress ulceration. Patients with CKD are at further risk of developing 
cardiovascular disease (CVD), which is a major cause of death in this group of 
patients (Weiner 2004). 
1.1.7. Chronic Kidney Disease Monitoring 
Patients with CKD undergo a series of blood and urine tests to either detect or 
diagnose kidney diseases or monitor kidney function and treatment responses.  
Usually patients with CKD are not diagnosed based on a single test, in fact, they 
need to be subjected to multiple tests and at different occasions to confirm a 
diagnosis. More information of these tests is provided below.  
A) Biochemistry tests 
The most common biochemistry tests performed for patients with CKD are shown 
in Table 1.3. 
Table 1.3: Biochemistry tests for patients with CKD 
Test  Reference ranges (may vary across units) 
Creatinine  50 – 120 µmol/L 
Urea 3 – 6.5 mmol/L 
Potassium  3.5 – 5 mmol/L 
Sodium  135 – 145 mmol/L 
Calcium  2.2 – 2.55 mmol/L 
Phosphate  0.8 – 1.6 mmol/L 
Magnesium  0.8 – 1 mmol/L 
Albumin  40 g/L 
Bicarbonate  20 – 30 mmol/L 
Glucose  Fasting 3.3 – 6.7 mmol/L 
Non-fasting <10 mmol/L 
Ferritin  Male: 24 – 300 µg/L 
Female: 15 – 300 µg/L 
Total iron-binding capacity 45 – 70 µmol/L 




Abnormalities in biochemistry tests are highly associated with CKD however, the 
level of derangement depends on factors such as the stage of CKD, patients’ 
characteristics, comorbidities and lifestyle (Gowda 2010).  
B) Haematological tests 
Haematological tests for patients with CKD are commonly performed as standard 
tests to identify any abnormalities and to diagnose CKD related anaemia. Table 
1.4 illustrates the most common haematological tests for patients with CKD 
(George 2018). Haematological parameters are commonly deranged in patients 
with CKD leading to complications like anaemia. However, derangements depend 
on the stage of kidney impairment (Babitt 2012). 
Table 1.4: Haematological tests for patients with CKD. 
Test  Reference ranges (may vary across units) 
Haemoglobin  Male: 13.5 – 18 g/dl 
Female: 12 – 16 g/dl 
White blood cell count 3.5 – 11 X 109/L 
Red blood cell count Male: 4.5 – 6.5 X 1012/L 
Female: 4.4 – 6 X 1012/L 
Platelets  150 – 400 X 109/L 
Prothrombin time 11 – 13.5 seconds 
Activated prothrombin time  28 28 – 34 seconds 
 
C) Urine tests  
Urine tests are the simplest non-invasive tests to perform for patients with CKD. 
Such tests include urinalysis dipsticks to identify proteins, blood traces, sugar 
and infection in the urine. There are some more specific urine tests for patients 
with CKD, such as 24-hour urine collection to assess the urine volume in 24 
hours to identify the renal function. Urine microscopy is also a test performed for 
patients with CKD to examine the urine for presence of blood cells, crystals or 
bacteria under the microscope (Baumgarten and Gehr 2011). 
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D) Kidney biopsy 
Usually kidney biopsy is performed to identify the underlying cause of CKD. The 
biopsy can also help identify the disease advancement over a period of time 
(Dhaun 2014). 
E) Immunological tests 
Some more specific tests such as the immunological investigations are used to 
identify the presence of any autoimmune antibodies in the blood or urine to 
diagnose any immunological disease related to the kidney (Winearls 2015). 
F) Radiological examinations 
These tests are used to guide the size and locations of the kidney as well as 
looking for any structural damage in the kidney or blockages of any renal 
vessels. Imaging techniques such as ultrasounds, computed tomography, 
magnetic resonance imaging and x-rays are the most widely used for patients 
with CKD (Moghazi 2005). 
G) Kidney function measurements 
The Glomerular Filtration Rate GFR can be measured through some invasive tests 
or estimated by calculations using serum creatinine levels. 
The most common equations used to estimate the GFR in adults are the 
Cockcroft and Gault equation and the Modified Diet in Renal Disease (MDRD) 
equation (Baumgarten 2011).  
1.1.8. Economic burden of Chronic Kidney Disease 
CKD is considered one of the high cost conditions globally with huge economic 
burden on any healthcare provider.  Renal replacement therapies are considered 
significantly costly treatment modalities yet cost-effective therapeutic options. A 
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study published in 2018 estimated the health-related quality of life burden of 
CKD per million of the population with diabetes to rise from £7.08 billion to £11.4 
billion between 2012 and 2025 in the UK (Nguyen 2018). 
1.1.9. Management of Chronic Kidney Disease 
The first ever attempt to treat a patient diagnosed with early stages of CKD is to 
prevent the progression of the disease where a renal replacement therapy (RRT) 
would be required. RRT is usually required when almost 85% or more of kidney 
function is lost (Obrador 2002). 
The currently available treatment options for CKD patients using RRT are either 
one of the dialysis modalities such as haemodialysis, peritoneal dialysis or a gold 
standard treatment option such as kidney transplantation. The latter is 
recognised as the preferred approach for CKD treatment, from both clinical and 
economic perspectives (Winkelmayer 2002). 
Most of the patients with CKD suffer from co-morbid conditions requiring medical 
interventions (Kovesdy 2012). Usually, these patients have polypharmacy, which 
on its own is a risk for a further insult to the kidneys. The role of the pharmacist 
therefore, through contributions to the better management of medications, is 
crucial for delaying the progression of CKD, and so for improving the quality of 
the care provided to this group of patients (Joy 2005). 
1.2. Clinical pharmacy 
Clinical pharmacy has advanced since it was first introduced in 1960s with many 
emerging definitions, which placed the patient at the centre of the practice (Rotta 
2015, Dreischulte 2016). Many new models of care and frameworks of practice 
such as pharmaceutical care, medication therapy management and 
comprehensive medication management have evolved in subsequent years 
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(McBane 2015, Dreischulte 2016). Given that clinical pharmacy is perhaps the 
most widely accepted broad generic term, it will be adopted in this work. 
1.2.1. History of clinical pharmacy 
From a historical perspective is evident that clinical pharmacy practice has 
developed significantly since its inception. From drug-supply oriented profession 
to providing high level advanced patient centred care in addition to many other 
roles. In 1990 Hepler and Strand suggested that pharmacists take more 
proactive roles in providing patient centred care by preventing, identifying and 
resolving drug therapy related problems for better patient outcomes (Hepler and 
Strand 1990). Later the concept of pharmaceutical care was developed and was 
defined as the pharmacist’s contribution to patient care to ensure optimisation of 
medication therapy in order to improve health outcomes (Dreischulte 2016). 
In the UK, clinical pharmacy was evolved from ‘ward pharmacy’ in early 60s and 
the role has expanded since then to a more independent well recognised clinical 
role (Cotter 1995). 
1.2.2. Clinical pharmacy services in the United Kingdom 
Pharmacy practice and clinical pharmacy in the UK has developed over the last 
two decades. The UK government and health authorities constantly promote that 
interventions delivered by pharmacists and their teams are safe and of a high 
quality (Root 2017). The NHS England and NHS Improvement and Health 
Education England have been leading a visionary approach to medicines 
optimisation that requires the right knowledge and skills for pharmacy 
professionals. To achieve success for such initiatives, pharmacists will need to 
develop to meet the highest standards of professionalism and be equipped with 
more clinically oriented training and education (Health Education England 2019). 
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Pharmacy practice and education in the UK is guided by the RPS advanced 
pharmacy framework along with other NHS and governmental policies related to 
pharmacy profession (Royal Pharmaceutical Society 2013). Expansion of 
pharmacy services in the UK has led to ever more innovative services being 
initiated in a variety of healthcare settings. This has included; medicines 
information, therapeutic drug monitoring services, patient education and 
counselling, medicines reconciliation, medication review, pharmacist led chronic 
disease management clinics and implementation of models of pharmacist 
independent prescribing practice delivered within the pharmacist’s scope of 
competency (Tonna 2007).  
Clinical pharmacy services were initially offered in hospital settings and 
developed at later stage into providing services in community setting and 
involved providing seamless care. There are several models of care practised by 
pharmacists, this is evident in a range of settings including the GP practices. 
Some of these models include: 
 Practice based pharmacist: practise within the GP practice team and provide 
direction and guidance on evidence-based medicines (NHS England and NHS 
Improvement 2019). 
 Primary care pharmacists: practice in a primary care facility and support 
through prescribing and analysing service development related to medicines 
management (NHS England and NHS Improvement 2019). 
 Community pharmacists: practice within a community pharmacy and provide 
crucial services in line with the community pharmacy contractual framework 
(NHS England and NHS Improvement 2019). 
 Intermediate care pharmacist: practice between primary care and secondary 
care healthcare facilities to support discharge services and reduce hospital 
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admissions by supporting patients in their home environment (NHS England 
and NHS Improvement 2019). 
 Clinical specialist pharmacist: also known as (Advanced practitioners), they 
provide a specialist service such as nonmedical prescribing in a specific area of 
competence (NHS England and NHS Improvement 2019). 
 Nonmedical prescriber (NMP): NMP is considered an advancement in clinical 
pharmacy practice in the UK. Pharmacist with additional qualification of NMP 
are allowed to prescribe independently within their area of competency (NHS 
England and NHS Improvement 2019). 
The NHS prioritised pharmacists’ contribution to key important areas with a 
healthcare facility.  
One of the priorities was management of chronic conditions with many models of 
care practising in all healthcare organisations. Pharmacist contributions are well 
appreciated in the management of conditions like diabetes, cancer, 
cardiovascular and respiratory care (Royal College of General Practitioners 
2015). Although patients with CKD are very vulnerable and require input from 
pharmacists, there was not much focus in the RPS policy statement on GP 
practise based pharmacists on pharmacist’s contribution in the care for patients 
with CKD. 
Another priority of the NHS published by the RPS in the polypharmacy document 
in the UK is to utilise the pharmacy workforce in polypharmacy management in 
elderly patients taking more than six medications by reviewing current 
medicines, consulting and counselling patients, optimising medication used and 
minimising side effects and drug related hospital admissions (Royal 
Pharmaceutical Society 2019). Polypharmacy can have complicated medication 
regimen and may include high cost drugs leading to huge burden on healthcare 
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system if not addressed timely and efficiently. Pharmacists can help patients 
understand the need for having multiple medications and can help patients use 
their medication in safe and effective way (International Pharmaceutical 
Federation 2012). The NHS Scotland developed a polypharmacy guidance 
realistic prescribing in 2018 as a roadmap to more rationale prescribing for 
elderly patients (Scottish Government Polypharmacy Model of Care Group).  
One of the additional priorities of the NHS in the UK is to utilise pharmacy 
workforce in the optimisation of antimicrobial use through antimicrobial 
stewardship (Gilchrist 2015). Since the start of the stewardship programme, 
pharmacists accelerated and embedded the development of the programme 
(Gilchrist 2015).  
The positive impact that pharmacists made in providing various clinical services 
and direct patient-facing care increased the demand for more clinical and 
patient-centre oriented pharmacy education and both undergraduate and 
postgraduate level. Qualifying more pharmacists will provide a pharmacy 
workforce ready to integrate in provision of clinical services once they completed 
their degree.  
1.2.3. Role of clinical pharmacy in the care of patients with CKD  
Clinical Pharmacists are involved in different areas of managing patients with 
CKD, such as patients receiving either type of dialysis (haemodialysis or 
peritoneal dialysis), patients received kidney transplantation, patients with any 
stage of CKD (pre-dialysis), acute kidney injuries (AKI), and general patients 
with renal impairments and other co-morbidities (Joy 2005, Joy and Matzke 
2007). 
The number of patients with CKD is expanding globally, therefore the need for 
specialised pharmacists with renal knowledge is crucial (Muros-Ortega 2014). 
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Within the multidisciplinary team, pharmacists have great scope to provide care 
to CKD patients (Stemer and Lemmens-Gruber 2011). 
 There are some key roles for renal pharmacist such as renal drug management 
cost, which is a huge burden on the healthcare system in any nation and most of 
the expenditure for this group of patients goes to treatment for co-morbidities 
like anaemia and expensive drugs such as immunosuppression (Chisholm 2001). 
Other significant roles that clinical pharmacists play in serving CKD patients is 
managing some of the complications such as anaemia, renal mineral bone 
disease and hypertension, in addition to running pharmacist led clinics for 
general purposes as medication review clinical or more specialised as transplant 
clinics (Mason and Bakus 2010). 
A Joint Opinion by the Nephrology and Ambulatory Care Practice and Research 
Networks of the American College of Clinical Pharmacy discussing the importance 
of the clinical pharmacist as an integral member of the multidisciplinary team 
was published in 2005. The report highlighted the important roles of the clinical 
pharmacist in the care of CKD patients and emphasised that the clinical 
pharmacist is one of the important pillars of the multidisciplinary team for 
providing better care to CKD patients. Figure 1.4 below shows all the 




Figure 1.4: Multidisciplinary approach to CKD care. (Joy 2005). 
 
Another study carried out in Spain by Via-Sosa et. al. looking into the value of a 
drug dosing service provided by community pharmacists in poly-medicated 
elderly patients with renal impairment concluded that a drug dosing service for 
elderly patients with renal impairment in community pharmacies can identify and 
solve drug related problems. However, the study highlighted that the results 
could be better if the practice is in collaboration with doctors which means that 
the study could not demonstrate good collaboration between doctors and 
pharmacist. The control group in the study was taken retrospectively, while the 
intervention group was prospectively studied which could be taken as a drawback 
of the study where there might be differences between the two groups (Via-


















Recently (2016), Chang et al. published a paper on using pharmacists to improve 
risk stratification and management of stage 3A chronic kidney disease. The 
authors conducted a cluster-randomised trial in seven primary care settings in 
Pennsylvania in the USA to assess the feasibility of pharmacist medication 
therapy management (MTM) in patients with CKD in addition to other co-
morbidities. The clinics were divided into a control (four clinics) and intervention 
group (three clinics) were the pharmacist were instructed to follow KDIGO driven 
protocol intended to test for proteinuria as a primary outcome over a follow-up of 
one year. The study arms were not equally distributed, as the type of patients 
seen in the control group were different than the ones seen in the intervention 
group. Also, a follow-up period of one year to assess the development of 
proteinuria was not sufficient enough to draw a conclusion. This research also 
emphasised on multidisciplinary collaboration for the success of implementing 
such services. Although the study appreciated pharmacist’s role in MTM yet the 
authors expressed for future studies to establish the effectiveness of pharmacist 
MTM on slowing CKD progression and improvement in cardiovascular outcomes 
(Chang 2016). 
The common limitation of both studies mentioned above was the lack of 
multidisciplinary approach in managing CKD patients. To establish a new service 
in any healthcare organisation it is important to have support from within 
organisation or support from an external body. For pharmacists in the UK who 
are caring for patients with CKD, the UK Renal Pharmacy Group is considered an 
important external, independent organisation to support the establishment and 
development of pharmacy practice to provide better care for patients with CKD 
and other renal diseases.  
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The next section will highlight the establishment of the UKRPG, the aim and the 
main responsibilities of the group. 
1.3. Professional leadership for renal diseases: The United Kingdom 
Renal Pharmacy Group 
The UK Renal Pharmacy Group (UKRPG) was first established in early 1980s with 
almost 50 people interested and joined the group. The group was interested in 
sharing knowledge and experience to help members provide best care in the area 
of renal medicine.  Their aim is ‘to facilitate high quality, value-for-money 
education, training and research for pharmacists involved in provisions of 
pharmaceutical care to patients with renal disease’. In 2002 the group 
established its own website (www.renalpharmacy.org.uk) to enable access to all 
registered members to discussion forms and access various useful resources, 
with limited access to resources to non-registered members.  
The UKRPG is now an affiliated group to the British Renal Association (BRA) to 
allow working in teams on many renal related projects nationally and 
internationally.   
They have organised many conferences and educational meetings, they 
established their first printed guide ‘An A-Z of drug use and guide to patient 
counselling in renally impaired adults’, almost 1000 copies of this guide were 
sold. One of the milestones of the group was to publish The Renal Drug 
Handbook in 1999, which was sold internationally and is a recognised reference 
to vast majority of renal pharmacists. The latest version of the handbook was the 
5th edition which was published in 2018.  The UKRPG developed a competency 
framework for pharmacists providing care to renal patients including CKD 
patients in 2009. The rationale of this framework was to support advanced-level 
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of practitioners progressing to the consultant-level of renal clinical pharmacy 
practice (Bradley 2009). The competency framework also provides guidance to 
pharmacists working in other clinical areas (such as Critical Care, General 
Medicine and Care of the Elderly) who will encounter patients with CKD on a 
regular basis (Bradley 2009). Despite the advancement of nonmedical 
prescribing in the UK, the competency framework lacked information about 
pharmacist’s role as a prescriber. It is expected to have an updated version of 
the framework with more focus on pharmacist prescribing for patients with CKD. 
1.4. Nonmedical prescribing 
Another core element of pharmacist’s role in providing care to CKD patients is 
the ability to prescribe and modify prescribed medications in more effective 
ways. Unfortunately, this privilege is not legal worldwide, in fact, only a few 
countries permit this practice.  In the UK the first pharmacist prescriber was 
registered by the Royal Pharmaceutical Society of Great Britain (RPSGB) in 2004 
(Tonna 2007). Nonmedical prescribing is aimed to improve overall patient care 
and optimise pharmacotherapy (Stewart 2012). Many different models of 
nonmedical prescribing exist but the most common models in the UK are the 
supplementary prescribing model and independent prescribing model (Stewart 
2012). Nonmedical prescribing involves a range of multidisciplinary team 
members including: pharmacists, nurses, dieticians, physiotherapists and 
radiographers (Stewart 2017).   
The process of prescribing is challenging in patients with CKD because of decline 
in the renal function and need for multidrug regimen for managing co-morbidities 
in CKD patients. This challenge becomes even more complex when the 
pharmacist deals with drugs mainly eliminated through the kidneys. Therefore, 
22 
 
selecting the most suitable drug and dosing modification should be carried out 
cautiously in CKD patients to prevent the occurrence of drug related problems 
particularly for renally cleared drugs (Dowling 2010). A recent study by Molnar et 
al. assessing potentially inappropriate prescribing for patients with CKD reported 
that involving a pharmacist in the care for patients with CKD can improve 
prescribing practice, which demonstrates the importance of pharmacist 
prescribing practice in the process of management for better patient outcomes 
(Molnar 2020). 
1.5. Structure, process, outcomes 
This research will be framed within the typology of structures, processes and 
outcomes based on Avedis Donabedian’s Framework for the research of 
healthcare quality (Donabedian 1990). 
Structure (factors that affect the context in which care is delivered) refers to the 
“characteristics of the settings where the pharmacists perform. This includes 
tangible resources like facilities and equipment, human resources including the 
number and qualifications of the practising pharmacists (Donabedian 1988). 
Processes (sum of all actions that make up healthcare) represents the nature of 
services in providing care to CKD patients. It may also include the activities 
performed by the patient's in order to seek care and the practitioner's activities 
in the diagnosing process and making therapeutic recommendations (Donabedian 
1988). 
Outcome (effects of healthcare on patients or society) comprises “the effects of 
care on the health status of patients and populations”, i.e. it encompasses a 
change in patient health status as a result of a health care service. To ensure a 
balanced outcome an ECHO model as an approach which further divides the 
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outcomes into three dimensions (Economic, Clinical and Humanistic Outcomes) 
(Kozma 1993). 
As suggested by Donabedian, a solid and good structure surges the chances of 
well-developed processes, and good process rises the likelihood of worthy 
outcomes (Donabedian 1990). Following the adoption of clinical pharmacy as a 
new way of patient centred practice, a shift from structure and process toward 
an emphasis on outcomes emerged (Mullins 1996), as outcomes are the ultimate 
validators determining the extent of benefit or harm to the patient (Donabedian 
1966). This, however, does not mean that outcome measures should be 
assessed in isolation to structure or process measures. Rather, the goal is to 




1.6. Aims and objectives/research questions of this doctoral   
programme 
In view of the complexity of CKD and the need for medication management in 
the safest and effective way, pharmacists are positioned well as an important 
member of the multidisciplinary team to care for these patients. To help 
characterise the role and experiences of pharmacists caring for patients with 
CKD, the UKRPG members would be ideal partners to help meet the aim and 
objectives of this doctoral programme. The proposed research was registered 
with the research degree committee at the Robert Gordon University (Appendix 
1.1). The overall aim of this doctoral research was to explore the experiences 
and the expertise of clinical pharmacists to scope structure, process and outcome 
of clinical pharmacy services in the care for patients with CKD.  
The aim and objectives/research questions of each stage and phases of this 
doctoral research are listed below: 
A) Aim and research questions of the systematic review (Stage 1) 
The aim of the systematic review was to appraise, synthesise and present the 
available evidence for the structures, processes and related outcomes of clinical 
pharmacy practice in the care for patients with CKD.  
The specific review questions were: 
1. What clinical pharmacy practice related resources (structures, e.g. the 
multidisciplinary team, clinical pharmacy skill mix and time allocation) are in 
place and how are these matched to healthcare needs and demands to enable 
provision of care to chronic kidney disease (CKD) patients? 
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2. What activities are performed (processes, e.g. medication review, prescribing) 
to care for patients with CKD, how and when are they performed? 
3. What are the outcomes of the structure and the processes on the effectiveness 
(Economic, Clinical, and Humanistic Outcomes (ECHO) model) (Kozma 1993) 
of care provided? 
B) Aim and research questions of the quantitative survey (Stage 2, 
Phase 1) 
The main aim of the survey was to determine the behaviours and experiences of 
pharmacist members of the UK Renal Pharmacy Group on provision of care of 
patients with Chronic Kidney Disease. 
Specific research questions included: 
1. What are the characteristics of general models of clinical pharmacy practice in 
terms of structures and processes and how have these models been developed, 
implemented and evaluated?  
2. What are the characteristics models of pharmacist prescribing practice in 
terms; supplementary vs independent, site of and support for practise, 
competency areas, process of prescription writing etc and how have these 
models been developed, implemented and evaluated? 
3. What are the positive and negative experiences on development and 
implementation of these models of practice? 
4. What are the key areas for future practise development and what are the 
recommendations for implementing these developments? 
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C) Aim and objectives of the qualitative interviews (Stage 2, Phase 2) 
The qualitative interview phase aimed to explore from a professional perspective, 
the development, implementation and evaluation of pharmacist prescribing for 
patients with Chronic Kidney Disease in the UK. 
Specific research objectives included: 
1. To describe and characterise the models of pharmacist prescribing practice. 
2. To explore the facilitators and barriers relating to implementation of 
pharmacist prescribing.  
3. To describe the plans, actions and parameters used for evaluating prescribing 
practice.  




































This doctoral research was carried out in two stages and the second stage was 
undertaken in two phases: 
Stage 1: a systematic review of the literature 
A systematic review of clinical pharmacy practice in the care of Chronic Kidney 
Disease patients was undertaken; (Chapter 3, Al Raiisi 2017, Al Raiisi 2019). 
Stage 2: data generation 
Phase 1: a questionnaire based online survey to the pharmacists’ members of 
the UK Renal Pharmacy Group (UKRPG) to determine the behaviours and 
experiences of clinical pharmacists’ members of the UK Renal Pharmacy Group 
on provision of care of patients with CKD (Chapter 4, Al Raiisi 2020). 
Phase 2: semi-structured telephone interviews with participants from the UKRPG 
to explore from a professional perspective, the development, implementation and 
evaluation of pharmacist prescribing for patients with Chronic Kidney Disease in 
the UK. 
In this chapter a brief discussion on the Medical Research Council Framework for 
Developing and Evaluating Complex Interventions (MRC 2016), systematic 
reviews, research philosophies, different methodologies, theoretical frameworks 
and method approaches will be described. The use of certain methodological 
approaches, philosophical paradigms and specific methods for this proposed 
research will be justified. Characteristics of robustness in quantitative research 
and rigour in qualitative research will be explained and their use will be justified. 
Good research governance as an important aspect of good quality research will 
also be highlighted in this chapter.  
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2.1. The Medical Research Council Framework for Developing and 
Evaluating Complex Interventions 
The Medical Research Council (MRC) is a UK government funding agency devoted 
to the improvement of UK people’s health through supporting and encouraging 
high-standard research in all branches of medical science (MRC 2016).  
The MRC framework for complex interventions to improve health was developed 
in 2000 with an aim to develop, evaluate and help implement complex 
interventions to improve human health. Complex interventions were defined as 
interventions with different interacting components and dimensions of 
complexity. Details on the complexity dimensions of an intervention and the 
implications for development and evaluation are presented in Table 2.1.  
Table 2.1: Dimensions of complexity and the implications for development and 
evaluation of an intervention. Adapted from Craig 2008. 
Dimensions of an intervention complexity: 
 
• Number of interactions between components within the experimental and control 
interventions 
• Number and difficulty of behaviours required by those delivering or receiving the 
intervention 
• Number of groups or organisational levels targeted by the intervention 
• Number and variability of outcomes 
• Degree of flexibility or tailoring of the intervention permitted 
 
Implications for development and evaluation of complex studies: 
 
• A good theoretical understanding is needed of how the intervention causes change, 
so that weak links in the causal chain can be identified and strengthened 
• Lack of impact may reflect implementation failure (or teething problems) rather than 
genuine ineffectiveness; a thorough process evaluation is needed to identify 
implementation problems. 
• Variability in individual level outcomes may reflect higher level processes; sample 
sizes may need to be larger to take account of the extra variability, and cluster- rather 
than individually-randomised designs considered. 
• Identifying a single primary outcome may not make best use of the data; a range of 
measures will be needed, and unintended consequences picked up where possible. 
• Ensuring strict fidelity to a protocol may be inappropriate; the intervention may work 




The MRC framework has been used extensively by researchers as guidance to 
choose the most suitable research methods. The framework has also been used 
by funding bodies to help assess the constraints on complex intervention 
evaluation design. The framework was developed to guide stakeholders and end 
users to weigh up the available evidence for a given intervention considering the 
methodological approaches and the constraints that could impact their decision in 
the assessment of complex intervention. 
The MRC framework focuses on the development through to implementation of a 
complex intervention with all necessary steps required for a successful 
implementation. The development-assessment-evaluation-implementation 
process is summarised by the MRC framework in Figure 2.1.
 
Figure 2.1: The development-assessment-evaluation-implementation 
process according to the MRC framework. Adapted from Craig 2008. 
Assess 
feasibility/piloting:
1. Test the procedures
2. Estimate recuitment
3. Determine sample size
Evaluate:
1. Assess effectiveness







1. Identify the evidence-base
2. Identify/develop theory
3. Model process & outcome
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A) Development phase 
The MRC suggests following a systematic development of an intervention by 
identifying the most suitable evidence-base through systematic literature search, 
identifying or developing the best available theory and modelling the intervention 
at early stage before evaluating it at a final phase, such as pre-trial economic 
evaluations. 
B) Feasibility and piloting phase 
This stage focuses on the testing procedures in order to be acceptable through 
appropriate estimation of recruitment process and calculation of suitable sample 
size. This step is considered vital however, scholars suggest that the step in 
often neglected (Power 2004). A pilot study within this phase may help highlight 
the major doubts that rises during the development phase. Cautious 
interpretation of the pilot phase is warranted to avoid misjudgement of the 
required sample size for the scaled-up evaluation. To ensure a smooth transition 
between the pilot and the full-scale evaluation the MRC suggested series of a mix 
of quantitative and qualitative methodological approaches in order to design a 
complete scaled-up evaluation. 
C) Evaluation phase 
It is important to be aware of the most suitable research approach and select the 
best fit method to answer the research question. In this phase of the MRC 
framework it is suggested to consider randomisation in order to assess 
effectiveness since it is the most robust approach to avoid selection bias in two 
opposing groups. This phase also highlights the importance of having a clear 
understanding of the processes of the intervention so that it is possible to 
provide clear justification into the failure or success of the intervention. This also 
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facilitates optimisation and maintenance of positive outcomes that may relate to 
the intervention. Similarly, assessing the cost-effectiveness can be of additional 
value to make the results more meaningful for stakeholders. One of the key 
aspects of the evaluation phase is the selection of the outcome measures and the 
ability to deal with multiple outcomes during the data analysis.  
D) Implementation phase 
During the implementation phase it is essential to disseminate the findings of the 
research undertaken to evaluate a complex intervention. This will help translate 
the findings into routine practice or incorporate it in a policy to be accessible to 
decision-makers. In order to ensure the implementation of an intervention is 
successful, it is important to understand change in behaviour as well as to 
understand the facilitators and barriers to the change process which might 
require further research to support implementation. The MRC framework 
emphasises during this phase the importance of long-term follow-up and 
monitoring to be able to identify any adverse events which were not possible to 
identify in the early phases. Monitoring the long-term outcomes is also 
considered important to be able to assess whether the outcomes are 
transferrable to wider practice or not in the long-term.    
Despite the wide use of the MRC framework, a number of limitations were 
identified in the 2000 framework which was considered and incorporated in the 
revised version in 2008 (Anderson 2008). 
The MRC works in partnership with UK Research and Innovation (UKRI), which is 
a non-departmental public body established in 2017. The UKRI aims to maximise 
the contribution of all stakeholders to ensure that world-class research and 
innovation continue to develop in the UK (UKRI 2018). It is formed by seven 
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research councils including the MRC, innovate UK and Research England (UKRI 
2018). 
 This doctoral research will focus on the implementation phase of the MRC 
framework given that the clinical pharmacy service provision in the care for 
patients with CKD is an established role in the UK.  The implementation phase 
has three components (MRC 2016): 
1. Dissemination of findings: The initial step to identify if the service provision 
findings were published or not was to extensively and systematically review 
the literature to enable understand of whether or not these findings were 
translated into current practice. 
2. Surveillance/monitoring: in order to promote implementation of a service, it is 
important to explore pharmacists’ behaviours and experiences that are vital 
for the service as well as the consideration for the need to change certain 
behaviours on a solid scientific ground. It is also vital to reflect on the barriers 
and facilitators for the implementation of the service as a monitoring process. 
This was achieved by the first phase of the second stage of this doctoral 
research through conducting a survey to the pharmacists’ members of the 
UKRPG to identify behaviours and experiences of clinical pharmacists caring for 
patients with CKD. 
3.  Long-term follow-up: the second phase of the second stage of this doctoral 
research focused on evaluating the service of pharmacist prescribing for 
patients with CKD in the UK through conducting semi-structured telephone 
interviews with the participants to identify the models of prescribing, long-
term follow-up needs and further development of pharmacist prescribing 
services for patients with CKD.  
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2.2. Systematic review 
To start a research project, it is always beneficial to develop an understanding of 
what is already known about the selected topic; this will identify the nature of 
previous work including study design and also identify gaps in knowledge so 
helping inform the direction and design of this doctoral work.  
Systematic reviews are considered to be positioned at the top of evidence-based 
literature hierarchy as shown in Figure 2.2 (Heaton 2000). A systematic review 
aims to identify as many as possible relevant high-quality research papers on a 
particular subject or research question and using explicit methods to synthesise 
and integrate the findings of these studies (Khan 2001). Figure 2.2 below shows 
the hierarchy of evidence from literature.   
 




Many different types of literature review are identified in the literature. Fourteen 
types were described by Grant and Booth (2009) however, a few such as review 
of reviews and narrative reviews were not included in their paper yet were 
described by MacLure (2016). Table 2.2 below describes each type of literature 
review.  
Table 2.2: Types of literature reviews.  Adapted from Grant and Booth 2009. 
Label Description 
Critical review Establishes extensive literature research and critical evaluation of its 
quality. It includes analysis and conceptual innovation. Usually results 
in hypothesis or model 
Literature review Generic term: published materials exploring current literature. Might 




Identify gaps in research through mapping out and categorising 
existing literature 





Combination of results from different types of research methods such 
as combining quantitative and qualitative research or outcome with 
process studies 
Narrative review Provides latest knowledge description about a specific topic without 
describing the methodological approach 
Overview Generic term to summarise the literature in an attempt to review the 






A review technique to integrate or compare the findings from qualitative 
studies highlighted the themes or constructs generated as a result 
Rapid review Aims to assess what is already known about a policy or practice, 
within a timeframe by reviewing and critically appraising existing 
literature 
Review of reviews Tends to systematically review systematic reviews 
Scoping review Preliminary assessment of available research literature to identify the 
nature and extent of evidence (usually including ongoing research) 
State-of-the-art 
review 
Aim to report more current matters and offer new perspectives on an 
issue  
Systematic review Tends to systematically search, appraise and synthesise literature, 




Merit combination of critical review and comprehensive search process 




Uses some elements of systematic review process (e.g. postgraduate 
assignments) 
Umbrella review Gathering evidence from multiple reviews with a focus on broad 




At the start of this doctoral research, the doctoral student carried out a scoping 
literature search of the available literature on the selected topic to identify the 
gap in knowledge on the structure, process and outcome of clinical pharmacy 
practice in the care for patients with CKD. However, in order to develop a 
comprehensive understanding of the selected topic, the doctoral student carried 
out a systematic review of clinical pharmacy practice in the care of Chronic 
Kidney Disease patients. 
Systematic reviews aim to appraise, synthesise and present the available 
evidence on a given topic or to answer a research question (MacLure 2016). 
Knoll (2018) identified the major elements of a systematic review: identifying, 
selecting, synthesising and appraising literature that meet set inclusion and 
exclusion criteria using explicit methods, to answer a research question and 
obtain reproducible findings, and to identify gaps to be targeted in future 
research. The importance of publishing a priori protocol for a systematic review 
was also emphasised (Knoll 2018). Figure 2.3 below shows the key steps in 
conducting systematic reviews (Wright 2007, Knoll 2018). 
 































The Centre for Reviews and Dissemination (CRD 2015) highlighted that before 
undertaking a systematic review it is of paramount importance to check in the 
databases whether or not there is an existing or ongoing review on the topic to 
justify carried out the review. Another important element of a systematic review 
is developing and publishing a review protocol which must include the review 
question/s, inclusion and exclusion criteria, search strategy, study selection, data 
extraction, quality assessment, data synthesis and the plan for dissemination of 
the findings (CRD 2015). One of the important benefits of publishing a protocol is 
to copyright the review being carried out to avoid other researchers duplicating 
the review. 
Systematic review protocols can be developed and published by numerous 
organisations such as the Centre for Reviews and Dissemination (CRD) at the 
University of York, the Cochrane Collaboration and the Joanna Briggs Institute. 
To enable the doctoral student to become familiar with the protocol writing 
process and with conducting systematic review a training course was 
undertaken.  This was provided by the Joanna Briggs Institute in collaboration 
with Robert Gordon University (RGU). The protocol was developed by following 
the CRD guidance (CRD 2015) to enable the doctoral research to follow 
comprehensive searching process, determination of inclusion or exclusion criteria 
and choosing the most appropriate tool for quality assessment with extensive 
discussions among the research team. The doctoral student developed and 
published the review protocol with the supervisory team guidance at the CRD (Al 
Raiisi 2017). 
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Chapter 3 will provide details of the systematic review carried out by the doctoral 
student in accordance with the guidance provided by the CRD (2015). 
2.3. Research philosophy 
There are numerous research philosophies that strengthen a doctoral research 
(Stewart and Klein 2016). A research philosophy is a way or a belief of ways by 
which data about a phenomenon are gathered, analysed and used. It is 
important to address the research philosophy in early stages of a research to 
ensure the researcher is aware of the beliefs and the assumptions related to the 
research paradigm and that the research is aligned in terms of research aim, 
methods used and research outcomes leading to a coherent research design 
(Creswell 2014). 
2.3.1. Research paradigm 
Creswell (2018) used the word ‘worldview’ for paradigms, where he defined it as 
“essential set of beliefs that guide action” in other word paradigm is known as 
general philosophical directions towards the nature of research brought to any 
study” (Creswell 2018). 
Paradigm can also be defined as a “Wide outline of beliefs, perceptions and 
understanding within which theories and practices derive” (Kivunja and Kuyini 
2017). Components of a paradigm are explained below and summarised in Table 
2.3. 
Ontology of a paradigm is related to the researcher’s assumptions to believe that 
something is real or make sense. Ontology helps the researcher to conceptualise 
the form of reality in order to understand how to make sense of the data 
gathered (Kivunja and Kuyini 2017). 
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Epistemology is concerned about the nature of knowledge and how a researcher 
come to know the truth or the reality. It is about the relation between the 
researcher and the research participants or subjects (Kivunja and Kuyini 2017). 
Axiology is related to the theory of moral and ethical issues and values in a 
research context. It comprises of defining, understanding and evaluating the 
behaviours relating to the research (Kivunja and Kuyini 2017). 
Methodology of a paradigm is related to the process of research and the 
approach used to answer a research question (Kivunja and Kuyini 2017). 
Table 2.3: Components of a paradigm. Adapted from Creswell 2014. 
Component of a paradigm 
Ontology  Science of being (reality) 
Epistemology  Theory of knowledge (how/what?) 
Axiology Role of values in research 
Methodology  Research approach adopted 
 
2.3.2. Paradigms in qualitative and quantitative research 
There are well defined known paradigms in any research that are broadly 
discussed in the literature: positivism, postpositivism, constructivism, 
transformative and pragmatism. The most important elements of each paradigm 







Table 2.4: Paradigms in qualitative and quantitative research. Adapted from 
Creswell 2014, 2018. 
Paradigm Description 
Positivism  Assumes reality exists and can be measured. 
 Deductive approach. 
 Mostly quantitative. 
Postpositivism  Deterministic philosophy where causes determines outcomes. 
 Reduce ideas into small sets to test. 
 Are mostly quantitative approaches.  
 Concerned with experience and empirical observation.  
 Particular knowledge is backed up by scientific verification of 
theory. 
Constructivism  Mostly qualitative. 
 Understandings from a personal perspective. 
 Multiple participant meanings. 
 Generates theories 
Transformative   Mostly qualitative but can be quantitative as well. 
 Politically constructed and subjective. 
 Collaborative. 
 Power and justice. 
 Prone to change. 
Pragmatism   Can be both qualitative and quantitative (mixed-method). 
 Consequences of actions. 
 Problem-centred. 
 It is focused on real-life practices. 
 Pluralistic.   
 
2.3.3. Research onion 
A theoretical concept of research onion proposed by Saunders et al. which 
provides a relation between research philosophies, approach to theory 
development, methodological choices, research strategies, time horizon and 
method by which data will be gathered (Saunders, Lewis and Thornhill 2012). 










Figure 2.4: The research onion (Saunders, Lewis and Thornhill 2012) 
 
Each layer of the research onion is described as followed: 
Research philosophy is considered the infrastructure of a research which defines 
the nature of reality, sources of knowledge, values, beliefs and ethics of the 
research (Saunders, Lewis and Thornhill 2012). 
Approach to theory development helps distinguish between research which starts 
with an existing theory leading to the generation of research questions, and 
research which starts with observing a phenomenon and leads to establishing a 
theory (e.g. deductive versus inductive) (Melnikovas 2018). 
Methodological choices are determination for a choice about an approach to a 
research either qualitative or quantitative or mixed of both (Melnikovas 2018). 
Research strategy is the mean by which data will be generated and analysed 
(e.g. survey, case study, experimental, grounded theory) (Melnikovas 2018). 
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Time horizon is the timeframe within which the research will take place whether 
data will be collected over a specific period of time (cross-sectional) or data will 
be collected repeatedly over a long period of time (longitudinal) (Melnikovas 
2018). 
Techniques and procedures (methods used) is about the tools used to generate 
and analyse data including the choice of sample group and developing the data 
collection tool (Melnikovas 2018). 
2.4. Methodological approaches 
Research designs vary from qualitative, quantitative to multi-method and mixed-
methods approaches to be able to direct the research towards appropriate 
procedures in a logical way. Table 2.5 below summarises the different types of 
research designs elaborating on the characteristics of each design.   
Table 2.5: Qualitative versus Quantitative methodologies. Adapted from 
Andrew and Halcomb 2009, Creswell 2018. 
      Qualitative Quantitative 
Purpose  Explore the meaning of individuals 
experiences, culture, issues and cases 
Examining relationships between 




Broad and general research question 
(no hypotheses) 
Narrow and specific research 
question 
(hypotheses driven) 
Data  Words (interview, case studies), 
photographs, videos 
Numerical data  
Data collecting 
tools used 
The researcher is the main data 
gathering tool (structured or semi-
structured or unstructured interviews, 
narratives, case studies, documentary 
analysis, focus group) 
Designed and validated tools are 
used (questionnaires, surveys, 
measurements and other tools) to 
enable generate numerical data 
Analysis  Create themes (inductive, as data 
formed without use of theory) 
 
Using statistics (deductive, based 
from existing theory) 
Final reports  Narratives Statistical reports (more rigid) 
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Limitation Takes lots of time in transcribing data 
Results may be biased 
Misinterpretation of different 
parameters 
Trustworthiness and authenticity 
Not generalisable to population 
Numbers can lead to false 
perceptions 
More expensive 




Mixed-method approach involves either combining or integration both the 
qualitative and the quantitative approaches. Several types of mixed-method 
research are described in Table 2.6.  
Table 2.6: Approaches used in mixed-methods. Adapted from Bowling 2014 
and Creswell 2014. 
Method  Description  




Usually researcher starts with quantitative approach and after 
analysing the data builds on it and explains in more details by using 
qualitative approach. 
 
Exploratory sequential  The researcher carries out a qualitative research first to explore the 
individuals view, analyse the results and use it to identify and design 
appropriate instrument and to generated information that are used 
to carry the quantitative phase. 
  
Transformative  This method is used to assess a theoretical perception at different 
stages of analysis. 
 
Embedded  In this design only one data collection phase is used, during which a 
predominant method (quantitative or qualitative) nests the other 
less priority method (qualitative or quantitative, respectively). It 
uses one instrument of data collection containing open-ended and 
close ended questions to generate both types of data at the same 
time.  
 
Multiphase  This method is a complex design that may involve all the above-
mentioned methods (convergent, explanatory, exploratory, 
transformative and embedded designs). Multiphase mixed-methods 
enable researchers to examine an issue through a series of phases. 
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2.4.1. Justification of philosophical approach for this doctoral research 
The overall philosophy that fits this doctoral research is the positivist approach. 
The doctoral research explored structures, processes and related outcomes of 
clinical pharmacy practice for the care of patients with CKD. Although each phase 
of stage 2 was aligned within a different paradigm. This doctoral research 
followed an explanatory mixed-method approach with each phase labelled with a 
suitable methodological approach (Andrew and Halcomb 2009, Creswell 2018). 
Each stage and phase of this doctoral research and the use of philosophy is 
explained as followed. 
Stage 1, Phase 1 
This phase will be a systematic review aiming to appraise, synthesize and 
present the available evidence for clinical pharmacy practice in the care of 
Chronic Kidney Disease patients. This systematic review will focus on 
quantitative studies which fit-in well with the positivist paradigm.  
Stage 2, Phase 1 
Phase 2 of this research lines up with positivism paradigm, where the focus is to 
determine the behaviours and experiences of UK pharmacists providing care to 
patients with CKD through conducting a cross-sectional survey. 
Stage 2, Phase 2  
This phase aligns with the constructivism paradigm, where semi-structured 
telephone interviews with participants from the UKRPG to evaluate the service of 
pharmacist prescribing for patients with Chronic Kidney Disease in the UK was 
employed. 
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2.5. Methods  
The next step in any research is to select the appropriate method to answer the 
research questions. Methods are the techniques that will enable the researcher to 
generate and analyse the data. Qualitative, quantitative and mixed-method 
research approaches have different methods.  
2.5.1. Quantitative research approaches 
A) Philosophical assumption 
The quantitative research approach reflects positivism philosophical assumption 
which postulates the relations between variables to either answer theory guided 
research questions or hypotheses via experimental research or surveys (Creswell 
2018). These approaches depend on the numerical power and their ability to 
characterise the population in an accurate and vigorous fashion (O’Leary 2017).  
B) Methodologies in quantitative research 
Different types of methodologies in quantitative research are described in Table 
2.7. 
Table 2.7: Quantitative research methodologies. Adapted from Watson 2015, 
Creswell 2018. 
methodology Short description 
Case control 
studies 
In a case-control study participant who have been exposed to a 
risk factor are identified and compared with that of controls or who 
are not exposed to the risk factor. 
Risk of selection bias and validation of information is challenging. 
The statistical techniques for analysing case-control studies are too 
complex. 
Cohort studies A cohort study uses a defined group (people with a shared 
characteristic). 
More informative about how individuals change over time. 
Are more difficult to conduct and are susceptible to attrition. 
Randomised 
controlled trials 
Used to test the effect of treatments on people. 
Considered to be the best method for testing the link between 
cause and effect in clinical interventions. 
Its essential features are randomisation and use of a control group. 
RCTs should preferably be blind. 
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The RCT is rated near the top of the hierarchy of evidence, at level 
II, as a method of providing evidence for clinical practice. 
Survey based 
approaches 
Frequently involve distributing questionnaires, or they may be 
conducted by interview or observation. 
Surveys cannot easily distinguish between cause and effect, but 
they are useful for gathering large amounts of data to describe 
samples and populations. 
Are relatively easy to conduct. 
 
C) Quantitative methods 
Quantitative methods help researchers to study phenomena of interest through 
measuring or observation where the researcher acts as an observer with no 
influence on the participants or the findings of a research (Bowling 2009). Table 
2.8 below lists the most common research methods in quantitative approach. 
Table 2.8: Quantitative research methods. Adapted from Creswell 2014, 2018 
and Bowling 2014. 
Method Description 
Correlational  Exploring and observing relationship 
among variables using numerical 
analyses. It is mostly descriptive 
correlation design and observational in 
nature. 
Descriptive  Observation to describe a variable or a 
phenomenon. Data collection is usually 
through observation, and includes cross-
sectional and longitudinal designs. 
Experimental  Focuses on causality with control of 
independent manipulated variables. Most 
common techniques used with this 
method is true experiments with control 
groups 
Quasi-experimental Focuses on causality with control of 
independent non-manipulated variables. 
Techniques used are pre- and post-test, 
or post-test only. As well as single-subject 
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designs and the use of surveys and 
questionnaires. 
 
Stage 2, phase 1 of this doctoral research employed quantitative method in a 
form of cross-sectional online survey which deemed most suitable approach.  
D) Survey definition 
A survey design is believed to numerically describe behaviours, attitudes, trends, 
experiences and opinions of a studied population (Creswell 2018). Surveys are 
widely used method in many disciplines of research due to the advantage of 
being structured, easy to perform, measurable data generations and 
statistically sound results. However, it is also important for the researcher to be 
aware 
of the disadvantages associated with surveys which can impact the reliability of 
the data. These includes: respondents state at the time of completing the 
survey, leading answers and risk of biases (will be discussed in details later in 
this Chapter). 
E) Survey types 
There are few key issues a researcher needs to consider before choosing a 
survey method due to different surveys types (O’Leary 2017). Table 2.9 describe 








Table 2.9: Survey types and related issues. Adapted from O’Leary 2017. 
Q1: Are you targeting a sample or a whole population? 
Census: does not depend on a sample, involves 
everyone in a defined population 
 
E.g. all pupils in a specific school 
Cross-sectional surveys: uses a sample to represent a 
population and generalise findings or cross-section of 
participants 
 
Mostly used, e.g. community survey (targeting a 
sample to represent the whole community) 
Q2: is the intention of the survey is to describe or explain? 
Descriptive surveys: the aim is to describe your 
participants by gathering either demographic, 
behaviours and attitudinal information 
 
E.g. political election surveys that describe voters 
and voting intentions 
Explanatory surveys: aim to determine cause and 
effect and build complex understandings (why certain 
phenomena occur) 
 
E.g. investigating the causes that leads to 
customer dissatisfaction and determine the 
relative weight of each cause. 
Q3: will the survey be at a point of time or will it be over a period, would it explore change in 
time or people? 
Trend surveys: similar to cross-sectional but at more 
than one point of time and similar participants. The 
aim is to realise if a classifications or perceptions of 
participants change over time 
 
E.g. a survey conducted in two phases over a 5-
year period, to assess if attitudes towards an issue 
are changes or remained the same during the 5 
years. 
Panel study: it involves researching the same 
participants with same questions at more than one 
point of time. The aim is to see if people themselves 
change over time 
 
E.g. same as above with same respondents to 
assess attitudes are shifted as people get older 
Q4: what is the method of administering the survey? 
Face-to-face surveys:  
Advantages includes high response rate, motivates 
participants, allow questioning and clarifications, 
prompting, allow building trust between researcher 
and participant  
Disadvantages: lengthy and expensive, limited 
regions, no confidentiality, and requires training for 
the researcher 
 
E.g. shopping mall survey, when a participant is 
stopped by someone with a clipboard to ask few 
questions 
Telephone surveys: 
Advantages: less expensive, permit wide geographical 
cover, more anonymous, prompting and allow 
clarifications 
Disadvantages: lower response rate, participants can 
hang up at any point, limited to participants with a 
phone 
 
e.g. market research (method of choice) 
but more challenging in social science due to large 
number of participants getting annoyed 
 
Self-administered mail/e-mail/online surveys:  
Advantages: very confidential, permit wide 
geographical cover, allow participants to answer at 
their own time 
Disadvantages: risk of low response rate, no room for 
clarifications or questioning, sometimes costly (snail 
mail version). Limited to participants with internet 
access. Risk of not reaching the participant (junk mail) 
 
Includes email and online surveys which saves 
thousands on printing and postage. 
Most social science surveys 
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For the purpose of this research project, the most appropriate survey method 
was a mix of census and cross-sectional online survey where the whole 
population of renal pharmacists’ members of the UK Renal Pharmacy Group and 
clinically practising in the UK were targeted in a given timeframe.  
F) Survey tools 
Questionnaires are the most widely used tool in survey design which can either 
be paper based format or an online questionnaire (Creswell 2014, O’Leary 2017). 
Online questionnaires are preferred and popular form of survey tool with wide 
range of software to create, store and analyse data (O’Leary 2017). Robert 
Gordon University licensed Bristol online survey tool (JISC) was used to design, 
distribute and store the data for this phase of the doctoral research.   
G) Population and sampling design in quantitative research 
In a quantitative research the answer to a research question is considered 
sufficient if answered by some population rather than the whole population to 
enable generalise the findings. Therefore, it is important to define the population 
of interest explicitly before selecting a sample (O’Leary 2017).  
Sampling is defined as a process to select a group of subjects that represents a 
population to answer a research question (Garson 2012). In order to be able to 
generalise the findings to a population, it is important to ensure that the selected 
sample is appropriate, represent the population and the selection process was 
unbiased. To achieve optimum sample size, it is suggested to use a power 
calculation (Bowling 2002). Two most common sampling techniques are 
probability and non-probability sampling. Each technique suggests different 
sampling methods as described in Table 2.10 and Table 2.11. Most of the survey-
based research employ random sampling with various strategies such as simple 
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random sampling, systematic sampling, stratified sampling, cluster sampling and 
multi-stage sampling (O’Leary 2017).  
Table 2.10: Probability sampling techniques. Adapted from Jansen and Laurie 2016, 




Simple random sample 
(each unit in the 
homogenous population 
has an equal chance of 
being selected through 
a random selection 
process either manually 
or electronically) 
 Minimal or no sampling bias. 
 Population characteristics 
not required. 
 Robust form of sampling. 
 Affordable and accessible for 
certain population types 
(e.g. students at a 
University) 
 
 Hard to achieve random sample in 
practice. 
 Can be extremely costly for dispersed 
populations (e.g. nation-wide 
samples). 
 Can lead to insufficient respondents in 
certain categories of interest for the 
statistical analysis (e.g. minority 
ethnic groups). 
 Sampling by an untrained person may 
lead to misinterpreted instructions and 
improper selections of sample.  
Systematic random 
sample (sample is 
acquired by choosing 
the first sample on 
random basis and the 
subsequent sample at 
planned interval) 
 Widely used. 
 Easily implementable by 
anyone. 
 Efficient and easy 
implementation in real-life 
situations. 
 Avoid risk of researchers 
unintentionally selection 
bias. 
 Not truly random sampling. 
 Selection of Nth number may prevent 
selection of certain units. 
Stratified sample 
(dividing the whole 
population into different 
subgroup, then 
employing random 
sampling within the 
subgroups) 
 Superior to simple random 
sampling because of 
reduced chance of sampling 
error. 
 Works well for populations 
with multiple attributes. 
 Useful when comparing 
variable group sizes. 
 Useful to observe existing 
relationships between two or 
more subgroups. 
 Can be expensive to perform. 
 More knowledge about the population 
characteristics is required.  
 Selection of variables to use to stratify 
the sample may be complicated if the 
research has many important 
variables. 
Cluster sample (to 
enable random 
sampling obtained by 
selecting clusters or 
subgroup from a large 
population) 
 Allows face-to-face 
probability sampling when 
no sufficient contact details 
of participants are available. 
 Comparable strengths to 
simple random sampling if 
structured efficiently. 
 May be complicated to perform. 
 Extremely expensive if employed for 




(combination of various 
sampling techniques) 
 Enables identifying the 
limitations and analysis 
requirements for a given 
project. 
 Complex to define and implement. 






Table 2.11: Non-probability sampling techniques.  Adapted from Jansen and Laurie 2016, Grove 




Convenience sample (ideal to 
select the entire population in 
non-random means) 
 Fast, easy to perform 
and inexpensive 
technique. 
 Beneficial to get initial 
idea of a research (pilot).  
 Sampling bias (selected sample 
might not represent the 
population). 
 Cannot generalise findings to 
the wide population. 
Quota sample (selecting a 
convenience sample but within 
the bounds of predetermined 
quotas (e.g. 50% male, 50% 
female)) 
 Similar strengths as 
convenience sampling, 
just a little harder. 
 Quotas confirm enough 
units are selected from 
each category 
appropriate to the 
research.   
 Sampling bias (selected sample 




(identifies, cases of interest or 
new participants from 
participants involved in the 
research) 
 A useful technique to 
identify hard-to-access 
groups. 
 Helps establish some 
trust and credibility 
which may help gain 
participation in the 
research. 
 Sometimes the only 
feasible option. 
 May impact on participant 
diversity. 
 Sampling bias (non-
representative sample). 
Purposive/judgement/theoretical 
sample (selection of participants 
based on researcher’s knowledge 
and professional judgment) 
 Can gain insights that 
are useful for developing 
theoretical explanations 
by targeting specific 
individuals or groups 
within a population. 
 Researcher can exercise 
explicit judgement in 
identifying who would be 
most interesting to 
include in the sample, 
thus the sampling 
process benefits from the 
knowledge and 
experience of the 
researcher. 
 Sampling bias (risk of non-
representative sample). 
 The researcher’s judgement 
may unintentionally skew the 
selection of participants leading 
to potentially unreliable data.  
 
For the purpose of this doctoral research, the entire population of the clinical 
pharmacists’ members of the UKRPG were targeted with convenience sampling 
technique followed for the first phase of stage 2 of this doctoral research. 
Sampling details for the qualitative research will be discussed in section 2.5.2 
(F). 
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H) Data analysis 
The data analysis techniques vary in qualitative and quantitative methods; 
however, the purpose of data analysis remains the same. Data analysis helps 
obtain useful and practical information to enable describe the data, identify 
relations between variables and compare them if required and helps predict the 
outcomes of a research. Data analysis is more than just presenting numbers; 
therefore, it is researchers’ responsibility to deal with the data in a strategic, 
intuitive and creative way in order to interpret the data. It is suggested to follow 
a reflective approach for data analysis with awareness of the research question, 
aim, methodological constraints and the use of relevant theory (O’Leary 2017). 
The process of reflective analysis as suggested by O’Leary is described in Figure 
2.5. 
 
Figure 2.5: The process of reflective analysis (O’Leary 2017). 
 
Quantitative research is associated with statistical analysis and classified into 





Table 2.12: Statistical analysis for quantitative research (O’Leary 2017). 
Descriptive statistics Inferential statistics 
Involved the whole targeted population. Involves a sample to represent a population 
and generalise findings. 
Used to describe basic features of a data set 
and summarise variables. 
Used to draw conclusions that extend beyond 
the immediate data. 
Help organise, analyse and present data in a 
meaningful fashion. 
Compares, test and predict future outcomes. 
Provides measures of central tendency, 
dispersion and distribution shapes. 
Provides analysis of variance and hypothesis 
tests. 
Use nominal, ordinal, interval and ratio data 
types. 
Use nominal, ordinal, interval and ratio data 
types. 
Standard calculations in various statistics 
programmes. 
Huge range of statistical tests available. 
Results are presented in form of tables, charts 
and graphs. 
Results are presented in form of probability 
scores. 
 
For the purpose of this doctoral research the survey data were analysed 
descriptively since the whole pool of Clinical pharmacist members of the UKRPG 
and caring for patients with CKD was targeted. The data analysis required the 
use of a statistical software and the latest version of Statistical Package for the 
Social Sciences (SPSS® version 25) was used.  The survey response was not of 
sufficient number to allow the use of inferential statistics to determine any 
differences in sub-groups, hence, was not employed in the analysis. 
2.5.2. Qualitative research approaches 
Qualitative research has made huge strides in social science research in recent 
years (Creswell 2018). Qualitative research is best defined as ‘its ability to 
explore and understand the lived experiences of human and social problems’ 
(O’Leary 2017).  
A) Philosophical assumptions 
It is important to consider the philosophical assumptions, research approaches 
and the most suitable paradigm prior to undertaking a research project. 
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Furthermore, considering the most appropriate methodologies and methods for a 
research is equally important. The philosophical assumptions in relation to 
qualitative research are described in Table 2.4 above.  
For the sake of stage 2 phase 2 of this doctoral research, ontology as a 
philosophical approach deemed most suitable, since the reality is based on the 
experiences and views of the participants aiming to explore the development, 
implementation and evaluation of pharmacist prescribing for patients with CKD in 
the UK. 
B) Methodologies in qualitative research 
Research methodology help signpost the stepwise progress of research process 
to enable generate meaningful findings. There are several qualitative research 
methodologies including ethnography, grounded theory, case study, narrative 
and phenomenology. These methodologies are described in Table 2.13. 
Table 2.13: Qualitative research methodologies. Adapted from Creswell 2014, 2018. 
Method Description Suitable study 
design 
Data generation Analysis   







of a case/s, event 
or process.  
The tools used to 









generation for the 
case/s 
Ethnography  It focuses on 
culture or context.  
Studying similar 
patterns of 
actions of a 
cultural group in a 
natural setting. 
Data collection 




Rich description of 





Grounded theory This method 
derives a general 





Multiple stage of 
data collection to 




Tools used for this 
method are 
mostly in a form 
of series of data 
collection through 
open and axial 
coding 
techniques.   
Data analysis 
through different 
types of coding. 
Narrative It focuses on 
sequences of 
events of 
individuals to form 
a consistent story. 
 
Studying the lives 
of individuals 
through stories of 
individual lives. 





well as analysing 
documents. 
Data analysis by 









enable develop a 
theory.  
Studying the lived 
experiences of 
individuals in 
relation to a 
phenomenon and 
describing it. 
The most suitable 
procedures used 












experiences of a 
phenomenon. 
 
This phase of the doctoral research (stage 2 phase 2) followed a qualitative 
research approach. The aim of this phase was to explore the development, 
implementation and evaluation of pharmacist prescribing (phenomenon) for 
patients with CKD in the UK.  The most suitable methodological approach for this 
phase was phenomenological approach to address the research aim. This 
approach was the most suitable methodology to explore the experience of 
individuals with the same phenomenon in different contexts or settings to enable 
detailed understanding of the practice hence, suggest further development to the 
service (Creswell 2018). One important step to consider when employing 
phenomenological approach is to reflect on, acknowledge and bracket out 
researchers own experiences in the field.  
C) Bracketing 
Bracketing is defined as a method to minimise the potentially negative effects of 
preconceptions that may impact the research process (Tufford and Newman 
2010). Bracketing is a way to protect the researcher from the effects of 
assessing emotionally challenging materials, since the researcher might have a 
connection with the research topic which may have preconceptions that influence 
the data gathering and interpretation process (Tufford and Newman 2010). The 
researcher should address bracketing and incorporate it in the personal 
background statement where all relevant experiences related to the phenomenon 
must be highlighted (Creswell 2018). Neutral stance was considered throughout 
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this doctoral research by acknowledging and bracketing doctoral students 
professional background. 
D) Methods of data generation in qualitative research 
Many different types of data generation methods can be employed in qualitative 
research including observations, interviews, documents and audio-visuals as 
described in Table 2.14. 





Options  Advantages  Disadvantages  
Observations  Complete concealed role of 
participants and research 
 Observer as participant, 
researcher’s role is known. 
 Participant as observer, 
observation is secondary to 
participant role. 
 Complete observer, researcher 
only observes without 
participation. 
 Researcher’s direct 
experience with the 
participant. 
 Researcher can document 
information timely. 
 Uncommon incidences can 
be noted immediately. 
 Good approach for noting 
issues out of the comfort 
zone of participants. 
 Researchers might be seen 
as intrusive. 
 Observed private 
information cannot be 
reported. 
 Researcher might not have 
sufficient observing skills. 
 Certain group of 
participants (e.g. children) 
can be challenging. 
Interviews  Face-to-face, one-on-one, in-
person interview. 
 Telephone-researcher interview 
by phone. 
 Focus group-researcher 
interview group of participants. 
 E-mail, internet interview. 
 Advantageous when 
participants cannot be 
directly observed. 
 Historic information can 
be provided. 
 Line of questioning can be 
controlled by the 
researcher. 
 Provides indirect 
information filtered 
through the views of 
interviewees. 
 Information provided in a 
designated location, not 
the natural field setting. 
 Researcher’s presence may 
bias responses. 
 Participants are different 
with different perceptions. 
Documents  Public documents- minutes of 
meetings or newspapers. 
 Private documents, journals, 
diaries, or letters. 
 Allow a researcher to 
obtain the language and 
words of participants. 
 Convenient and 
unobtrusive source of 
information. 
 Only gives data that 
participants given 
attention to. 
 A written work which save 
time of transcribing. 
 Participants have different 
perceptions. 
 Documents might be 
protected and unavailable 
for access. 
 Access to information can 
be in hard to find locations. 
 Need transcribing or 
scanning. 
 information may be 
incomplete. 
 Documents may not be 






 Art objects 
 Computer messages 
 Sounds 
 Film 
 May be an unobtrusive 
method of obtaining data. 
 Allows participants to 
directly share their reality. 
 Creative and capture 
attention. 
 May be difficult to 
interpret. 
 May not be accessible 
publicly or privately. 
 The presence of an 
observer may be disruptive 
and affect responses. 
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One-to-one interviews seemed to be the most appropriate method of data 
collection in phase 2 of the doctoral research to allow data generation from 
participants individually to allow full exploration of their experiences and views 
around prescribing for patients with CKD. However, telephone interviews were 
deemed to be the best choice for interviewing participants for this phase. Most of 
the interviewees were from different geographical locations in the UK, in addition 
this approach allowed participants to select the date and time of interview 
according to their preferences.  
E) Interview designs 
Since interviews were the selected method for this phase, it is hence important 
to identify different designs of interviews including structured, semi-structured 
and narrative or unstructured as presented in Table 2.15.  
Table 2.15:  Interview types and issues. Adapted from O’Leary 2017. 
 
Type of interview 
 
Definition Strengths Weaknesses 
Structured interviews Follow a pre-established 
set of questions with 
standard approach of 
delivery. 
 Data collection is 
organised with accurate 
response. 
 Can be used in large 
sample. 
 Easy flow of interview due 
to standard format. 
 Replicable as same 
structure of interview. 
 Reliable results and quick 
to obtain. 
 Assessment scope of 
results is limited. 
 Loss of detailed 
responses. 
 Limits participants 
options of selecting 
responses. 
 Research forced to 
follow to the interview 
schedule. 
 Time consuming.  
Semi-structured 
interviews 
A flexible approach with 
guided set of questions, 
however, participants 
response can inform the 
interview direction. 
 Defined question plan to 
allow the researcher to 
prepare and analyse the 
questions in advance. 
 Flexible approach to obtain 
intended data. 
 Most widely used method. 
 Reliable qualitative data 
generation. 
 Reliability factors are 
questionable. 
 Comparison of 
responses become 
difficult since no two 




Known as described 
conversation between 
researcher and 
participant with an aim 
in mind to obtain data, 
mostly in a form of a 
story with minimal 
number of questions. It 
intends to build rapport 
with the participant in 
order to obtain rich 
data. 
 Very easy to express 
without being dictated. 
 Detailed response can be 
obtained. 
 Conversation help 
participants clarify any 
doubts about a question. 
 Flexible approach of the 
whole research process. 
 Time consuming. 
 Due to unstructured 





The most appropriate interview approach for this phase of the doctoral research 
was semi-structured interviews, to allow flexible structure to pursue detailed 
response from the participants in relation to their background and experience. 
This form of interview will also allow in-depth insight for exploring complex 
interventions such as prescribing, experiences, opinions and emotions (Longhurst 
2009). Semi-structured interview was of added value to researcher to be able to 
ask probing questions whenever further information was required or more 
clarification was needed during the interview process. 
F) Population and sampling design in qualitative research 
As described earlier in this chapter, the whole population of the UKRPG was 
targeted for the survey, from which a purposive sample was selected for the 
semi-structured interviews. Furthermore, the researcher also employed snowball 
sampling technique by requesting the interviewees to suggest other clinical 
pharmacists prescribing for patients with CKD to increase the number of 
participants to ensure data saturation. 
G) Sample size in qualitative research 
The misconception of unimportance of numbers of participants in qualitative 
research is tackled by many scholars in the literature (Sandelowski 1995, Coyne 
1997). The most important aspect of sample size in qualitative research is to 
ensure the sample is not too large to challenge extracting meaningful rich data 
and not too small sample to prevent achieving data saturation (Flick 2018). 
Creswell however suggests that sample size in qualitative research depends on 
the design used (i.e. narrative research can include one to two participants; 
phenomenology from three to ten; grounded theory from 20 to 30 participants; 
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ethnography could employ one single group with multiple artefacts and case 
studies might include four to five cases) (Creswell 2018).  
H) Data saturation 
To draw meaningful conclusion from qualitative data analysis, it is important to 
ensure that the data encompass all information needed in relation to research 
aim. To achieve that level of significant data analysis, data saturation needs to 
be attained. Data saturation is defined as the point when no further information 
or data is generated from the participants (Lowe 2018). Data saturation may also 
indicate that no further recruitment of participants required. Two main data 
saturation models described in literature are the thematic saturation model and 
the theoretical saturation model.  
Thematic saturation is achieved when no new themes emerge from the data 
analysis. In contrast, theoretical saturation is achieved when the data obtained 
cannot develop any further theory derived from the data (Glaser and Strauss 
2009).  
Francis et al. proposed four principles for postulating data saturation as 
described the Table 2.16. 
Table 2.16: The four principles for data saturation. Adapted from Francis 2010. 
Principle Description 
 
Setting priori for 
‘initial analysis 
sample’ 
 This priori set the sample size at first round of analysis to allow deciding about 
data saturation. 
 The numbers will depend on the complexity of research question/aim, interview 
schedule, diversity of participants and the type of analysis used. 
 Sampling should be based on stratification factors that are relevant to the study 
aim and objective. 
 Initial sample of at least 10 interviews  
Setting priori for 
‘stopping criterion’ 
 How many more interviews are required to perform and analyse with no new 
emerging themes from the data before deciding that data saturation is achieved. 
 Stopping criterion at further three interviews after the initial 10 interviews without 
generating new themes.  
Independent coders  At least two independent researchers to analysis the data and agreement level 
reported in order to obtain robust and reliable analysis. 




For the qualitative phase of this doctoral research, data saturation was chosen as 
criteria to stop recruiting more participants for the interviews. 
I) Qualitative data analysis 
Wide range of different data analysis techniques are available with two main 
approaches including the deductive approach and the inductive approach. 
Deductive approach involves qualitative data analysis based on a theoretical 
predetermined structure whereas, the inductive approach is not based on a 
theoretical ground and the researcher has may develop theory from analysing 
the data (Creswell 2018). Five main categories of qualitative data analysis widely 
discussed in literature as listed in Table 2.17. 
Table 2.17: Main categories of qualitative data analysis (Creswell 2018). 
 
Analysis category Description 
 
Thematic analysis Defined as identifying patterns of meaning across a set of qualitative data that 









Analysing verbal data or written data in association to its social context, to 




This approach is used to analyse data for a theoretically underpinned research. 




Interpreting qualitative data to develop theory in relation to research question or aim 
in an inductive fashion.  
 
The qualitative phase of this doctoral research was underpinned by a theoretical 
framework and the literature, hence, framework approach to analyse the data 
was the most suitable approach. Details on the use of the theoretical framework 
is covered in section 2.7.1. 




Figure 2.6: Steps of framework approach to data analysis (Creswell 
2018). 
Thematic approach requires systematic steps to perform as described in Table 
2.18. 
Table 2.18: Phases of thematic analysis. Adapted from Braun and Clarke 2006. 
Step of thematic analysis 
 
Description 
1. Familiarisation  
 
This initial phase is to transcribe the data, reading 
and re-reading the data, to become clearly familiar 
with its content. 
 
2. Generating initial codes  This phase involves generating concise labels 
(known as codes) to recognise important features of 
the relevant data to answer the research question. It 
also involves coding the complete dataset, and after 
that, organising all data relevant to each other. 
 
3. Search for themes  
 
Sorting codes into potential themes. Gathering all 
data relevant to each potential theme.  
 
4. Review themes  
 
Enhance potential themes, confirm codes within 
theme are coherent together. Ensure different 
themes are different from each other. 
 
5. Define and name themes  
 
Further analysis to refine the details of each theme, 
and clearly produce each theme’s definition and 
name to distinguish the themes from each other.  
 
6. Final analysis and report writing  
 
Final analysis of extracts to demonstrate themes 
 
 
Step 1: Data familarisation: through listening to the recordings, 
transcribing, reading the transcripts, taking notes of important 
details and repeating the step as frequently as needed.
Step 2: Initial coding: to the data using the underpinned theory as 
a starting point.
Step 3: Indexing: by assiging all important statements to the 
relevant construct of the framework as well as to other meaningful 
themes.  
Step 4: Chating: synthesis of the data by matching the themes 
with the participants quotes.
Step 5: Mapping and interpreting: map emerging themes with the 
framework domains and constructs, writing the interpretations to 
the findings in details.
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The method used for this qualitative research was semi-structured interviews. 
Data analysis was performed by following stepwise approach from word to word 
transcribing (verbatim) to grouping the data and coding as guided by the 
underpinned theoretical framework. The findings were categorising into themes 
based on the 29 constructs of the theoretical framework.  Starting from an 
accurate transcript of data followed by coding in most coherent, distinctive and 
consistent themes in the theoretical context with CFIR. data were then analysed 
and interpreted by matching the themes to the participants quotes.  
2.6. Ethical principles  
Healthcare research is subject to consideration to meeting ethics standards 
ensuring respect to all research subjects and protection of their rights (Masic 
2014). The main aim of any research is to add wealth of knowledge in an area of 
interest but this aim must not take advantage over rights of the involved 
individuals. It is therefore the responsibility of the research to ensure that the 
protection of individuals, dignity, integrity, rights, confidentiality and privacy of 
the participants is protected (Slowther 2006, Masic 2014). This could be achieved 
by meeting all legal, and ethical standards of the organisation where the 
research is conducted (Stevenson 2015). 
Core ethical considerations for any health-related research includes respect of 
autonomy, justice, prevention of harm and promoting benefit (Slowther 2006). 
2.6.1. Respect of autonomy 
To maintain integrity of the participants, it is important to provide them with 
detailed information sheet with information about the research (accurate, clear 
and comprehensive), as well as to obtain consent for participation with 
appropriate documentation.  
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Participants involved in this doctoral research were provided with information 
leaflet about the study by sending an introductory email through the UKRPG 
group administrator. The leaflet included information about the research aim and 
objectives, research related frequently asked questions and information on 
participation rights and data protection. The participants were informed that by 
completing the questionnaire their consent will be given to share the anonymised 
data with the research team and for publication. However, for phase 2 
(interviews) a signed consent was obtained from each participant prior to 
scheduling the interview. 
2.6.2. Justice 
The main issued to be considering to maintain justice is the compliance with all 
legislations and policies of a given organisation and ensuring all participants are 
treated in the same way in relation to the research. 
This doctoral research was in accordance with the research ethics at RGU (Robert 
Gordon University 2016a) and the research governance and integrity policy 
(Robert Gordon University 2016b). Details of ethical considerations for each 
phase of this doctoral research is presented in the relevant Chapter for each 
phase.  
2.6.3. Prevention of harm 
A key element of any research ethical codes in the importance to eliminate to 
minimise the potential risk of harm to participants or even to the research team. 
Such risks can be associated more with clinical trials however, some potential 
risks such as identification of participants, disclosure of sensitive information may 
be potential risks related to any discipline (Slowther 2006).  
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For the purpose of this doctoral research, all phases of the research were 
designed with great consideration to participant’s identification confidentiality; 
where needed, participants were described by assigned numbers and all 
identifiers were deleted from the transcripts to ensure anonymity in accordance 
with the requirements of the Data Protection Act (2018).   
2.6.4. Promotion of benefit 
General and specific benefits of the research findings to the participants and the 
society is an important aspect to encourage participation in the research. These 
benefits must be clearly indicated at the time of applying for ethical approval by 
demonstrating the primary aim of the research, rationale of the study and 
potential benefits to all stakeholders.  
The recruited participants for this doctoral research were all professional 
pharmacists practising in the care for patients with CKD across the UK. All the 
approached participants were informed in the introductory email that the 
research findings may help improve patient care and provide evidence base for 
prescribing practice and clinical practice for the care for patients with CKD. 
2.7. The use of theory to underpin approaches to research 
Consideration of theoretical underpinning in research is an important aspect to 
ensure addition of meaningful findings of research to fill the gap in knowledge.  
Use of theory can enhance robustness and rigour of both quantitative and 
qualitative research respectively, with an added value when transferring research 
findings into practice (Stewart and Klein 2016). 
Theoretical underpinning may be considered at any phase of a programme of 
research from developing the research questions, setting aim and objectives, 
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formulating the proposal, constructing data gathering tools and data analysis to 
interpreting the results (Stewart and Klein 2016).  
Use of theories, models and frameworks in implementation research is gaining 
popularity across disciplines. 
A theory is defined as a statement of relationships between units or constructs 
observed in the experimental world leading to clarification of why and how 
certain relationships lead to specific events (Wacker 1998).  
A model is best known as a simpler version of a phenomenon and a certain 
aspect of a phenomenon, which cannot necessarily represent the reality. Models 
are often similar to theory with no clear differentiation between them, however, 
models are known to be specifically explanatory, whereas theory is both 
explanatory and descriptive.  
A framework generally represents a structure, overview, system, outline or plan 
consisting of multiple descriptive categories such as constructs, variables or 
concepts and the associations between them which are supposed to explain a 
phenomenon of interest (Nilsen 2015). A framework differs from a theory or a 
model by not being explanatory but only describing the phenomenon within a 
category (Frankfort-Nachmias 2008).  
The aims of use of theories, models and frameworks in implementation science is 
to be able to describe and guide the process of translating research findings into 
meaningful outcomes in practice, to identify the facilitators and barriers for 
implementation and to be able to evaluate the implementation effectively as 
described in Figure 2.7. 
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Figure 2.7: Three aims of the use of theoretical approaches in 
implementation science and the five categories of theories, models and 
frameworks (Nilsen 2015). 
The five main categories of theories, models and frameworks used in 
implementation research are described in Table 2.19. 
Table 2.19: Categories of theories, models and frameworks used in implementation 
science (Nilsen 2015). 
Category Description 
Process models The aim is to specify the phases in the process of translating research 
findings into practice.  
 
Determinant frameworks The aim is to understand and/or explain the facilitators and barriers 
influencing the implementation outcomes. Some frameworks also 
specify relationships between some types of determinants. 
 
Classic theories  Classic theories usually originate from different fields, e.g. psychology, 
sociology and organisational theory. 
They can be useful to understand and/or explain different of aspects of 
implementation. 
 
Implementation theories Implementation theories are developed by researchers (from scratch 
or by adapting existing theories) to offer understanding and/or 
explanation of different aspects of implementation. 
 
Evaluation frameworks These frameworks help evaluate certain aspects of implementation in 


























This doctoral research was based on the determinant and evaluation frameworks 
given the aim for this research was to scope structures, processes and related 
outcomes of clinical pharmacy practice in the care for patients with CKD. There 
are a number of frameworks to evaluate services or interventions and determine 
facilitators and barriers referred to in the literature. Some of these frameworks 
were described by Nilsen (2015) including RE-AIM (Reach, Effectiveness, 
Adoption, Implementation, Maintenance) and PRECEDE-PROCEED (Predisposing, 
Reinforcing and Enabling Constructs in Educational Diagnosis and Evaluation-
Policy, Regulatory, and Organizational Constructs in Educational and 
Environmental Development). Despite evaluation frameworks being described in 
a category of their own, it has been suggested that the other four categories as 
listed in Table 2.18 may be used in evaluating services or interventions (Nilsen 
2015). Hence, frameworks such as the Theoretical Domains Framework (TDF) 
(Cane 2012), Normalisation Process Theory (NPT) (Murray 2010) and 
Consolidated Framework for Implementation Research (CFIR) (Damschroder 
2009) have been used as determinant and evaluation theories and frameworks 
(Nilsen 2015). 
Given that the focus of Stage 2 of this doctoral research was to explore 
pharmacists’ clinical and prescribing practice in terms of experiences and 
behaviours, as well as to determine the barriers and facilitators for implementing 
such services it was suitable to underpin the research with CFIR which involves 
large number of constructs for implementation research. 
2.7.1. The Consolidated Framework of Implementation Research 
The Consolidation Framework for Implementation Research (CFIR) is a meta-
framework which goes beyond assessing intervention effectiveness, to identifying 
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contextual influences that explain the heterogeneity of implementation success 
across settings using multiple theories (Damschroder 2009). The CFIR was 
developed in 2009 by researchers associated with the Quality Enhancement 
Research Initiative (QUERI) to lead research that encourages rapid-cycle 
evaluation of the implementation of a complex health-related intervention 
systematically, and the use the findings as a guide to improve implementation 
(Keith 2017). The CFIR was developed after extensive review of published 
theories (19 theories, frameworks and models) to help identify and evaluate 
translation of research findings into practice. Table 2.20 below shows the models 
reviewed in the development of the CFIR, which has been described as a 
theoretical framework completing the contribution of the existing evidence base 
related to implementation research, rather than replacing it (Damschroder 
2009).  
Table 2.20: List of models analysed for the development of the CFIR. Adapted from 
Damschroder 2009. 
1. Conceptual model for considering the determinants of diffusion, dissemination and 
implementation of innovations in health service delivery and organisation (Greenhalgh 2004) 
2. Conceptual model for implementation effectiveness (Klein and Sorra 1996) 
3. Dimensions of Strategic Change (Pettigrew 1992) 
4. Theory-based Taxonomy for Implementation (Leeman 2007) 
5. PARiHS Framework: Promoting Action on Research Implementation in Health Services (Rycroft-
Malone 2004) 
6. Ottawa Model of Research Use (Graham 2004) 
7. Conceptual Framework for Transferring Research to Practice (Simpson 2002) 
8. Diagnostic/Needs Assessment (Kochevar and Yano 2006) 
9. Stetler Model of Research Utilisation (Stetler 2001) 
10. Technology Implementation Process Model (Edmondson 2001) 
11. Replicating Effective Programs Framework (Kilbourne 2007) 
12. Organisational Transformation Model (VanDeusen 2007) 
13. Implementation of Change: A Model (Grol 2007) 
14. Framework of Dissemination in Health Services Intervention Research (Mendel 2008) 
15. Conceptual Framework for Implementation of Defined Practices and Programs (Fixsen 2005) 
16. Will it Work Here? A Decision-maker's Guide to Adopting Innovations (Brach 2008) 
17. Availability, Responsiveness and Continuity: An Organisational and Community Intervention 
Model (Glisson 2008) 
18. A Practical, Robust Implementation and Sustainability Model (PRISM) (Feldstein 2008) 
19. Multi-level Conceptual Framework of Organisational Innovation Adoption (Frambach 2002) 
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2.7.2. CFIR domains and constructs 
The CFIR is comprised of five major domains: intervention characteristics, outer 
setting, inner setting, characteristics of individuals and process. There are 39 
underlying constructs and sub-constructs that can potentially influence efforts to 
change the practice and each sub-construct is clearly defined as listed in Table 
2.21. The constructs and sub-constructs can be used as implementation and 
evaluation criteria in three different ways: they may  
1. Raise awareness for potential influential factors,  
2. Facilitate the analysis of pivotal processes and outcomes and  
3. Help organise all findings of an implementation process to explain the 
outcomes (i.e., to understand what worked where and why).  
CFIR can also be used to identify potential barriers and facilitators if used before 
or during an implementation. This, in turn, helps guide the selection of strategies 












Table 2.21: Consolidated Framework for Implementation Research Constructs. Adapted 
from Damschroder 2009. 




I. INTERVENTION CHARACTERISTICS   
A Intervention Source Perception of key stakeholders about whether the intervention is 
externally or internally developed. 
B Evidence Strength & Quality Stakeholders’ perceptions of the quality and validity of evidence 
supporting the belief that the intervention will have desired 
outcomes. 
C Relative Advantage Stakeholders’ perception of the advantage of implementing the 
intervention versus an alternative solution. 
D Adaptability The degree to which an intervention can be adapted, tailored, 
refined, or reinvented to meet local needs.  
E Trialability The ability to test the intervention on a small scale in the 
organisation, and to be able to reverse course (undo 
implementation) if warranted. 
F Complexity Perceived difficulty of implementation, reflected by duration, 
scope, radicalness, disruptiveness, centrality, and intricacy and 
number of steps required to implement.   
G Design Quality & Packaging Perceived excellence in how the intervention is bundled, 
presented, and assembled. 
H Cost Costs of the intervention and costs associated with 
implementing the intervention including investment, supply, and 
opportunity costs.  
II. OUTER SETTING   
A Patient Needs & Resources The extent to which patient needs, as well as barriers and 
facilitators to meet those needs, are accurately known and 
prioritised by the organization. 
B Cosmopolitanism The degree to which an organization is networked with other 
external organizations. 
C Peer Pressure Mimetic or competitive pressure to implement an intervention; 
typically, because most or other key peer or competing 
organisations have already implemented or are in a bid for a 
competitive edge. 
D External Policy & Incentives A broad construct that includes external strategies to spread 
interventions, including policy and regulations (governmental or 
other central entity), external mandates, recommendations and 
guidelines, pay-for-performance, collaboratives, and public or 
benchmark reporting. 
III. INNER SETTING 
A Structural Characteristics The social architecture, age, maturity, and size of an 
organisation. 
B Networks & Communications The nature and quality of webs of social networks and the 
nature and quality of formal and informal communications within 
an organization. 
C Culture Norms, values, and basic assumptions of a given organization. 
D Implementation Climate The absorptive capacity for change, shared receptivity of 
involved individuals to an intervention, and the extent to which 
use of that intervention will be rewarded, supported, and 
expected within their organization. 
1 Tension for Change The degree to which stakeholders perceive the current situation 
as intolerable or needing change. 
2 Compatibility The degree of tangible fit between meaning and values attached 
to the intervention by involved individuals, how those align with 
individuals’ own norms, values, and perceived risks and needs, 
and how the intervention fits with existing workflows and 
systems. 
3 Relative Priority Individuals’ shared perception of the importance of the 
implementation within the organization. 
4 Organizational Incentives & Rewards Extrinsic incentives such as goal-sharing awards, performance 
reviews, promotions, and raises in salary, and less tangible 
incentives such as increased stature or respect. 
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 Table 2.21 (continued...): Consolidated Framework for Implementation Research Constructs. 
Adapted from Damschroder 2009. 




5 Goals and Feedback The degree to which goals are clearly communicated, acted 
upon, and fed back to staff, and alignment of that feedback with 
goals. 
6 Learning Climate  A climate in which: a) leaders express their own fallibility and 
need for team members’ assistance and input; b) team 
members feel that they are essential, valued, and 
knowledgeable partners in the change process; c) individuals 
feel psychologically safe to try new methods; and d) there is 
sufficient time and space for reflective thinking and evaluation. 
E Readiness for Implementation Tangible and immediate indicators of organizational commitment 
to its decision to implement an intervention. 
1 Leadership Engagement Commitment, involvement, and accountability of leaders and 
managers with the implementation. 
2 Available Resources The level of resources dedicated for implementation and on-
going operations, including money, training, education, physical 
space, and time. 
3 Access to Knowledge & Information Ease of access to digestible information and knowledge about 
the intervention and how to incorporate it into work tasks. 
IV. CHARACTERISTICS OF 
INDIVIDUALS 
  
A Knowledge & Beliefs about the 
Intervention 
Individuals’ attitudes toward and value placed on the 
intervention as well as familiarity with facts, truths, and 
principles related to the intervention.  
B Self-efficacy Individual belief in their own capabilities to execute courses of 
action to achieve implementation goals. 
C Individual Stage of Change Characterization of the phase an individual is in, as he or she 
progresses toward skilled, enthusiastic, and sustained use of the 
intervention. 
D Individual Identification with 
Organization 
A broad construct related to how individuals perceive the 
organization, and their relationship and degree of commitment 
with that organization. 
E Other Personal Attributes A broad construct to include other personal traits such as 
tolerance of ambiguity, intellectual ability, motivation, values, 
competence, capacity, and learning style. 
V. PROCESS 
A Planning The degree to which a scheme or method of behavior and tasks 
for implementing an intervention are developed in advance, and 
the quality of those schemes or methods. 
B Engaging Attracting and involving appropriate individuals in the 
implementation and use of the intervention through a combined 
strategy of social marketing, education, role modeling, training, 
and other similar activities. 
1 Opinion Leaders Individuals in an organization who have formal or informal 
influence on the attitudes and beliefs of their colleagues with 
respect to implementing the intervention. 
2 Formally Appointed Internal 
Implementation Leaders 
Individuals from within the organization who have been formally 
appointed with responsibility for implementing an intervention 
as coordinator, project manager, team leader, or another similar 
role. 
3 Champions Individuals who dedicate themselves to supporting, marketing, 
and ‘driving through’ an [implementation], overcoming 
indifference or resistance that the intervention may provoke in 
an organization. 
4 External Change Agents Individuals who are affiliated with an outside entity who formally 
influence or facilitate intervention decisions in a desirable 
direction. 
C Executing Carrying out or accomplishing the implementation according to 
plan. 
D Reflecting & Evaluating Quantitative and qualitative feedback about the progress and 
quality of implementation accompanied with regular personal 
and team debriefing about progress and experience. 
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2.7.3. Use of CFIR in healthcare practice research  
The CFIR has been cited by more than 1,660 scholars according to PubMed 
citation report. The CFIR framework has been used across a wide range of 
health-related research and promoted advancement in implementation research.  
Findings from CFIR based research help researchers understand more about 
what works, where and why (Damschroder 2009). Use of the CFIR also aids 
researchers in predicting implementation success across different settings; it 
may also be used as a guide to influential evaluation of implementation services 
(Damschroder 2009). One of the uses of the CFIR framework is in pre-
implementation assessments to enable identification of potential facilitators and 
barriers to implementation of a service or intervention from the perspective of 
the individuals and organisations involved in the implementation. 
The CFIR has been widely used in a range of clinical pharmacy related studies 
and reviews to explore the implementation of new innovations and services 
(Robins 2013, Weir 2019, Baumgartner 2020, King 2020). 
The CFIR provides a list of clearly defined constructs and sub-constructs which 
can be used as a guide to aid conceptualisation of the research idea, generate 
appropriate research questions, help design the data collection tool and analyse 
and interpret data. 
This doctoral research was guided by the use of the CFIR throughout both phases 
of Stage 2 to categorise and quantify elements of pharmacists’ clinical and 
prescribing practice and to understand the heterogeneity of this practice. Data 
collection tools for the questionnaire and the interviews, data analysis and 
interpretation were informed by CFIR constructs. 
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2.8. Quality assurance in quantitative and qualitative research 
To ensure the evidence based on research findings are reliable for quantitative 
research, trustworthy for qualitative research and applicable for both types of 
research to a wider context it is important to consider the quality criteria of any 
research approach. Despite the similarity in quality standards for both qualitative 
and quantitative research, the approaches are different in terms of conception 
and operationalisation (Frambach 2013).  
2.8.1. Quality assurance in quantitative research 
Robustness in quantitative research is achieved by four important principles in 
order to add new trustworthy knowledge to the body of evidence (Frambach 
2013). 
The first important principle is the truth value of evidence, which can be attained 
through internal validity known as the level of accuracy of the findings in relation 
to the independent variables (Frambach 2013).  
The second quality principle is around the applicability of evidence by 
maintaining external validity of the research. External validity is related to the 
extent to which the findings are generalisable to the wider population (Frambach 
2013).  
The third principle is related to the consistency of the evidence by means of 
reliability which is defined as (the extent to which the findings are consistent if 
the research is repeated) (Frambach 2013). 
The fourth and final principle of research quality is associated with the neutrality 
of evidence which is achieved through eliminating personal biases that could 
impact the quality of the research known as objectivity (Frambach 2013).  
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Table 2.22 presents the four quality principles for quantitative research with 
potential techniques to enhance research quality.  
Table 2.22: The four quality principles for quantitative research. Adapted from 
Frambach 2013. 




Techniques to enhance quality 




 Accurate sample size calculation (power calculation). 
 Sufficient description of intervention. 
 No loss of participants, or clear justification for non-respondents. 
 Standardisation of intervention. 






 Population generalisability by random or stratified sampling 
techniques. 
 Potential for replicating the research (ecological generalisability). 





Reliability   Ability to repeat measures to ensure internal consistency (classical 
test theory). 
 Evaluate if any variance impacting the outcomes (generalisability 
theory). 





Objectivity   Use of double blinding techniques for data collection. 
 Anonymity of participants identification. 
 Ability to avoid judgemental interpretation to findings. 
 Data protection for accountability. 
 
2.8.2. Quality assurance in qualitative research 
To establish rigour in qualitative research for trustworthy findings, it is suggested 
to follow the four quality principles for qualitative research (Frambach 2013). 
The first principle of truth values of evidence can be achieved by credibility which 
is defined as ‘whether or not the findings are consistent with participants views 
and beliefs in order to be trustworthy by the wider population’ (Frambach 2013).  
The second principle of applicability which can be accomplished through 
transferability of the findings to other contexts, other people or other settings 
(Frambach 2013).  
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The third quality principle is related to consistency of the evidence by means of 
dependability which is related to the logical research process (Frambach 2013). 
The fourth quality principle is concerned with the neutrality of evidence which 
could be attained by confirmability that the results are solely based on the 
extensive process of analysis and reflects participants views instead of 
researchers’ biases (Frambach 2013).  
Table 2.23 presents the four quality principles for qualitative research with 
potential techniques to enhance research quality. 
Table 2.23: Quality principles for qualitative research and techniques to enhance 
research quality. 
Quality principle Criteria in 
qualitative 
research  
Techniques to enhance quality 
Truth value of 
evidence  
Credibility   Use of different data source (data triangulation). 
 Used of multiple methods (methodological triangulation). 
 Involvement of several researchers (investigator triangulation). 
 Use of multiple theories (theory triangulation). 
 Data collection over a timeframe (prolonged engagement). 





Transferability   Detailed description of findings to provide meaningful results (thick 
description). 
 Thorough explanation of sampling strategy. 





Dependability   Reach data saturation until no new themes emerge. 
 Continuous data analysis to inform further data collection (iterative 
data collection). 
 Regular data analysis to ensure no further themes emerging 
(iterative data analysis). 
 Being open and flexible towards the research topic and process 




Conformability   Looking for available literature to confirm or disconfirm findings. 
 Discussion of research process and results with experts in field 
(peer debriefing). 
 A record of reflection on the process and any influences of the 
researcher (reflexivity). 
 Clear documentation of the research process, the steps and any 
decision made during the research with reasoning (audit trail).  
 
2.8.3. Bias in research 
Bias is defined as any tendency to diverge from the truth in any step in 
conducting a research from setting research questions, designing data collection 
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tool, data collection process, analysis and interpretation leading to false 
conclusions (Šimundić 2013).  Each study type has different methodology-related 
limitations with potential for various types of biases. Therefore, it is important for 
the researcher to be aware of the possible sources of biases so that these may 
be addressed and minimised. Table 2.24 describes the most common form of 
biases in research whether it is researchers’ bias or participants’ bias (Sarniak 
2015). 




Type of bias 
 
Description  Mitigation approaches 
Confirmation bias Research have certain beliefs and 
hypothesis and what to confirm these 
beliefs through participants responses.   
To mitigate confirmation bias, 
researcher must regularly assess 
participants responses and challenge 
their own hypothesis and assumptions.   
Culture bias Researcher view at the issues through 
cultural lens which lead to creates 
assumptions in relation to influences and 
motivations. It can also lead to being 
judgmental towards a culture based on 
own cultural values. 
Researcher need to respect cultural 
differences and take it into account 
without making assumptions. 
Question order 
bias 
Setting questions in a leading way that 
could influence answers. Participants are 
driven to certain answers as an impact to 
question wording that could affect their 
thoughts and attitudes to the subsequent 
question. 
Although this type of bias is 
unavoidable, asking some general 
questions before being very specific, 
and positive questions before negative 
could minimise bias.  
Leading question 
bias 
This type of bias lead to biased results as 
researchers try to achieve contain answer 
either to confirm a hypothesis, build 
rapport with respondents or overrate the 
understanding of the respondents. 
This could be minimised by asking 
questions in participants language and 
understandings bearing in mind their 
thoughts. No assumptions should be 
made about the relationship between 
respondent’s emotions and behaviours. 
 
Halo effect bias Type of cognitive bias where the 
researcher or participants have the 
potential to have an impression on further 
responses based on a single trait which 
might influence multiple judgments or 
ratings. Mostly in qualitative research. 
This can be minimised if the researcher 
knows what are they looking for and 
how to interpret the responses by 
asking the right question at the right 
order. As well as being aware of the 




Acquiescence bias Also known as ‘yes saying’ bias, where 
the respondents tend to pick the positive 
responses and some would just want to 
complete the questionnaire with any 
response.  
To mitigate this type of bias, 
researchers must consider respondents 
views when designing the tool rather 
than providing an obvious right answer. 
Social desirability 
bias 
This type of bias occurs as participants 
desire to pick the most liked and 
acceptable answer to present themselves 
in best position. 
Researcher must assure the 
respondents about the anonymity of 
responses and well as making it clear 
while questioning that it they can 
answer according to their thoughts and 
not according to social desirability. 
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Using third person language could also 
help minimise such biases.  
Habituation bias Respondents select similar answers to 
similar format of questions. Also known as 
‘biological response’. 
To minimise this type of bias, 
researchers should formulate the 
questions in a way to keep respondents 
engaged and use different types of 
wordings for further questions. 
Sponsor bias When the respondents know the 
researcher or the sponsor of the research, 
so they tend to answer in a way that 
creates bias. 
To minimise such biases, researchers 
must use neutral stance, no 
reinforcement to certain positive 
answers. 
 
All types of biases were considered at each stage of this doctoral research. 
Information on how bias was considered and addressed in each phase is 
presented in Chapters 4 and 5.  
2.8.4. Reflexivity in research 
Reflexivity is defined as ‘an awareness of the effect of the researcher on the 
research process’ (Barry 1999). In 2017, Attia and Edge classified reflexivity as 
two interrelating elements: prospective reflexivity which is related to the effect of 
the researcher on the research and retrospective reflexivity which associated 
with the effect of the research on the researcher (Attia and Edge 2017).   
Reflexivity has been used in qualitative research to enable researchers present 
rigorous and quality findings of their research by being aware about their values 
and background that may influence the research process (Palaganas 2017). 
Reflexive practice is considered the gold standard to ensure trustworthiness of 
research results. Reflexivity is not an easy process yet is considered to be one of 
the main pillars of qualitative research. A researcher involved in qualitative 
research can have a great impact on the process of data generation and 
interpretation, therefore reflexivity, through acknowledgement about self-efficacy 
and the potential to have unconscious influence on the research, is important 
(Dodgson 2019).      
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The researcher account responsible to clearly identify or describe all the relevant 
associations between themselves and the respondents (such as cultural 
background, social status, professional stance, ethnicity, sex and age). 
Acknowledging the similarities or the differences will enhance credibility of the 
research findings (Berger 2015).  
The doctoral student and the research team ensured that all measures as 
described in literature were considered throughout this doctoral research 
programme to minimise the impact of the research team’s professional 
background on the quality of the research. The research student’s background as 
a clinical pharmacist was acknowledged and bracketed to eliminate or minimise 
any bias, however, the research student has no prescribing qualifications nor 
experience hence, all measures were taken to try to minimise the impact on the 
qualitative research process. The research student was aware of the impact of 
being a pharmacist and the potential to affect the research process however, the 
student acknowledged and bracketed her background throughout the process of 
this research and was guided by experienced supervisors who are experienced 
pharmacists and academics to try to minimise any such influence. 
2.9. Summary 
This doctoral research followed a positivist approach and was performed in two 
stages. The first stage was a systematic review of the available literature on 
clinical pharmacy practice in the care of patients with CKD (Al Raiisi 2017, Al 
Raiisi 2019). Findings of the systematic review were used to identify the gap in 
the knowledge base hence, informed the development of Stage 2, the data 
generation stage of the doctoral programme which was in two phases. An 
explanatory sequential mixed-method approach was employed for this, 
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underpinned CFIR as a theoretical framework. Data were generated by carrying 
out two phases of research with members of the UKRPG all across the UK: 
Phase 1: an online survey to determine the behaviours and experiences of 
pharmacist members of the UK Renal Pharmacy Group on provision of care of 
patients with Chronic Kidney Disease.  
Phase 2: the qualitative interview phase aimed to explore the development, 
implementation and evaluation of pharmacist prescribing for patients with 
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3.  Introduction 
This chapter provides details on the systematic review carried out by the doctoral 
student on clinical pharmacy practice in the care of Chronic Kidney Disease 
patients. A systematic review was performed as phase 1 of this doctoral research 
to provide a base for the development of the research programme.  
The previous chapter illustrated the types of reviews with details on the steps to 
conduct a systematic review. As described earlier in Chapter 2, systematic 
reviews appraise, synthesise and report pertinent literature that are directly 
related to the review questions.  
Synthesis of quantitative studies can either be descriptive/narrative or statistical 
(meta-analysis). Heterogeneous data as analysed descriptively with clearly 
identifying the source of potential heterogeneity (JBI 2013). This systematic 
review was appropriate for narrative synthesis due to heterogeneity in the data 
obtained from the included papers. The systematic review was published in 2019 
(Alraiisi 2019). 
3.1. Search of existing systematic review on the topic 
Following databases were searched to identify and pre-existing systematic review 
within the topic proposed by the doctoral student: the Cochrane databases of 
systematic reviews, the centre of reviews and dissemination, Medline, PubMed, 
International Pharmaceutical Abstracts and google scholar. One similar 
systematic review was identified. In 2012, Salgado et al. published a systematic 
review, ‘Pharmacists’ interventions in the management of patients with chronic 
kidney disease: a systematic review’ which included synthesis of the peer 
reviewed literature to March 2010 (Salgado 2012). Given the developments in 
clinical pharmacy globally, it was likely that further research has been reported 
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since that date. There is a need to further establish the evidence base of the 
impact of clinical pharmacy in the care of CKD patients. 
3.2. Systematic review aim and questions 
The aim of this review was to appraise, synthesise and present the available 
evidence for the structures, processes and related outcomes of clinical pharmacy 
practice as part of the multidisciplinary care of patients with CKD. The specific 
review questions were: 
• What clinical pharmacy practice related resources (structures, e.g. the 
multidisciplinary team, clinical pharmacy skill mix and time allocation) are in 
place and how are these matched to healthcare needs and demands to enable 
provision of care to chronic kidney disease (CKD) patients? 
• What activities are performed (processes, e.g. medication review, prescribing) 
to care for patients with CKD, how and when are they performed? 
• What are the outcomes of the structure and the processes on the effectiveness 
(Economic, Clinical, and Humanistic Outcomes (ECHO) model) (Kozma 1993) of 
care provided? 
3.3. Ethical considerations 
The Ethics panel of the School of Pharmacy & Life Sciences, Robert Gordon 
University indicated that ethics approval was not required for this systematic 
review. 
3.4. Review protocol development 
The protocol was constructed in accordance with PRISMA-P (Preferred Reporting 
Items for Systematic review and Meta-Analysis Protocols) standards (Moher 
2015). The protocol of this systematic review was accepted and registered with 
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the International Prospective Register of Systematic Reviews (PROSPERO). The 
registration number is CRD42017065258 (Appendix 3.1) (Al Raiisi 2017).  
3.5. Method 
3.5.1. Data Sources 
The systematic review  was conducted and reported in accordance with PRISMA 
(Preferred Reporting Items for Systematic Review and Meta-Analysis) standards 
(Moher 2010).  
The Cochrane database was searched to identify any relevant systematic 
reviews. An electronic search of relevant databases (PubMed, International 
Pharmaceutical Abstracts (IPA), Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), Medline and Scopus) was conducted from March 2010 to 
December 2018 thus providing an update on the review of Salgado et al. 
(Salgado 2012). The search was carried out using Medical Subject Headings 
(MeSH) and other appropriate subject headings and text words where applicable. 
Scoping searches were conducted prior to finalising the search strategy. Boolean 
operators such as truncations (*), wild cards ($), adjacent search options (e.g. 
adj2) were used where relevant. The following grouped terms were initially 
searched separately then in combination by two independent reviewers (FA & 
SC). The primary search was conducted using the improved search strategy of 
the same terms as the original review as follows: 
PubMed, IPA, CINAHL: (“pharmaceutical services” [MH+] OR “pharmacy” [MH+] 
OR “Pharmacies” [MH] OR “Pharmacists” [MH] OR “clinical pharmacist*” [TI / AB 
/ SU] OR “clinical pharmacy” [TI / AB / SU] OR “clinical pharmacies” [TI / AB / 
SU] OR “pharmacist*” [TI / AB / SU] OR “pharmaceutical services” [TI / AB / SU] 
OR “pharmacies” [TI / AB / SU] OR “pharmacy” [TI / AB / SU]) AND (“kidney 
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diseases” [MH+] OR “renal replacement therapy” [MH+] OR “proteinuria” [MH+] 
OR “CKD” [TI / AB / SU] OR “nephropathy” [TI / AB / SU])  
Scopus: 
(“Pharmaceutical care” [TI/ABS/KEY] OR “Pharmacist” [TI/ABS/KEY] OR “Clinical 
pharmacy” [TI/ABS/KEY]) AND (“Chronic Kidney Disease” [TI/ABS/KEY] OR 
“Renal replacement Therapy” [TI/ABS/KEY] OR “Haemodialysis” [TI/ABS/KEY] 
OR “Kidney failure” [TI/ABS/KEY]) 
The bibliography list of included studies was reviewed to further identify 
additional references.  
3.5.2. Study Selection and Data Extraction 
Only quantitative studies (randomised and non-randomised controlled and 
uncontrolled trials, cohort studies and before and after evaluations) published in 
peer-reviewed journals were included in the review. Papers published in English 
and focusing on researching clinical pharmacy practice and the role of the 
pharmacist in managing patients with CKD were included. Studies not addressing 
the topic, literature based only on conceptual models, i.e. lacking empirical 
evidence, grey literature including conference proceedings, abstracts and 
unpublished studies were excluded. Observational studies were excluded since 
they did not address the aim of this review. 
Title and abstract screening and quality assessment for inclusion were conducted 
independently by two reviewers (FA and SC), with any disagreements resolved 
by discussion with a third independent reviewer (DS). 
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3.5.3. Quality assessment 
An independent, duplicate quality assessment of each study was undertaken (DS, 
TJ, FA & SC). All controlled, uncontrolled and descriptive studies were assessed 
using the mixed-methods appraisal tool (MMAT) (Appendix 3.2), a validated and 
unique tool for appraising different types of study designs (Pluye 2011). All 
controlled studies included in this review were additionally assessed for quality 
using the Downs and Black’s (Appendix 3.3) method in line with the original 
review (Downs and Black 1998), a validated tool with a scoring scale consisting 
of 27 questions grouped into five domains (reporting, external validity, bias, 
confounding and power). The total score is 32 and is expressed as rates, the 
higher the score the better the quality of the paper in terms of methodology 
(maximum is 1) (Downs and Black 1998). To classify scores, the approach of 
Machado et al. was applied (Machado 2007), (i.e. < 0.5 was considered ‘weak’, 
0.5 – 0.69 were ‘fair’, 0.7 – 0.79 ‘good’ and 0.8 – 1.0 ‘very good’).  
3.5.4. Data extraction  
Data extracted included: primary author, year of publication, aim/ objectives, 
design, duration, setting, participants, pharmacist interventions, key findings or 
main outcomes and conclusion. Structures, processes and outcomes were 
adapted from Donabedian’s quality of care model (Donabedian 1988). Structure 
was defined as the ‘resources required for the pharmacist to be able to provide 
care to renal patients such as requiring special training, availability of policies 
and procedures for practice etc.’. Process was defined as ‘the activities that are 
performed by the pharmacist on a daily basis or on specific intervals and how 
and when they are performed. These activities may include: daily clinical rounds, 
involvement in patients’ management plans, medication reviews, therapeutic 
recommendations and pharmacist prescribing. Outcome measures included 
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clinical outcomes such as: clinical parameters, medication-related adverse 
events, mortality and morbidities, humanistic outcomes such as: quality of life 
and economic outcomes such as: rate of hospitalisation and cost of inappropriate 
therapies. In addition, pharmacists’ intervention was defined in the previous 
review as “any action with the aim of modifying the process of use of drugs, 
either in patients’ activities or in medical or health care practitioners’ activities” 
(Salgado 2012).  
3.5.5. Data synthesis 
Due to heterogeneity in the data obtained from the included papers (type of 
patients, study design, outcomes measured), only descriptive and narrative 
synthesis was possible. All findings were considered by two independent 
reviewers to ensure robustness and consistency in execution of the review 
process.  
3.6. Results 
3.6.1. Study Selection and Data Extraction 
No systematic reviews were identified from the Cochrane database and no 
additional primary studies were identified from the bibliography lists of included 
studies. 
Databases searches identified 4140 potential articles to screen further for 
eligibility as shown in Figure 3.1. Only 47 articles met the inclusion criteria and 




Figure 3.1: PRISMA Chart describing study retrieval and selection 
(Moher 2009). 
 
3.6.2. Quality assessment 
The Downs and Black’s mean score of the 20 controlled studies was 0.557 (SD = 
0.075). All papers presented ‘fair’ quality with the exception of four that scored < 
0.5 and was therefore considered ‘weak’ quality. The quality assessment of all 
the included studies using the MMAT tool for the randomised (n = 10), non-
randomised (n = 20) and descriptive studies (n = 17) are shown in Figures 3.2, 
3.3 and 3.4. 
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Figure 3.2: Stacked bar chart representing quality of quantitative 
randomised controlled trials (n = 10) 
 
Figure 3.3: Stacked bar chart representing quality of quantitative non-
randomised studies (n = 20) 
 
Figure 3.4: Stacked bar chart representing quality of quantitative 
descriptive studies (n = 17) 
Footnote: The % values above represents the proportion for each response as agreed between 







Are there clear quantitative research questions or 
objectives?
60%0%
5. In the groups being compared, are the participants 
comparable?
6. Are there complete outcome data (80% or above), or 
acceptable response rate (60% or above)?
3. Are participants (organizations) recruited in a way that 
minimizes selection bias?
4. Are measurements appropriate regarding the 
exposure/intervention and outcomes?












Are there complete outcome data (80% or above)?
Is there low withdrawal/drop-out (below 20%)?
Do the collected data allow address the research 
question  or objectives?
Is there a clear description of the allocation 
concealment  (or blinding when applicable)?
Are there clear quantitative research questions or 
objectives? 
Is there a clear description of the randomization?









5. Are measurements appropriate (clear origin, or validity 
known, or standard instrument)?
Is there an acceptable response rate (60% or above)?
3. Is the sampling strategy relevant to address the 
quantitative research question?
Is the sample representative of the population 
understudy?
2. Do the collected data allow address the research 
question or objectives?




3.6.3. Data extraction 
Tables 1 and 2 detail the data extraction characteristics of controlled and 
uncontrolled studies included in the systematic review (Cooney 2015, Pourrat 
2015, Vessal 2010, Via-Sosa 2013, Gheewala 2014, Staino 2015, Belaiche 
2012a, Mousavi 2013, Dashti-Khavidaki 2012, Holm 2015, Chen 2013, Arrabal-
Durán 2014, Barnes 2014, Belaiche 2012b, Castelino 2011, Dashti-Khavidaki 
2013, Ramadaniati 2016, Qudah 2016, Geerts 2012, Ohnishi 2011, Jiang 2014a, 
Cabello-Muriel 2014, AbuRuz 2013, Jiang 2013, Aspinall 2012, Jiang 2014b, 
Aberger 2014, Adibe 2017, Kelly and Booth 2008, Debenito 2014, Chang 2016, 
Patricia and Foote 2016, Joost 2014, Santschi 2011, Venkateswararao 2016, Rani 
2013, Dashti-Khavidaki 2009, Chia 2017, Mateti 2017, Anderegg 2018, Mateti 
2018a, Mateti 2018b, Tuttle 2018, Xu 2018, Alshamrani 2018, Chandrasekhar 
2018 and Imamura 2018).
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To evaluates the 











73.3 (7.7)  
(1) A 3-h training 
workshop for community 
pharmacists.                                                                           
(2) A communication 
network to facilitate the 
transfer of clinical 
information between the 
pre-dialysis clinic and 
community pharmacists                                                                                           
(3) A pharmaceutical 
consultation service by 
hospital pharmacists with 
expertise in nephrology. 
(n = 48) 
Usual care 
(n = 41) 
Adjusted mean BP changes, were (-
6.9/-0.4 mmHg in ProFiL patients) 
compared with (+4.7 / +2.2 mmHg in 
UC) (between groups differences, P 
value = 0.021/0.348).                                                                                       
At 6 months, 44% of ProFiL and 24% 
of UC patients achieved their BP 
targets.                                                                                                            
Patients with written hypertension
recommendations had a greater 
decrease in mean systolic BP (-11.6 
mmHg; P value = 0.035), and BP was 
controlled in a higher proportion of 















To compare the quality 
of ESA prescribing and 
monitoring for patients 
with NDD-CKD in 
Veterans Affairs 













at ESA Clinic  
76.2 (12.0) 
 
Dosing and monitoring 
ESA therapy by 
pharmacists 
(n = 314) 
Usual care at ESA clinic 
site (n = 91) 
Usual care 
(n = 167) 
More haemoglobin values were in the 
target range in pharmacist-managed 
ESA clinics (71.1% vs 56.9% for 
usual-care sites; P<0.001).  
Veterans in pharmacist-managed ESA 
clinics had more haemoglobin 
measurements on average (5.8 vs 3.6 
in usual-care sites and 3.8 in usual 

















To assess the impact of 











pharmaceutical care in 
addition to the standard 
care of the ward as the 
case group (n = 26) 
Control 
group  

































To evaluate the 
effectiveness of the 
community pharmacist 
intervention in 
addressing the problem 
of dosing inadequacy 
as a consequence of 
renal impairment in 
patients over 65 years 
that were taking 3 or 
more drugs when 











Pharmacists used a 
questionnaire to write a 
report to GPs detailing the 
DRPs detected and 
suggesting changes in 
therapy. GPs to provide 
written reply to the 
pharmacists within 14 
days 
(n = 178) 
Control 
group  
(n = 176) 
The difference in the prevalence of dosing 
inadequacy between the control and 
intervention group before the pharmacists’ 
intervention was 0.73% (95% CI (−6.0) - 
7.5) and after the pharmacists’ intervention 
it was 13.5% (95% CI 8.0 - 19.5) (p < 
0.001) while the difference in the mean of 
drug-related problems per patient before 
the pharmacists’ intervention was 0.05 
(95% CI( -0.2) - 0.3) and following the 
intervention it was 0.5 (95% CI 0.3 - 0.7) 













of a referral 
hospital 
To demonstrate that 
the intervention of a 
pharmacist in a 
monitoring program for 
patients with CKD 
improves the outcome 









including patient interview, 
medication history taking, 
identification of 
inappropriate doses of 
nephrotoxic drugs, daily 
check of laboratory 
parameters and proposing 
dose adjustments to 
physicians. 
(n = 124) 
Control 
group  
(n = 125) 
Significant differences were noted when 
comparing CrCl between discharge and 
admission in both the control and 
intervention groups (5.1 ± 0.9 vs. 6.4 ± 1.0 
p<0.01).                                                                                                                                                                                                                                                        
The rate of acceptance of the pharmacists’ 














To assess adherence to 
monitoring guidelines, 
along with efficacy and 
safety outcomes, and 
to quantify medication 
utilization expenditures 
among patients using 
ESA therapy managed 
by a clinical pharmacy 










Clinical pharmacy services 
provided to patients 
attending the Clinical 
Pharmacy Anticoagulation 
and Anaemia Service.  
(n = 31) 
Usual care 
(n = 70) 
Time to achievement of haemoglobin target 
was 28 days in the pharmacist-managed 
group compared with 41 days in the usual 
care group (P = 0.135), while the proportion 
of patients achieving target haemoglobin 
was 96.8% compared with 95.7%, 
respectively (P = 0.654). Patients in the 
pharmacist-managed group used less ESA 
during the 6-month period, leading to an 
annualized savings of 1288 USD per patient 




































critically ill patients 












The pharmacists assessed 
the patients receiving 
CRRT daily during ICU 
rounds, and then made 
dosage adjustment 
interventions when 
needed. (n = 106) 
No-
interventio
n group  
(n = 103) 
Suspected adverse drug events in the 
intervention group were significantly lower 
than the pre-intervention group (35 in 27 
patients versus 18 in 11 patients, P<0.001). 
However, there was no significant difference 
between length of ICU stay and mortality 
after pharmacist dosing adjustment, which 
was 8.93 days vs 7.68 days (P=0.26) and 
30.10% vs 27.36% (P=0.39), respectively.               
The majority of identified ADEs caused 
significant injury (48.6% in the pre-
intervention period and 44.4% in the post-
intervention period) to the patients 
involved; the number of these ADEs differed 














To evaluate the effect 
of clinical pharmacist 
participation in an ICU 





180 patients  






critically ill patients 
receiving CVVH daily 
during ICU rounds, and 
made antimicrobial dosage 
adjustment interventions 
when needed. 
(n = 93) 
Control 
group  
( n = 87) 
Pharmacists made 256 antimicrobial dosing 
adjustment recommendations for patients 
receiving CVVH, of which 224 (87.5%) 
recommendations were accepted by 
physicians. In control group, pharmacist 
dosing adjustment resulted in £1637.7 
(2669.5 USD) cost savings per patient, and 
2.36 times reduction of antimicrobial-related 
adverse drug events (ADEs) (11 vs 26, P = 
0.002), while length of ICU stay and 
mortality in ICU showed no 











unit at a 
university 
hospital 
To investigate the 

















care and counselling 
provided by the clinical 
pharmacist after the 
transplantation. 
Additional meetings with 
clinical pharmacist at out-
patient transplantation 
care (minimum once per 
quarter up to maximum of 
once a month). (n = 35) 
Standard 
care group 
(n = 39) 
Adherence was significantly improved in 
patients of the ICG (91%) compared with 
SCG (75%) during the first year after 
transplantation 
(P = 0.014). Daily adherence measures 
were already improved within 30–40 days 
after start of intensified patient care.  
Intensified care patients also showed 
significantly better results for taking 
adherence (P = 0.006), pill count (P = 




























Primary care To evaluate the effect 
of a pharmacist-based 
quality improvement 
program on 1) 
outcomes for patients 
with CKD and 2) 
adherence to CKD 
guidelines in the 










patient education and a 
CKD registry 
(n = 1,070) 
Usual care 
(n =1,129) 
Improvement in the primary process 
outcome, measurement of PTH (16.1% in 
the control arm vs. 46.9% in the 
intervention arm; P <0.001).                                                                                    
Subjects in the intervention arm were 
prescribed more classes of antihypertensive 
medications than those in the control arm (P 
= 0.02).                                                                                                                          
Increased % of subjects with a phosphorus 
and urine albumin to creatinine ratio 
measured for intervention arm.                                                                                                                                                                                                   
Satisfaction with the intervention was very 















To determine if a 
pharmacist-executed 
comprehensive chart 
review could serve as 
sufficient substitution 
for direct participation 
during outpatient clinic 
visits in the post-
discharge follow-up 










chart review for patients 
who attended the 
transplant nephrology 
clinic. 
(n = 170) 
Comparato
r group  










Primary care To examine the 
feasibility of using 
pharmacist MTM to 
improve proteinuria 
screening and CKD 
management in a 










Pharmacist MTM arm 
received additional support 
from the pharmacist at the 




based screening and 
management guidelines  
(n = 24) 
Control 
group 
(n = 23) 
The pharmacist MTM intervention did not 
significantly improve total proteinuria 
screening at the population level (OR 2.6, 
95 % CI: 0.5–14.0; p = 0.3). However, it 
tended to increase screening of previously 
unscreened patients (78.6 % in the 
pharmacist MTM group compared to 33.3 % 
in the control group; (OR 7.3, 95 % CI: 




























s units of a 
university 
hospital  
To evaluate clinical 
pharmacists role in the 
management of blood 
pressure in 
haemodialysis patients 







51.7 (18.5)  
Physician-pharmacist 
collaborative care to 
optimize antihypertensive 
pharmacologic 
therapy (n = 29) 
Control 
group  
(n = 27) 
46% of patients in the intervention arm 
achieved BP target (mean home BP 
≤135/85 mmHg) compared to only 14.3 % 
of patients in the control arm (p = 0.02).                                                       
Average decline in weekly mean home SBP 
was 10.9 ± 17.7 mmHg in the intervention 
arm (p = 0.004) 
Weekly mean home systolic blood pressure 
increased by 3.5 ± 18.4 mmHg in the 
control arm (p =0.396).                                                                                                                                                                                                 










clinic of a 
tertiary 
hospital  
To determine whether 
a collaborative care 
(CC) model with 
pharmacist 
involvement can 
reduce admissions and 
healthcare utilization in 
patients receiving 
dialysis, compared to 
usual care (UC). 








modules and received 4 
sessions of training with 
an experienced pharmacist 
before they could provide 
the service independently. 
Usual care 
(n =190) 
CC reduced admissions by 27% (IRR 0.73, 
95% CI 0.54–0.99, p=0.047) and shortened 
mean LOS by 1.3 days (6.7 (2.6) versus. 
8.0 (3.2), p<0.001) compared to UC. No 
significant differences in mortality (p = 
0.189) or mean healthcare utilization cost 
(p = 0.165) between groups. 
Pharmacists identified 515 DRPs with 429 

















To assess the impact of 
Pharmaceutical Care 
(PC) on the HRQoL 
among 
HD patients. 












TH,  48 (17) 
in GH and 
53.77 
(11.87) in 
CH                                 
(1) The PC group received 
the usual care along with 
pharmaceutical care 
delivered by a qualified 
registered pharmacist. The 
customized 
care plan was designed 
and delivered to the 
patients on monthly basis 
based on the condition and 
need of the patient by the 
WHO-FIP 
Pharmaceutical care 
model. (2) The QoL was 
assessed using validated 
KDQoL-36 instrument. 
Usual care 
(n = 75) 
The HRQoL scores were significantly 
improved over time in the domains noticed 
with regard to the “physical functioning, 
general health, emotional well-being, social 
functioning, symptom/problem list, and 
effects of kidney disease” in all the three 
centres of PC group compared to UC group 
with P <0.05.  
The baseline HRQoL score of KDQoL-36 
domains such as ESRD-targeted areas were 
not significantly different in the UC group 
vs. PC group in all the three HD centres. 
The pharmaceutical care provided by a 
trained pharmacist had positive impact in 
HRQoL of HD patients. 
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To determine if 
hypertensive patients 
with comorbid DM and 
CKD receiving a 
pharmacist 
intervention had 
improved BP control 
and greater reduction 
in mean BP at 9 
months compared with 
those receiving usual 
care. 






patients to review 
medications, assessed 
knowledge and then 
educated the patients on 
HTN. Individualised care 
plans were prepared and 
presented to the physician 
108 
patients 
Intervention group had significantly greater 
mean systolic blood pressure reduction 
compared with usual care at 9 months (8.64 
mm Hg; 95%, CI -12.8 to -4.49, p<0.001). 
The intervention group had significantly 
higher BP control at 
9 months than usual care (adjusted odds 
ratio (OR) 1.97, 95%, CI 1.01–3.86, p = 
0.047 and OR 2.16, 95% CI 1.21–3.85, p = 
0.0102, respectively) 
Mateti et 















To assess the impact of 
pharmaceutical care on 
medication adherence, 
Hb levels, blood 
pressure (BP), and 
interdialytic weight 
gain (IDW) among HD 
patients. 
78 patients  As (53) Tailored care plan has 
been designed and 
provided to the PC group 
patients on monthly basis 
based on the situation of 
the patient by the “WHO-
FIP Pharmaceutical care 
model”. 
Usual care 
(n = 75) 
The PC group had significantly reduced its 
IDW and BP levels in comparison to UC 
group at different time intervals with a 
statistical significance of P <0.05. The Hb 
levels and medication adherence rate scores 
of HD patients had significantly increased in 
PC group compared to UC group at different 
time intervals. 
Mateti et 















To assess the cost-
effectiveness of 
pharmaceutical care 
versus usual care on 
treatment costs in the 
patients undergoing 
maintenance HD. 
78 patients  As (53) (1)The pharmacist 
provided PC to the PC 
group patients on monthly 
basis regarding the 
knowledge about the 
medications, disease, 
lifestyle and medication 
chart review. 
(2) The annual costs of 
medications, HD, 
laboratory tests, and 
travel were collected. 
The economic outcomes 
were assessed by 
incremental cost-
effectiveness ratio (ICER). 
Usual care 
(n = 75) 
The incremental cost-effectiveness ratio for 
academic, government, and corporate 
hospitals HD patients of PC group compared 
with UC group were 86,230 Indian Rupee 
(INR)/Quality adjusted life year (QALY) ~ 
(1223.03 USD), 231,016.66 INR/QALY ~ 
(3276.6 USD), and 87,430 INR/QALY ~ 




Abbreviations: ADEs adverse drug effects, BP blood pressure, CI confidence interval, CKD chronic kidney disease, CrCl creatinine clearance, CRRT continuous renal 
replacement therapy, CVVH Continuous Veno-Venous Hemofiltration, DRPs drug related problems, ESA Erythropoiesis stimulating agent, GPs general practitioners, HD 
haemodialysis, HRQoL health-related quality of life, ICG intensified care group, ICU intensive care unit, KDIGO kidney disease: Improving global outcomes, MTM medication 
therapy management, NDD-CKD non-dialysis dependant chronic kidney disease, OR odds ratio, PTH parathyroid hormone, SBP systolic blood pressure, SCG standard care 































To determine the effect 
of a medication 
therapy management 
intervention on acute 
care utilization after 
hospitalization in 
patients with CKD not 
on dialysis. 





A 1- to 2-hour in-home 
visit from a pharmacist for 
a medication therapy 
management (medication 
review, action plan and 
list) within 7 days of 
hospital discharge. 
69 patients The primary outcome (composite of 
hospitalisation/ emergency department/ 
urgent care centre visits) occurred in 44% 
of the intervention group and 41% in control 
group (p=0.72). Hospital readmission rate 
was n=19 (26%) in the intervention group 
and n=18 (26%) in the control group 
(p=0.95). No difference in achievement of 
goals for BP, haemoglobin, phosphorus, or 
parathyroid hormone. 










clinics of a 
medical 
centre. 
To evaluate the 
behavioural and 
physiological outcomes 
of pharmaceutical care 








The pharmacists provided 
face-to-face interviews, 
check-ups for laboratory 
examinations, and 
discovery 






Patients in the RE group possessed better 
knowledge for self-care (49.6±4.8 vs 
38.8±9.1; P < .001); however, the 
differences at 12 months became 
insignificant (56.4± 5.9 vs 56. ±4.7; P = 
0.72) after patients in the IR group had also 
received routine pharmaceutical care. 
Besides, serum creatinine level of the RE 
patients was stable without significant 
variation (P = 0.93), but it demonstrated a 
rising trend in IR patients (P < .01). 
Patients satisfactory with the intervention 
was 95.2%. 
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N (at baseline) Age (years), mean 
(SD) 
Kelly et al. 2008 




Diabetes unit of a 
secondary hospital 
To offer stepwise 
intensive treatment to 
patients with diabetic 
nephropathy picked up 
at the traditional 




63.4 (8.6) Frequent visits to 
pharmacist led clinic 
for treatment 
optimisation, checking 
of BP, renal function, 
HbA1c, ACR, FBC, 
calcium and 
phosphate. Medical 
history taking by two 
sources. 
Significant 













wards of a large 
university hospital 
To understand the 
types of services 




wards, the acceptance 
by physicians and the 




52.5 (14.1) Uniform 
documentation of all 
clinical pharmacy 








Nephrology ward of a 
university hospital 
To determine the 




prescription errors at 
the nephrology ward of 
a referral hospital. 
76 CKD patients 47.7 (17.2) CP reviewed 
medication orders and 
intervention was made 
after agreement of the 
attending physician. 
Although 89.5% of 
the detected errors 
caused no harm, 
4(4.7%) of the 




length of stay, and 
2 (2.3%) led to 
permanent patient 
harm. 








nephrology of a 
teaching hospital 
To explore the 
potential clinical 
significance of the 
MRPs and the 
acceptance of 
recommendations 
made by clinical 
pharmacists. 
308 CKD patients NR Medication history 
interview, clinical and 
medication review by 
pharmacist. 
Recommendation were 










Study setting Aim Participants Pharmacist interventions Main clinical outcomes 














unit of a tertiary  
hospital 
To explore the role of the 
pharmacists’ participation, we 






62 Pharmacists provided drug 
information on renal anaemia 
to physicians, performed 
medication use evaluations 
based on laboratory data, 
proposed plans to change 
prescriptions based on 
medication use evaluations 
and provided drug information 
and lifestyle care point to 
patients. 
The counselling by 
pharmacists significantly 
decreased haemoglobin 
levels in the high group 
(12g/dl) and significantly 
increased them in low group 
(10g/dl).  
 








nephrology clinic  
To identify DRPs by a trained 
CP, their frequency and 
associated comorbidities.  
67 CKD 
patients 
70 The CP interviewed patients 
and established a 
pharmacological profile, 
checked for drug–drug 
interactions, verified dose 
adaptation according to the 
last renal function tests and 
searched for self-medication 
and its potential 
nephrotoxicity. The 
pharmaceutical proposals 
were validated with the 
consulting nephrologist so as 
to optimise therapy during the 
following renal consultation. 
Not reported 








of a university 
hospital 
To assess the impact of 
clinical pharmacy services in 
outpatient nephrology clinics. 
42 CKD 
patients 
64.9 (2.2) Identification of DRPs by CP 













Study setting Aim Participants Pharmacist interventions Main clinical outcomes 













treatment centre of a 
teaching hospital 
To assess the impact 
of clinical pharmacy 




patients who were on 




86 HD NR CP reviewed patients 
medications and proposed 
modification according to 
laboratory data results to 
treating physicians. 
Serum Calcium was increased in 
hypocalcaemia patients and 
decreased in hypercalcaemia 
patients until it reached the 
optimal range in both groups.  
A decline in serum Phosphate level 
was noted in hyperphosphataemia 
patients.  
There was an increase and 
decrease in serum iPTH in 
suboptimal and supraoptimal range 
patients, respectively. 
Haemoglobin concentration 
increased in anaemic patients and 
serum ferritin reached target 
values in all patients. Total 
cholesterol, low-density lipoprotein 
cholesterol and triglycerides 
decreased to near-optimal values 
in dyslipidaemia patients. 










help of a pharmacy 
medication alert 
system based on the 
renal function of 
patients aged ≥70 





81 (6.7) The pharmacists used a 
pharmacy medication alert 
system to assess the 
medication in relation to the 
reported eGFR and provided 
an alert for target drugs 
according to the Dutch 
guidelines for drug 




























of a general 
teaching hospital 
To implement and 
evaluate the impact 
of pharmaceutical 
care service for 
hospitalised CKD 
patients in Jordan 
130 CKD 
patients 
56.3 (17.8)   The pharmacist Identified TRPs                                               
and interventions were discussed 
during ward rounds. Patients 
education and interview to improve 
patient adherence.  
17% of all TRPs were resolved, 5.5 
%were improved, and 37.4 %were 









centre of a 
general hospital 
To evaluate the 
prevalence of DRPs 
identified and the 
types of interventions 
made by MMS 
pharmacists. 
30 HD 62.3 (10.0) Patients requested to bring their 
medication and see the pharmacist 
before the appointment with their 
physician. Pharmacist reviewed 
patients records, counsel the 
patients, identified and reported 
DRPs. 
Not reported 







surgical ICU of a 
university-
affiliated hospital 
To evaluate the 
benefits that may 
result from involving 
pharmacists in the 


















Pharmacists completed 1 month of 
training before the study was 
started. 
During the intervention period, the 
pharmacists assessed septic 
patients receiving CRRT daily and 
adjusted the dosage of 
antimicrobial drugs when needed. 
Recommendations were made to 
physicians and nurses at that time. 
All pharmacist recommendations 
were verbal and recorded on a 
specially designed pharmacist 
intervention form. 
Dosing adjustments were related to a 
reduced length of ICU stay from 10.7 
± 11.1 days to 7.7 ± 8.3 days 
(p=0.037) in the intervention group, 
and to cost savings of 3525 USD 
(13463 ± 12045 vs. 9938 ± 8811, 
p=0.038) per septic patient receiving 
CRRT in the ICU.  
Suspected antimicrobial adverse drug 
events in the intervention group were 
significantly fewer than in the pre-
intervention group (19 events vs. 8 
events, p=0.048). 
Dosing error events were significantly 
fewer in the post-intervention phase 
than in the pre-intervention phase (54 














Study setting Aim Participants Pharmacist 
interventions 
Main clinical 
outcomes achieved N (at baseline) Age (years), mean 
(SD) 













therapy in kidney 
disease patients and 





related costs for 
these patients. 
Pre-test phase (375 
patients) 
Post-test phase (236 
patients) 
Pre-test phase  
51.2 (18.3) 




phase: patient chart 
review by CP, 
develop SUP 
protocol, and provide 
educational sessions 





physicians on the 
ward rounds and 
advised on starting 
or stopping SUP. 
Not reported 






Dialysis unit of a 
multispecialty 
university hospital 
To assess the 
medication 
knowledge of CKD 
patients undergoing 
HD, to assess the 
effect of a CP 
provided continuous 
patient education in 
improving 
medication 







in HD patients. 
 




interview to assess 
medication 
knowledge using 





























Transplant clinic of 
a large urban 
hospital 
To describes a telehealth system 
approach and preliminary results for 
the management of BP in renal 
transplant recipients and to enhance 
patient engagement and improve 
adherence to medications via a 
collaborative care, pharmacist-based, 
MTM program. 
66 Tx patietns 54 Telehealth system 
encompassing: home electronic 
BP monitoring designed to 
assess the efficacy of 
antihypertensive therapy. The 
pharmacist communicates BP 
reading data and dose 





and diastolic BP of 
6.0mm Hg and 
3.0mm Hg, 












department of a 
general university 
hospital 
To assess the characteristics of 
pharmaceutical interventions 
concerning the dose adjustment of 
these drugs in patients with CRF who 
are admitted into hospital. 
181 CKD 
patients 
77.6 (12.5) Medical history of each patient 
was reviewed by CP, 
recommendations for an 
adjustment were put in writing 
for the doctors. 
Not reported 










with a major, 
academic health 
system 
To increase the identification of CKD 
as a medical problem, increase the 
use of aspirin and ACEIs/ARBs in 
patients with CKD, and ensure that 
all medications prescribed to patients 
with CKD were dosed appropriately 
based on CG calculated CrCl.  
146 CKD 
patients 
71.6 (12.2) Review EMRs to identify CKD 
patients, review medication 
list, estimate CrCl and 




















Study setting Aim Participants Pharmacist 
interventions 
Main clinical 













Aged care facilities To investigate the number and nature of 
DRPs identified and recommendations 
made by pharmacists in residents of 
aged care facilities. 
To determine the extent of inappropriate 
prescribing of renally cleared medications 
in residents with CKD. 
847 CKD 
patients 
84.9 (8.8) DRPs identified, and 
recommendations made to 
resolve those DRPs by CP. 
Not reported 








department of a 
general hospital  
To describe the use of renal risk drugs in 
a population of patients with RI in 
an internal medicine department and 






The CP reviewed the 
patients’ drug regimen to 
classify DRPs related to 
renal function. DRPs 
identified were discussed 
with the physician. 
There was a significant 
correlation between the 
patients’ GFR and the 
number of DRPs, with an 
increasing number of 
DRPs with deteriorating 
renal function (p = 
0.001, r = 0.371). 









(1) To evaluate the ability of community 
pharmacists to identify drug related 
problems (DRP) in patients at risk for or 
suffering from renal impairment.                                                                    
(2) To evaluate the proportions of 
recommendations by CPs that lead to a 
modification by GP. 
177 CKD 
patients 
78.1 The community 
pharmacist filled an 
electronic form for each 
prescription and verify 
whether the drug had to 
be adapted to renal 
function or was 
contraindicated.                        
Potential modification was 










Dialysis unit of a 
teaching hospital 
To evaluate the patient perception and 
degree of adherence to various 
treatment modalities (medication use, 
dialysis, life style modifications) by renal 
failure patients on HD. 
To assess the effect of pharmacist’s 
interventions towards improving the 




(13.3)    
Patient counselling once in 
two weeks (total 3 
sessions) was provided. 
Printed information leaflets 
and written information on 
dialysis note in regional 
language were provided to 
the patients.                                                                        
Adherence pattern before 





























To identify the extent and type of 
medication discrepancies and MRPs 
experienced by dialysis patients during 
pharmacist-initiated medication reviews 
and determine if the resulting 
recommendations made by the pharmacy 
team to the patient's provider were 
accepted. 
90 HD NR Patients requested to bring 
their medication to dialysis 
unit and medication 
reconciliation conducted by 
the pharmacy team. 
Not reported 






Medical wards and an 
ICCU in a major 
teaching hospital 
To identify and evaluate drug-related 
problems (DRPs) in patients with CKD. 
105 CKD NR Identification of DRPs through 
the direct patient interview, 
discussion with nurses and 
assessment of patients’ 













Nephrology units of 
three tertiary 
hospitals 
To determine the prevalence of DTPs, 
identify the types of DTPs, and assess the 
outcomes of DTP interventions among 
renal patients receiving care in three 







Identify and report DRPs. 
Patient education and 
counselling.  
Not reported 
Alshamrani et al. 
2018 






haemodialysis unit of 
a tertiary hospital. 
To determine the prevalence of 
polypharmacy and the Medication Related 






The pharmacy resident 
reviewed electronic medical 
records and analysed each 
medication regimen for 














To evaluate medication adherence 
behaviour of patients using questionnaire 
and enhance adherence by various cost 
effective interventions which have greater 




- Patient counselling by 
pharmacist and patient 
information leaflet was carried 
out using a proper 
management plan and with 
the help of physician and 










Study setting Aim Participants Pharmacist 
interventions 
Main clinical outcomes 











Hospital. To determine whether 
multidisciplinary care could 
help prevent worsening renal 
function associated with CKD. 
150 CKD 
patients 
72.3 (10.5) The multidisciplinary 
care was provided by 






The eGFR significantly 
improved between before and 
after multidisciplinary care 
from − 5.46 to − 0.56 
mL/min/1.73 m2/year, 
respectively.  
Values for uric acid, LDL, and 
HbA1c were significantly 
reduced among patients with 
improved eGFR. 
Abbreviations: ACEi angiotensin converting enzyme inhibitors, ACR albumin:creatinine ratio, ARBs angiotensin receptor blockers, BMQ Brief medication questionnaire, BP 
blood pressure, CrCl creatinine clearance, CG Cockcroft-Gault, CKD chronic kidney disease, CP clinical pharmacist, CRF chronic renal failure, CRRT Continuous renal 
replacement therapy, DRPs drug related problems, eGFR estimated glomerular filtration rate, EMRs electronic medical records, FBC full blood count, GFR glomerular filtration 
rate, GP general practitioner, HbA1c glycosylated haemoglobin, HD haemodialysis, ICCU intensive critical care unit, ICU intensive care unit, iPTH intact parathyroid 
hormone, IQR interquartile range, MKAQ Medication knowledge assessment questionnaire, MMS Medication management service, MRPs medication related problems, MTM 
medication therapy management, NR not reported, RI renal impairment, SUP stress ulcer prophylaxis, TRPs therapy related problems, Tx transplantation.
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3.6.4. Study characteristics 
The 47 studies were carried out in a variety of geographic locations: USA (n = 
10), Iran (n = 5), India (n = 7), France (n = 3), Spain (n = 3), Jordan (n = 2), 
China (n = 2), Japan (n = 3), Singapore (n = 2), Nigeria, Taiwan, Australia, 
Saudi Arabia, Germany, Netherlands, Indonesia, Norway, Canada and the UK, (n 
= 1 in each country). Two studies from 2008 and 2009 were not included in the 
systematic review of Salgado et al (Salgado 2012), hence were considered as 
part of this review. Thirty-one studies were conducted in hospital settings 
(wards, intensive care units (ICU), clinics, departments and dialysis units) and 
16 in primary care settings, including clinics and community pharmacies. The 
follow-up time in all included papers ranged from 4 weeks to 24 months with a 
mean of 9.4 (standard deviation, SD = 5.08) months, with four studies with 
unclear duration. 
The majority of studies (n = 27) used an uncontrolled study design, 21 
prospective and six retrospectives. The remaining 20 were controlled, ten of 
which were randomised and ten non-randomised. According to Thomson Reuters 
Journal Citation Report at the time of publication the median impact factor of the 
journals of articles included was 1.348 (IQR 0.52 – 2.01), n = 45, two journals 
did not have an impact factor at the time of publication. 
Patient mean age was 46.7 – 84.9 years, with five studies failing to report age 
(Dashti-Khavidaki 2012, Castelino 2011, Ramadaniati 2016, Patricia and Foote 
2016, Chandrasekhar 2018). Of the total of 11,122 patients from all studies, 
9,151 were at various stages of chronic kidney disease not on dialysis, 1,036 
were haemodialysis (HD) dependent, 533 receiving other forms of renal 
replacement therapies such as continuous renal replacement therapy (CRRT) or 
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continuous veno-venous hemofiltration (CVVH), and 402 were transplant 
patients. 
Outcomes were reported in 37 papers, with 25 of these (67.6%) also reporting 
details of the processes of care, and four (10.8%) reporting structures, processes 
and outcomes. Outcomes reported were: clinical only (17, 45.9%), economic 
with linked clinical (5, 13.5%), humanistic with linked clinical (4, 10.8%), 
humanistic only (2, 5.4%) and economic only (2, 5.4%). The 10 remaining 
papers did not report outcomes measures with one (2.1%) that reported 
structure and process indicators only and 9 (19.1%) reported process indicators 
only. 
A) Resources for care provision: structures 
Structures were poorly reported in all studies, with only two giving some details 
of multidisciplinary team involvement (Chia 2017 and Imamura 2018), while, 
none on the pharmacist skill mix or time allocation. The only aspect of structures 
reported relating to training which was given in five studies. In one, pharmacists 
and pharmacy residents were engaged in a two-week training of literature review 
and patient assessments (Jiang 2014a). A community pharmacist-based study 
described a workshop covering clinical presentations of CKD, managing drug-
related problems and discussing patient cases (Santschi 2011). Similar training 
was described for community pharmacists, (Via-Sosa 2013) and hospital clinical 
pharmacists (Pourrat 2015), to enable them to identify patients with renal 
insufficiency and perform dose adjustments. A four-session course to all 
members of the multidisciplinary team prior to the study was described in one 
article (Imamura 2018). 
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B) Characteristics of clinical pharmacy practice: processes 
All studies provided some description of the processes undertaken by the 
pharmacists, although the detail provided varied considerably and was generally 
lacking. The majority of processes (often labelled as interventions) included 
medication chart review to identify any drug-related problems (DRPs) (Cooney 
2015, Pourrat 2015, Vessal 2010, Via-Sosa 2013, Gheewala 2014, Staino 2015, 
Belaiche 2012a, Mousavi 2013, Dashti-Khavidaki 2012, Holm 2015, Chen 2013, 
Arrabal-Durán 2014, Barnes 2014, Belaiche 2012b, Castelino 2011, Dashti-
Khavidaki 2013 and Ramadaniati 2016). Many studies reported pharmacists’ 
interventions in: modifying drug doses and recommending new 
pharmacotherapy; (Pourrat 2015, Gheewala 2014, Belaiche 2012a, Mousavi 
2013, Dashti-Khavidaki 2012, Chen 2013, Arrabal-Durán 2014, Barnes 2014, 
Castelino 2011, Dashti-Khavidaki 2013,  Qudah 2016, Geerts 2012, Ohnishi 
2011, Jiang 2014a, Cabello-Muriel 2014, AbuRuz 2013, Jiang 2013, Aspinall 
2012, Jiang 2014b, Chia 2017and Alshamrani 2018); interacting with a member 
of the multidisciplinary team; (Cooney 2015, Pourrat 2015, Vessal 2010, 
Gheewala 2014, Staino 2015, Belaiche 2012a, Dashti-Khavidaki 2012, Holm 
2015, Chen 2013, Barnes 2014, Ramadaniati 2016, Qudah 2016, Ohnishi 2011, 
Jiang 2014a, Cabello-Muriel 2014, AbuRuz 2013, Jiang 2013, Jiang 2014b, 
Aberger 2014, Adibe 2017and Kelly and Booth 2008) requesting and monitoring 
laboratory parameters; (Cooney 2015, Dashti-Khavidaki 2012, Chen 2013, 
Barnes 2014, Geerts 2012, Ohnishi 2011, Cabello-Muriel 2014, AbuRuz 2013 and 
Kelly and Booth 2008), assessing appropriateness of medications prescribed for 
hospitalised patients at each point of care; (Vessal 2010, Mousavi 2013, 
Castelino 2011, Dashti-Khavidaki 2013, Jiang 2014a, Cabello-Muriel 2014, 
AbuRuz 2013, Jiang 2013, Jiang 2014b andTuttle 2018). Fewer studies described 
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pharmacist processes at out-patient, pharmacist-led clinics relating to the 
management of specific CKD complications, such as anaemia; (Ohnishi 2011, 
Aspinall 2012, Debenito 2014) hypertension and diabetes; (Anderegg 2018) 
managing hypertension through telemedicine; (Aberger 2014) optimising 
dyslipidaemia management; (AbuRuz 2013, Chang 2016) improving haemoglobin 
A1c levels (HbA1c); (Kelly and Booth 2008) and emphasising smoking cessation; 
(AbuRuz 2013, Kelly and Booth 2008). Development of protocols and compiling 
and updating guidelines were also described in two studies (Mousavi 2013, 
Ohnishi 2011). Performing medication reconciliation (Patricia and Foote 2016); 
providing patient medication counselling, education on disease status or 
medication, conducting motivational interviews to improve adherence were also 
reported (Cooney 2015, Chen 2013, Barnes 2014, Castelino 2011, Dashti-
Khavidaki 2013, Ohnishi 2011, Cabello-Muriel 2014, AbuRuz 2013, Adibe 2017, 
Kelly and Booth 2008, Joost 2014, Santschi 201, Venkateswararao 2016, Rani 
2013, Mateti 2018a, Tuttle 2018, Xu 2018 and Chandrasekhar 2018). A number 
of studies reported pharmacists’ participation in ward rounds (Vessal 2010, 
Mousavi 2013, Jiang 2014a, AbuRuz 2013, Jiang 2013, Jiang 2014b), providing 
educational sessions to healthcare professionals (Mousavi 2013, Ohnishi 2011) 
and performing activities such as medication use evaluations (Ohnishi 2011). 
There were no reports of pharmacist prescribing activities; one study described 
the process of deprescribing to optimise medication use (Alshamrani 2018). 
Fewer studies provided any data on time spent on specific activities. Interaction 
time between pharmacist and patients were reported in two studies, varying 
from 15 to 30 minutes (Kelly and Booth 2008, Rani 2013) and the timeframe in 
which the services were provided ranged from daily (Jiang 2014a, Cabello-Muriel 
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2014, AbuRuz 2013, Jiang 2013, Jiang 2014b) to every three months (Joost 
2014). 
Across all studies, the pharmacists identified 5302 drug-related problems in 2933 
patients. Pharmacists made 3160 recommendations to healthcare professionals 
with an acceptance rate varying from 33.3% in a community setting; (Pourrat 
2015) 46.43% in a dialysis unit; (Alshamrani 2018) to around 95% in hospital 
settings (Vessal 2010, Holm 2015, Adibe 2017, Dashti-Khavidaki 2009, Chia 
2017, Tuttle 2018). Only three studies reported the clinical significance of 
recommendations. Of these 26% were of moderate significance (Castelino 2011), 
48.8% of major clinical significance (Dashti-Khavidaki 2009) and 47% of serious 
severity (Staino 2015). 
A pharmacist-based quality improvement programme consisting of pharmacists’ 
interactions with the patients and electronic collaboration with the physicians was 
associated with a significant improvement in the measurement of PTH during the 
study period (Cooney 2015). Pharmacists’ interventions led to medication 
therapy modifications (Pourrat 2015, Pourrat 2015, Vessal 2010, Via-Sosa 2013, 
Gheewala 2014, Staino 2015, Belaiche 2012a, Holm 2015, Chen 2013, Arrabal-
Durán 2014, Barnes 2014, Belaiche 2012b, Castelino 2011, Ramadaniati 2016, 
Geerts 2012, AbuRuz 2013, Adibe 2017, Patricia and Foote 2016) and resolving 
medication record discrepancies (Patricia and Foote 2016, Tuttle 2018). Patients’ 
compliance with ongoing blood pressure (BP) monitoring post kidney 
transplantation was significantly improved with pharmacists’ input (Aberger 
2014). Counselling by pharmacists significantly improved medication adherence 
in patients with CKD (Joost 2014, Rani 2013, Chandrasekhar 2018). 
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C) Clinical outcomes 
The final column of Tables 1 and 2 titled ‘Main outcomes achieved’ provides a 
detailed summary of main results and statistical significance values related to 
each of the studies summarised below. Clinical outcomes only were reported in 
(n = 17) studies. A pharmacist-based quality improvement programme in a 
pragmatic randomised controlled study reported that patients in the intervention 
arm were prescribed more classes of antihypertensive medications than those in 
the control arm (Cooney 2015). In a six-month cluster randomised trial, 
pharmacists attending a structured training and communication-network 
programme (ProFil) and managing hypertension in CKD patients demonstrated 
larger reduction in systolic blood pressure (BP) of the intervention group 
compared to the usual care group (Santschi 2011).  
Intervention in the management of BP in CKD and haemodialysis resulted in 
achieving target BP in the intervention versus the control group (Qudah 2016, 
Anderegg 2018, Mateti 2018a), significant reductions in mean systolic and 
diastolic BP in a group of kidney transplant recipients (Aberger 2014), and 
significant reduction in systolic and diastolic BP in diabetic nephropathy (Kelly 
and Booth 2008). Only one article showed that pharmacists’ intervention in an 
intensive care unit (ICU) setting reduced the length of ICU stay (Jiang 2013). 
Another study reported reduction in the length of stay in the intervention group 
by 1.3 days (p<0.001) and reduced unplanned admission by 27% (p = 0.047) 
(Chia 2017). One further study showed no difference of pharmacists’ intervention 
compared to usual care on hospital readmission outcomes (Tuttle 2018). 
Pharmacists were also involved in the monitoring of kidney function in patients 
with CKD and demonstrated significant differences in measuring CrCl between 
discharge and admission (Cabello-Muriel 2014). However, one study 
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demonstrated no difference in the mean serum creatinine or estimated 
glomerular filtration rate (eGFR) between the intervention and control groups (Xu 
2018). A retrospective controlled study reported improvement in eGFR, uric acid, 
cholesterol and HbA1c in the intervention group compared to the control group 
after multidisciplinary care, however, pharmacists’ contribution to the care was 
not clearly reported (Imamura 2018).                                                                 
Four studies gave outcomes of pharmacists managing anaemia in CKD patients 
(Ohnishi 2011, Aspinall 2012, Debenito 2014, Mateti 2018a), with significant 
haemoglobin values within target range in pharmacist-led clinic. Time to achieve 
target haemoglobin was 28 days in the pharmacist-managed group compared 
with 41 days in the usual care group (Debenito 2014). While the proportion of 
patients achieving target haemoglobin was not significant, pharmacist 
intervention significantly improved haemoglobin and iron monitoring by 
improving compliance to therapy (Debenito 2014). Pharmacist counselling 
significantly improved haemoglobin levels in one study (Ohnishi 2011), with 
haemoglobin concentration and Transferrin saturation (TSAT%) increasing 
significantly and serum ferritin reaching target values in a prospective 
uncontrolled study (Dashti-Khavidaki 2012). 
An uncontrolled study of the impact of on managing secondary complications of 
haemodialysis patients resulted in significantly increased median serum calcium 
in those with hypocalcaemia and decreased values in hypercalcaemia, a decline 
in serum phosphate in patients with hyperphosphataemia, and an increase and 
decrease in serum iPTH in patients with sub-optimal and supra-optimal levels 
respectively (Dashti-Khavidaki 2012). 
 113 
Pharmacists’ interventions in a pragmatic, cluster randomised study improved 
screening of proteinuria between an interventions compared to control group 
(Patricia and Foote 2016). A non-randomised controlled study of pharmacist 
involvement in a monitoring program for CKD reported significant differences in 
CrCl between discharge and admission in both the control and intervention 
groups (Cabello-Muriel 2014).  
D) Humanistic outcomes 
In a cluster, randomised study health related quality of life (HRQoL) improved 
significantly compared to control in a group of haemodialysis patients receiving 
pharmacist intervention over a 6-month period (Dashti-Khavidaki 2013). In a 
non-randomised controlled study, HRQoL domains were not significantly 
impacted by the additional pharmacist care in kidney transplants (Joost 2014). A 
multicentre RCT reported significant improvement in HRQoL scores in the 
intervention group compared to control (Mateti 2017). 
Patient satisfaction reported in two randomised controlled studies: 92% of 
patients had positive feelings about pharmacists’ involvement in their care and 
felt that the pharmacist provided beneficial information (Cooney 2015) and 43% 
of patients were ‘very satisfied’ with the care received and were willing to receive 
future care from the pharmacist (Chang 2016). A cross-sectional prospective 
study demonstrated that patients were greatly satisfied with the intervention (Xu 
2018). 
E) Economic outcomes 
Only seven studies reported economic outcomes resulting from pharmacist input 
(Mousavi 2013, Jiang 2014a, Jiang 2013, Aspinall 2012, Jiang 2014b, Debenito 
2014, Mateti 2018b). One study reported that pharmacists in the ICU could 
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contribute to significant cost savings in septic patients, with antimicrobial 
prescribing efficiencies accounted for 34.7% of total savings (Jiang 2013). In a 
study investigating an ICU pharmacist dosing adjustment programme, the mean 
ICU hospitalisation costs per patient decreased significantly with total savings of 
2669.5 USD per patient (Jiang 2014b). Jiang et al demonstrated that pharmacist 
dosing adjustment resulted in drug cost savings per patient of 2345.98 USD with 
antibiotics accounting for 64.5% of all cost savings. The presence of an ICU 
pharmacist resulted in 2346 USD savings per patient receiving continuous renal 
replacement therapy (Jiang 2014a). Debenito et al reported that the mean 
weekly dose of erythropoiesis-stimulating agents (ESAs) was significantly less in 
the pharmacist-managed group than the usual care group and the annualised 
ESA cost per patient reduced by 1288 USD (Debenito 2014), whereas, Aspinall et 
al reported lower average dose of darbepoetin in the pharmacist-managed ESA 
clinic compared to the usual care (Aspinall 2012). Mousavi et al showed that the 
cost per patient for inappropriate stress ulcer prophylaxis administration in 
patients with insufficient renal function was reduced by pharmacists’ intervention 
(Mousavi 2013). A multicentre RCT reported that pharmaceutical care costed 
more per quality adjusted life year (QALY) gained compared to usual care (Mateti 
2018b). 
3.7. Discussion  
3.7.1. Summary of key findings  
There are a number of important key findings that have arisen from this review 
and these are outlined below. Forty-seven new studies have been published in 
the intervening eight-year period since a previous similar review (Salgado 2012). 
Ten of these are of a ‘gold standard’ RCT design however, the quality of the 
controlled studies included is generally poor due to lack of providing sufficient 
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methodological information. Structures and processes were very poorly reported 
and none of the studies included consideration of pharmacist prescribing – which 
is considered in several countries, where it has been implemented, to be a 
significant advance in pharmacy practice.  The process indicators in the original 
review (Salgado 2012) and this review were very similar but this review 
identified papers with clear shift from only identifying drug-related problems to 
more involvement of the pharmacist in medication therapy management. Most of 
the studies in this review continue to focus on and report details of DRPs as an 
indicator of the process of pharmacy practice. Some of these considered the 
clinical significance of these DRPs but this was not universal. Less focus on 
clinical, humanistic and economic outcomes was observed in majority of the 
papers in both reviews. 
3.7.2. Interpretation of findings 
Many of the uncontrolled studies had a variety of quality deficiencies including; 
lack of comprehensive explanation of the pharmacists’ intervention, under-
reporting of adverse events and insufficient information to allow reproduction of 
the study for interested readers. Few studies lacked some important information 
leading to poor scoring of the study, such as lack of clarity in stating the study 
aim, (Jiang 2014a) the number of participants, the population from where the 
sample was drawn, duration of the data collection or the study period, frequency 
of follow-up, and some studies were unable to clearly state the distribution of the 
confounders in both groups (Cooney 2015, Jiang 2014a, Mousavi 2013, Aspinall 
2012, Dashti-Khavidaki 2013, Chang 2016).  
The majority of the 20 controlled studies were of ‘fair’ quality with the exception 
of four that were considered ‘weak’ (Mousavi 2013, Mateti 2018a, Mateti 2018b, 
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Xu 2018). High quality RCTs with low levels of bias generate the highest level of 
evidence (Burns 2011). However, the availability of high quality evidence in this 
area is limited with only 5 RCTs out of 47 included papers in this review and 4 in 
a previous review by Salgado et al (Salgado 2012). The RCTs in both reviews 
lacked sufficient information on the randomisation process, in addition to poor 
detail on any blinding process of the care-giver and the care-receiver (however, 
it might be a challenge to blind in some study designs) so jeopardising the 
quality of these studies (Mahboobi 2012). It is therefore evident that there has 
been a limited amount of high-quality research published for the benefits of 
clinical pharmacy practice in CKD. There is particularly a paucity of evidence 
from RCTs offering a robust evidence base for practice. Despite this criticism 
there is a growing body of information in relation to some aspects of clinical 
pharmacy practice that offers some insights to the developing quality of services 
provided making real and significant differences to the outcomes of patients. 
This, however, needs to be verified through even more robust RCTs that are 
better resourced, designed and executed.   
The gathering of more gold standard evidence such as RCTs is essential to 
enable measuring the impact of clinical pharmacists’ intervention in patients with 
CKD compared to standard care. Furthermore, there is an identified need to 
carry out studies with explicit details and accurate definitions including the 
setting, the participants, the randomisation process and the interventions of 
interest.  
It is of paramount importance that detailed descriptions of the interventions, in 
terms of structures and processes and outcomes, are included in publications to 
allow them to be reproduced and for readers to consider the studies within the 
context of their own practice (Salgado 2013). Most papers lacked sufficient 
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details of the clinical pharmacy practices so making it difficult to fully understand 
the activity. Without full insight to practice it is difficult to fully understand the 
context and characteristics of practice and so reproduce the structures and 
processes in wider settings. This is not just a deficiency of studies in CKD since a 
study by Schroter et al to assess the replicability of published clinical 
interventions, in a variety of clinical settings, reported that 57% of the studies 
had insufficient description of the intervention of interest to make it replicable 
(Schroter 2012). A tool produced by Correr et al to address the lack of 
intervention descriptions in clinical pharmacy research (Descriptive Elements of 
Pharmacist Intervention Characterization Tool) DEPICT is a validated instrument 
for accurately describing the details of pharmacist interventions performed as 
part of clinical pharmacy practice (Correr 2013). This tool could be used as a 
guidance to structurally describe the intervention of interest in pharmacy practice 
research.  
Additionally, it should be noted that in CKD there are no studies that have 
specifically investigated prescribing as part of clinical pharmacy practice and 
there are no full description of structure, processes and outcomes as they relate 
to prescribing practice. A systematic review by Tesfaye et al published in 2017 of 
the prevalence of inappropriate prescribing and the impact of pharmacists’ 
interventions reported significant reduction in inappropriate prescribing when 
physicians received immediate concurrent feedback from a clinical pharmacist 
(Tesfaye 2017). The review showed minimal involvement of the pharmacist in 
the role of prescribing for patients with CKD. Despite the increased recognition of 
prescribing models such as independent, supplementary or collaborative (Royal 
Pharmaceutical Society 2016), there was limited published evidence to lead to 
the best practice model for prescribing.  
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There is also a need to stimulate more of a research culture within clinical 
pharmacy practice. A paper by Peterson et al reported that lack of time, lack of 
opportunities, lack of training and never being asked to participate in a research 
were major barriers for pharmacists’ engagement in research (Peterson 2008). A 
systematic review by Awaisu et al. concluded that pharmacists are aware of the 
value of research to enable them advance pharmacy practice and indicate their 
willingness to be involved in independent research and in practice-based 
research networks. However, lack of time, training and support were the main 
barriers (Awaisu and Alsalimy 2015). 
3.7.3. Strengths and limitations 
A strength for this review is that the protocol was peer reviewed and registered 
with PROSPERO. The protocol was devised in accordance with PRISMA-P 
(Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 
standards (Moher 2015) and the systematic review was conducted and reported 
in accordance with PRISMA (Preferred Reporting Items for Systematic Review 
and Meta-Analysis) standards (Moher 2010). In terms of limitations, publication 
bias could potentially affect the selecting process of the articles, since no study 
was identified to show the negative impact of clinical pharmacy services in caring 
for patients with CKD. One further limitation is the exclusion of papers in 
languages other than English potentially leading to the omission of relevant 
papers.  
In conducting RCTs, it has been recognised that it is vital to be careful in the 
selection and recording of outcomes to build up a coherent dataset (Esposito 
2014, Beuscart 2018, Lombardi 2018 and Williamson 2017). Moreover, 
consistency in the use of outcomes will aid future users of the services and those 
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involved in resource allocation, planning and implementation of clinical pharmacy 
services (Lombardi 2018). It is evident from this review that where RCTs were 
conducted, there was no consistency in the selection and reporting of outcomes. 
These issues could be addressed with the development and application of agreed 
standardised sets of outcomes (Williamson 2017). Research on core outcome set 
definitions for clinical pharmacy practice is ongoing in many areas such as 
polypharmacy (Rankin 2018) but this appears to be lacking in CKD, which could 
be a potential area of work in the future. 
3.8. Conclusion 
There is some evidence for the outcomes of pharmacists’ intervention in patients 
with CKD but this is generally of low quality and insufficient volume. The 
controlled studies in this systematic review showed that pharmacist interventions 
improved patients’ clinical outcomes such as Hb levels, CrCl, PTH and calcium 
levels. However, these studies lacked detail on reporting of the humanistic 
outcomes and there remains a paucity of evidence demonstrating economic 
impact of pharmacists’ interventions.  
There is some evidence since the last review that shows positive contributions of 
pharmacists’ involvement in the multidisciplinary team to provide care to 
patients with CKD. This includes evidence on the structure, processes of care and 
the outcomes of pharmacists’ intervention in patients with CKD. More high-
quality research in this area is warranted.  
3.9. Further research 
The systematic review showed that there is some evidence in the literature 
carried out to explore pharmacist’s contribution in the care for patients with CKD. 
Nevertheless, the quality of the studies reported and comprehensiveness on 
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information related to structure, process and outcome of the care were lacking. 
Very few studies mentioned anything related to structures and limited studies 
reported outcomes of the care provided to the patients. It is also noted that only 
one study was included from the UK which shows lack of such research carried 
out in the UK. None of the studies employed theoretical underpinning in any 
stage of the research process. None of the included studies focused on 
pharmacist prescribing although, nonmedical prescribing is one of the most 
significant developments in the clinical pharmacy practice in the UK in the last 20 
years (Tonna 2007). Therefore, it is evident that there is a need for original 
primary research in this area in the UK. Following the identification of the gap in 
research, the next stage of this research is in two phases to generate primary 
data in this area of research. The first phase of the next stage focused on the 
determination of the behaviours and experiences of pharmacist members of the 
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4. Introduction  
A recently completed systematic review as a part of this doctoral research by Al 
Raiisi et al of clinical pharmacy service provision identified an evidence based 
derived from mostly poor methodological designed studies (Al Raiisi 2019). There 
is a need for well-designed studies describing UK practice which reflect recent 
developments such as nonmedical prescribing. This survey explored in details the 
models of care pharmacists provide for patients with CKD. This chapter illustrates 
the description of the models of care pharmacists deliver to patients with CKD 
and provide detailed views and experiences of the pharmacists in this area of 
practice. The details about the research aim, research questions, methods, 
results, discussion and conclusion are reported in great details in this chapter. 
4.1. Aim  
To determine the behaviours and experiences of pharmacist members of the UK 
Renal Pharmacy Group on provision of multidisciplinary care of patients with 
Chronic Kidney Disease. 
4.2. Research questions  
1. What are the characteristics of general models of clinical pharmacy practice in 
terms of structures and processes and how have these models been developed, 
implemented and evaluated?  
2. What are the characteristics of the models of pharmacist prescribing practice 
in terms of; supplementary versus independent, site of and support for practise, 
competency areas, process of prescription writing and how have these models 
been developed, implemented and evaluated? 
3. What are the positive and negative experiences on development and 
implementation of these models of practice? 
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4. What are the key areas for future practise development and what are the 
recommendations for implementing these developments? 
4.3. Method 
4.3.1. Questionnaire design 
The development of the survey tool followed a rigorous iterative process that 
initially involved reviewing the aim / objectives of the overall project to ensure 
that the survey tool was designed to meet these. Information from the literature 
and the previously completed systematic review in this area was used to 
generate initial ideas and concepts for inclusion. Furthermore, the content of 
‘Towards Advanced and Consultant Level Pharmacy Practice – A Competency 
Framework for Renal Pharmacists - UK Renal Pharmacy Group 2009’ (BRADLEY 
2009) was further used as a guide towards the construction of the questionnaire. 
The questionnaire design was also supplemented with more up to date resources. 
4.3.2. Design of the tool 
The constructs were used to frame key sections of the questionnaire. This 
resulted in robust structure and content that is relevant to the project aims and 
objectives. 
At the outset of the questionnaire, an initial screening question identified those 
UKRPG members not practicing clinical pharmacy in the UK. Remaining items 
were grouped into sections of: demographics, clinical practice (characteristics 
and types of clinical pharmacy services provided for outpatients and inpatients) 
and prescribing practice (development and implementation of prescribing 
practice, model of prescribing, areas and frequency of prescribing). 
Questionnaire items were of various types including, where appropriate, closed 
type questions and some open questions to allow respondents to provide 
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explanatory comments. Attitudinal type items on the development of clinical and 
prescribing practice used a 5-point Likert scale format. In the demographics 
section of the questionnaire, participants were asked to respond to a question 
relating to descriptors from Rogers Diffusion of Innovation theory these included 
whether they felt they were; ‘laggards’, ‘late majority’, ‘early majority’, ‘early 
adopters’ or ‘innovators’ (Lundblad 2003) 
Items on development and implementation of clinical and prescribing practice 
were derived from the Consolidated Framework for Implementation Research 
(CFIR), which is based on the principles of implementation theory (Damschroder 
2009). CFIR includes five major domains (intervention characteristics: aspects on 
the intervention that may impact the implementation success, outer setting: 
external influences on intervention implementation, inner setting: characteristics 
of the implementing organisation, characteristics of individuals: individuals 
attributes and belief towards the intervention and process: stages of 
implementation) with 39 underlying constructs and sub-constructs that can 
potentially influence efforts to change practice (Damschroder 2009). The most 
relevant constructs were used to guide the development of the survey questions 
to ensure comprehensive coverage of the most important elements of the clinical 
and prescribing practice of pharmacists in the care of patients with CKD. 
4.3.3. Expert panel review 
The questionnaire was developed by the research team (FA, SC and DS) and was 
checked and evaluated for face and content validity by a panel of experts from 
the university (KM, TM and KGS), from practice (BP) and from the board 
members of the UKRPG (CA and CM). 
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Feedback from the expert panel was received in a written form on the drafted 
questionnaire. Majority of the comments were related to typo errors and lack of 
understanding of a few questions. All comments were considered and edited 
before piloting the survey.  
4.3.4. Think a loud testing 
Think aloud testing of the tool was a one-to-one procedure where the researcher 
met with each of the experts (DG, MM and BP) in a quiet office. This procedure 
allows the readers of the questionnaire to think out loud to verbalise their 
thoughts throughout the process of reading the questionnaire. Think aloud 
testing help establishing cognitive validity of the questionnaire to ensure that the 
survey participants will respond in the manner intended by the researcher. The 
final version of the questionnaire was developed in ‘Online Surveys’, JISC, UK 
(formerly Bristol Online Survey Tool®, https://www.jisc.ac.uk/online-surveys) 
(Appendix 4.1). 
4.3.5. Pilot 
Piloting of the questionnaire was aimed to test for face and validity of the content 
prior to use in the main survey. It was also aimed to predict the response rate of 
the survey. 
The list of pilot participants was selected by a coordinator of the UKRPG and was 
totally anonymous for the research team. The questionnaire was piloted with a 
random sample of 14 (around 10% of the target population) members of the 
UKRPG. An email was sent to invite the UKRPG members to complete the pilot 
questionnaire with only six responded to the pilot survey (Appendix 4.2). As 
piloting resulted in only minor formatting changes, pilot data were included in the 
final dataset. 
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4.3.6. Techniques to maximise response rate 
To enhance the response rate evidence-based techniques were used. Monetary 
incentive in the form of a prize draw was used to encourage participations. An 
optional form was linked at the end of the questionnaire to opt in for the prize 
draw (Appendix 4.3). An information sheet was attached at the start of the 
questionnaire to familiarise the participants with the objectives and answer to 
frequently asked questions. Reminders were sent at two occasions on given 
intervals. The researcher attended the annual conference of the UKRPG which 
coincided with the launch of the survey. The conference was an opportunity to 
network with the participants and make them aware about the importance of the 
survey and encourage participation. The researcher also borrowed four iPads 
from the university and set them on the survey link for participants willing to 
complete the survey during the conference.   
4.3.7. Content of the questionnaire  
Section 1 (Screening question to identify the participants who are practising 
clinically in the care of patients with CKD in the UK) 
Section 2 (Demographics) 
Section 3 (About the clinical practice in CKD patient care) 
Section 4 (About the prescribing practice in CKD patient care) 
Section 5 (Key areas for future development) followed by a link to a separate 
questionnaire to opt in for prize draw and involvement in further research. In 
addition to the closed question items in the survey, at the end of each section, 
participants were asked to share their experiences and views more fully through 
provision of any open comments. 
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4.3.8. Distribution of the questionnaire 
The chair of the UKRPG was contacted to help distributing the link to the 
members anonymously. A coordinator was assigned for this purpose and the 
estimated number of the members was (n = 140). The coordinator was sent the 
email text (Appendix 4.4) with a link to the survey for distribution to the UKRPG 
members. There was no direct contact between the researcher and any of the 
participants. The questionnaire was addressed to the UKRPG member hence 
anonymous and a deadline for return was clearly stated in bold and highlighted 
font.  
4.3.9. Consent 
No separate consent form was included in the questionnaire and any completed 
response was dealt as consent to participate in the survey.  
4.3.10. Reminders 
During the pilot phase no reminders were sent and the deadline to complete the 
pilot questionnaire was set at four weeks. 
The original survey had two reminders at two weeks interval sent on beginning of 
week three and week five (Appendix 4.5 and 4.6).  
4.3.11. Survey setting 
Across the UK, pharmacist members of the UKRPG and practising clinically in the 
UK (currently 140 members) 
4.3.12. Inclusion and exclusion criteria  
A) Inclusion criteria 
All pharmacists registered with the UKRPG and clinically practise in the UK.  
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B) Exclusion criteria 
Any members of the UKRPG involved in the development and piloting of the 
survey tool. Any pharmacist not practising clinically in the UK, or working in a 
non-clinical role. 
C) Sampling frame/size 
The sampling frame was 140 pharmacists. No sampling was undertaken since the 
entire population of pharmacist members of the UKRPG was surveyed. 
4.3.13. Data collection 
An invitation email, with a link to the questionnaire and the participant 
information leaflet, was sent to the UKRPG coordinator to distribute to members. 
Evidence-based approaches were used to enhance the response rate (Nakash 
2006), namely an information sheet to outline study objectives and potential 
benefits, entry into a prize draw, and two reminders at monthly intervals. In 
addition, the lead researcher promoted the work at the annual UKRPG conference 
and encouraged the pharmacists to participant in the survey.  
Data were collected over a period of six weeks from 17th of September 2018 till 
28th of October 2018. 
4.3.14.  Data analysis 
Data were analysed using descriptive statistics using Statistical Package for the 
Social Sciences SPSS® Statistics Version 25; the population size and number of 
respondents limited the potential for inferential analysis. Free text comments 
were analysed independently by two researchers by using the Framework 
Approach to qualitative data content analysis (Gale 2013). 
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4.3.15. Ethical considerations   
The Ethical Review Panel of the School of Pharmacy and Life Sciences at Robert 
Gordon University, UK approved this study (S130) (Appendix 4.7). As the study 
recruited members of a professional network, formal National Health Service 
approval was not required.  
4.4. Results 
Seventy-one responses were received from the 140 participants invited to take 
part giving a response rate of 50.0%. Of the 71 responses, seven were not 
currently practicing clinical pharmacy giving 64 responses for analysis.  
Table 4.1 summarises demographics of the study participants. Almost three 
quarter were female (78.1%, n = 50) with just over half being 31-40 years of 
age (51.6%, n = 33). All were mainly practicing in secondary care setting as 
their main job sector (100%, n = 64), with (45.3%, n = 29) participants had 
experience of working in community pharmacy and very few in general practice 
(3.1%, n = 2). A majority of the respondents were practicing in England (75.0%, 
n = 48). Over a third (35.9%, n = 23) of the pharmacists have been providing 
care for patients with CKD for 1 – 5 years with 20.3% (n = 13) for 11 – 15 years 
and fifty-three (82.8%, n = 53) of respondents were nonmedical prescribers. 
Very few participants held any type of Royal Pharmaceutical Society faculty 
membership, with (7.5%, n = 5) holding stage II Faculty Member (MFRPSII) and 
only (4.7%, n = 3) with Faculty Fellow (FFRPS). More than half of respondents 
(57.8%, n = 37) indicated that they ‘think for some time before adopting new 
ways of working’ which corresponds with the ‘early majority’ category in Rogers 




Table 4.1: Demographic characteristics of participants (N=64) 
Title Categories  n (%) 
Sex Male 14 (21.9) 
Female 50 (78.1) 
Age  Less than 30 years 14 (21.9) 
31-40 years 33 (51.6) 
41-50 years 10 (15.6) 
51-60 years 7 (10.9) 
61 year and above 0 (0) 
Main job sector of practice  Secondary care 64 (100) 
Primary care 0 (0) 
GP practice 0 (0) 
Community pharmacy 0 (0) 
Other 0 (0) 
Geographical area of practice  England 48 (75) 
Scotland 10 (15.6) 
Wales 4 (6.3) 
Northern Ireland 2 (3.1) 
Academic qualifications 
(Multiple selection allowed) 
BSc 16 (10.2) 
MPharm 46 (29.3) 
Postgraduate diploma 49 (31.2) 
Postgraduate certificate 11 (7) 
MSc 16 (10.2) 
PhD 3 (1.9) 
Other 16 (10.2) 
Years qualified as a 
pharmacist 
less than a year 0 (0) 
1-5 years 9 (14.1) 
6-10 years 13 (20.3) 
11-15 years 17 (26.5) 
16-20 years 10 (15.6) 
More than 20 years 14 (21.9) 
Missing 1 (1.6) 
Years worked in hospital 
pharmacy  
Never worked in this sector 0 (0) 
Less than 1 year 1 (1.6) 
1-5 years 11 (17.2) 
6-10 years 12 (18.8) 
11-15years 20 (31.3) 
16-20 years 8 (12.5) 
more than 20 years 12 (18.8) 
Years worked in community 
pharmacy  
Never worked in this sector 19 (29.7) 
Less than 1 year 14 (21.9) 
1-5 years 13 (20.2) 
6-10 years 1 (1.6) 
11-15years 0 (0) 
16-20 years 1 (1.6) 
more than 20 years 0 (0) 
Missing  16 (25) 
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Table 4.1: Demographic characteristics of participants (N=64) (continued…) 
Title Categories  n (%) 
Years worked in GP 
practice  
Never worked in this sector 38 (59.4) 
Less than 1 year 2 (3.1) 
1-5 years 0 (0) 
6-10 years 0 (0) 
11-15years 0 (0) 
16-20 years 0 (0) 
more than 20 years 0 (0) 
Missing  24 (37.5) 
Work terms Fixed term/temporary full time  
(35 hours or more per week) 
13 (20.3) 
Fixed term/temporary part-time  
(less than 35 hours per week) 
3 (4.7) 
Permanent fulltime  
(35 hours or more per week) 
31 (48.4) 
Permanent part-time  
(less than 35 hours per week) 
16 (25) 
Secondment 0 (0) 
Missing  1 (1.6) 
Stage I Faculty Member 
(MFRPSI)  
Currently working towards 9 (14) 
Currently held 0 (0) 
Not applicable 39 (61) 
Missing  16 (25) 
Stage II Faculty Member 
(MFRPSII)  
Currently working towards 4 (6.3) 
Currently held 5 (7.8) 
Not applicable 39 (60.9) 
Missing  16 (25) 
Faculty Fellow (FFRPS)  Currently working towards 2 (3.1) 
Currently held 3 (4.7) 
Not applicable 40 (62.5) 
Missing  19 (29.7) 
Characteristics of the 
innovation  
I resist new ways of working, I am cautious 
in relation to new ways of working 
0 (0) 
I tend to change once most of my peers 
have done so 
4 (6.3) 
I think for some time before adopting new 
ways of working 
37 (57.8) 
I serve as a role model for others in relation 
to new ways of working 
10 (15.6) 
I am innovative with new ways of working 13 (20.3) 
Nonmedical prescriber  Yes 53 (82.8) 
No 11 (17.2) 
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Full data from the survey is provided in Tables 4.2 to 4.3 with key findings from 
each highlighted below.  
4.4.1. Clinical pharmacy services for inpatients 
All the respondents were providing care in the inpatient setting (n = 64) in a 
variety of areas as shown in table 4.2. The majority of respondents (87.5%, n = 
56) provided general pharmaceutical care, with pharmaceutical care specifically 
for dialysis patients provided by 84.4% (n = 54). Individual patient medication 
related education was provided by 85.9% (n = 55), while 81.3% (n = 52) of the 
respondents had regular meetings with the multidisciplinary team.  
 
Pharmaceutical care for transplantation patients was provided by 71.9% (n = 46) 
of the respondents with such services provided with a variety of frequencies but 
by more than half (54.3%, n=25) on a daily basis during the working week.  
Medicines reconciliation was the most frequently provided service with 89.1% (n 
= 57) of respondents indicating that this service was provided throughout the 
week (i.e. daily weekdays and daily weekdays and weekends) by 85.9% (n=49)  
 
Consulting inpatients with different CKD related conditions was performed by 
almost three-quarter of the participants, with 76.6% (n = 49) consulting patients 
with mineral bone disease, acute kidney injury by 76.6% (n = 49), other renal 
complications by 71.9% (n = 46) and consulting inpatients on haemodialysis or 
peritoneal dialysis by 70.3% (n = 45). These consultations were provided mostly 
on daily basis on weekdays or on an ‘ad hoc’ basis by most of the participants in 
the inpatient setting. 
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Compared to the above there were ‘Areas of care’ where respondents indicated 
they were less involved. Around two thirds of respondents indicated that they 
attended medical ward rounds with the multidisciplinary team (67.2%, n = 43) 
with a third of these (37.2%, n=16) indicating doing this on a daily basis during 
the working week. Targeted disease specific medication review services were 
also less developed with almost two thirds undertaking anaemia targeted review 




Table 4.2: Characteristics of clinical pharmacy services you provide for INPATIENTS with CKD (N=64) 
Area of care Provision 
of care 











Once/week Ad hoc  Missing 
n (%) n (%) n (%) n (%) n (%) n (%)  n (%) 
General pharmaceutical care  56 (87.5) 33 (58.9) 13 (23.2) 7 (12.5) 1 (1.8) 2 (3.6) 0 (0) 
Pharmaceutical care for patients receiving dialysis  54 (84.4) 32 (59.3) 8 (14.8) 6 (11.1) 2 (3.7) 6 (11.1) 0 (0) 
Pharmaceutical care for patients at transplantation /follow-
up 
46 (71.9) 25 (54.3) 8 (17.4) 6 (13) 3 (6.5) 4 (8.7) 0 (0) 
Full medication regimen polypharmacy review 50 (78.1) 27 (54) 6 (12) 8 (16) 2 (4) 6 (12) 1 (2) 
Targeted CKD renal medication review  50 (78.1) 23 (46) 6 (12) 10 (20) 2 (4) 9 (18) 0 (0) 
Targeted renal medication review: transplantation  47 (73.4) 18 (38.3) 7 (14.9) 6 (12.8) 2 (4.3) 13 (27.7) 1 (2.1) 
Targeted renal medication review: vasculitis  44 (68.8) 13 (29.5) 3 (6.8) 5 (11.4) 1 (2.3) 22 (50) 0 (0) 
Targeted renal medication review: anaemia  42 (65.6) 15 (37.5) 6 (14.3) 9 (21.4) 1 (2.4) 11 (26.2) 0 (0) 
Targeted renal medication review: hypertension  42 (65.6) 20 (47.6) 5 (11.9) 4 (9.5) 2 (4.8) 11 (26.2) 0 (0) 
Consulting inpatients with mineral bone disease  49 (76.6) 19 (38.8) 6 (12.2) 11 (22.4) 2 (4.1) 10 (20.1) 1 (2) 
Consulting inpatients with acute kidney injury  49 (76.6) 23 (46.9) 7 (14.3) 6 (12.2) 3 (6.1) 10 (20.4) 0 (0) 
Consulting inpatients with renal complication  46 (71.9) 24 (52.2) 7 (15.2) 9 (19.6) 0 (0) 6 (13) 0 (0) 
Consulting inpatients on haemodialysis or peritoneal 
dialysis  
45 (70.3) 24 (53.3) 5 (11.1) 7 (15.6) 3 (6.7) 6 (13.3) 0 (0) 
Medicines reconciliation  57 (89.1) 34 (59.6) 15 (26.3) 3 (5.3) 2 (3.5) 2 (3.5) 1 (1.8) 
Individual patient medication related education  55 (85.9) 23 (41.8) 6 (10.9) 8 (14.5) 7 (12.7) 10 (18.2) 1 (1.8) 
Meetings with multidisciplinary team  52 (81.3) 11 (21.2) 4 (7.7) 13 (25) 12 (23.1) 10 (19.2) 2 (3.8) 
Medical ward round with multidisciplinary team 43 (67.2) 16 (37.2) 5 (11.6) 9 (20.9) 8 (18.6) 3 (7) 2 (4.7) 
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4.4.2. Clinical pharmacy services for outpatients 
The provision of care in the outpatient setting was generally less frequent than 
the inpatient setting. The characteristics of services in the outpatient setting are 
provided in table 4.3. The most frequently performed activities included; 
providing general pharmaceutical care by 62.5% (n = 40) and meeting with the 
multidisciplinary team by 64.1% (n = 41). General pharmaceutical care for 
patients in an outpatient setting was performed by 40.0% (n = 16) of the 
respondents on a daily basis during weekdays, whereas, 32.5% (n = 13) were 
providing the care on an ‘ad hoc’ basis.  
 
Many of the respondents were providing pharmaceutical care for patients 
receiving dialysis (59.4%, n = 38) and transplantation (57.8%, n = 37). These 
activities were provided daily on weekdays by 34.2% (n = 13) and 35.2% (n = 
13) respectively.  Less frequently provided activities were; consulting for specific 
conditions including haemodialysis or peritoneal dialysis (34.4%, n = 22), other 
renal complications (31.3%, n = 20), acute kidney injury (14.1%, n = 9) and 
mineral bone disease (26.6%, n = 17) mostly on an ad hoc basis.  
 
Individual patient medication related education was performed by 59.4% (n = 
38) of the respondents, mostly either on an ‘ad hoc’ basis by 42.1% (n = 16), 
‘two to three times a week’ by 23.7% (n = 9) or ‘once a week’ by 21.1% (n = 8) 
of the respondents. Targeted disease specific medication reviews were again 
among the least frequently performed activities in the outpatient setting with 
only a quarter undertaking hypertension reviews (25%, n = 42), 34.4% 
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Table 4.3: Characteristics of clinical pharmacy services you provide for OUTPATIENTS with CKD (N=64) 
Area of care Provision 
of care 









Once/week Ad hoc  Missing 
n (%) n (%) n (%) n (%) n (%) n (%)  n (%) 
General pharmaceutical care  40 (62.5) 16 (40) 4 (10) 4 (10) 3 (7.5) 13 (32.5) 0 (0) 
Meetings with multidisciplinary team 41 (64.1) 3 (7.3) 2 (4.9) 10 (24.4) 13 (31.7) 9 (22) 1 (2.4) 
Individual patient medication related education  38 (59.4) 3 (7.9) 1 (2.6) 9 (23.7) 8 (21.1) 16 (42.1) 1 (2.6) 
Pharmaceutical care for patients receiving 
dialysis  
38 (59.4) 13 (34.2) 3 (7.9) 5 (13.7) 3 (7.9) 13(34.2) 1(2.6) 
Pharmaceutical care for patients at 
transplantation /follow-up 
37 (57.8) 13 (35.1) 2 (5.4) 7 (18.9) 5 (13.7) 9 (24.3) 1 (2.7) 
Medicines reconciliation  31 (48.4) 8 (25.8) 6 (19.4) 7 (22.6) 4 (12.9) 5 (16.1) 1 (3.2) 
Full medication regimen poly-pharmacy review 28 (43.8) 5 (17.9) 1 (3.6) 8 (28.6) 3 (10.7) 10(35.7) 1 (3.6) 
Targeted renal medication review: 
transplantation  
29 (45.3) 7 (24.1) 1 (3.4) 6 (20.7) 5 (17.2) 10 (34.5) 0 (0) 
Targeted CKD renal medication review  27 (42.2) 1 (3.7) 1 (3.7) 5 (18.5) 4 (14.8) 14 (51.9) 1 (3.7) 
Targeted renal medication review: vasculitis  22 (34.4) 1 (4.5) 0 (0) 3 (13.6) 4 (18.2) 14 (63.6) 0 (0) 
Targeted renal medication review: anaemia  21 (32.8) 1 (4.8) 2 (9.5) 2 (9.5) 7 (33.3) 9 (42.9) 0 (0) 
Targeted renal medication review: hypertension  16 (25) 1 (6.3) 1 (6.3) 2 (12.5) 2 (12.5) 9 (56.3) 1 (6.3) 
Consulting out-patients on haemodialysis or 
peritoneal dialysis  
22 (34.4) 2 (9.1) 3 (13.6) 4 (18.2) 1 (4.5) 11 (50) 1 (4.5) 
Consulting outpatients with renal complication  20 (31.3) 1 (5) 1 (5) 7 (35) 2 (10) 9 (45) 0 (0) 
Consulting outpatients with mineral bone 
disease  
17 (26.6) 1 (5.9) 1 (5.9) 2 (11.8) 5 (29.4) 8 (47.1) 0 (0) 
Consulting outpatients with acute kidney injury  9 (14.1) 1 (11.1) 0 (0) 1 (11.1) 1 (11.1) 6 (66.7) 0 (0) 
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4.4.3. Additional roles of pharmacists to support delivery of services 
Additional roles undertaken by the pharmacist to support delivery of patient care 
are shown in table 4.4.  
The most frequently performed additional roles were delivering education and 
training for other pharmacy staff (90.6%, (n = 58), other healthcare 
professionals (84.4%, n = 54/64) and students (81.3%, n = 52). The least 
frequently performed activities were academic research (7.8%, n = 5) and care 
home support (9.4%, n = 6). A number of respondents were planning to perform 
these activities within the next 12 months, with a third (34.4%, n = 22) of 
respondents planning to undertake academic research. Few (3.1%, n = 2), 



















Table 4.4: Additional roles undertaken by the pharmacist to support delivery of 








No plans Missing 
n (%) n (%) n (%) n (%) 
Audits/service evaluations/quality 
improvements 
46 (71.9) 15 (23.4) 1 (1.6) 2 (3.1) 
Care home support 6 (9.4) 2 (3.1) 52 (81.3) 4 (6.3) 
Academic research 5 (7.8) 22 (34.4) 33 (51.6) 4 (6.3) 
Providing education/training for other pharmacy 
staff 
58 (90.6) 5 (7.8) 0 (0) 1 (1.6) 
Providing education/ training for other 
healthcare professionals 
54 (84.4) 6 (9.4) 2 (3.1) 2 (3.1) 
Providing education/ training for students 52 (81.3) 6 (9.4) 5 (7.8) 1 (1.6) 
Providing education/ training for patient groups 31 (48.4) 9 (14.1) 21 (32.8) 3 (4.7) 
Providing education/ training for carers 29 (45.3) 6 (9.4) 25 (39.1) 4 (6.3) 
Providing mentoring for other pharmacy staff 56 (87.5) 5 (7.8) 2 (3.1) 1 (1.6) 
Providing mentoring for other healthcare 
professionals 
32 (50) 7 (10.9) 21 (32.8) 4 (6.3) 
Involved in production of national level 
guidelines, strategy or policy 
12 (18.7) 13 (20.3) 35 (54.7) 4 (6.3) 
Involved in production of in-house guidelines, 
strategy or policy 
56 (87.5) 4 (6.3) 2 (3.1) 2 (3.1) 
Involved in drug and therapeutics committee 
submissions 
48 (75) 7 (10.9) 7 (10.9) 2 (3.1) 
Participation in national working groups e.g. 
UKRPG 
29 (45.3) 5 (7.8) 27 (42.2) 3 (4.7) 
High cost drugs- predict, plan and monitor new 
innovations in terms of business care, funding 
and reimbursement 












4.4.4. Development and implementation of clinical pharmacy practice  
Table 4.5 provides responses to the statements on the development and 
implementation of clinical pharmacy practice in relation to CFIR domains and 
constructs. 
Overall the respondents held positive views on the statements. However, of the 
64 respondents the majority (61.0%, n = 39) agreed or strongly agreed on the 
need for more evidence around the benefits of clinical pharmacy in CKD within 
the CFIR domain of ‘intervention characteristics: evidence strength’.  
The highest levels of agreement were received for the CFIR domain ‘process of 
implementation’ and specifically related to opinion leaders (social influences). 
Almost all agreed/strongly agreed with the statements, “the actions and views of 
renal specialists influence my practice” (95.3%, n = 61) and, “the actions and 
views of other members of my profession influence my practice” (89.0%, n = 
57). 
Within the CFIR domain of ‘inner setting: learning climate and process’ there was 
clear disagreement with statements relating to having sufficient time to reflect 
on practice with more than half indicating they strongly disagree or disagree 
(56.2%, n = 36) and the ‘inner setting: available resources’ statement on having 
sufficient cover for continuation of the clinical services provided when not in the 
department with 68.8% indicating they strongly disagree or disagree (n = 44).  
The majority of respondents strongly agreed or agreed that they were burdened 
with having to provide other services taking them away from providing care 
(65.6%, n = 42). Almost two thirds of respondents strongly disagreed or 
disagreed that they had sufficient administrative support to facilitate their 
practice (65.6%, n = 42).  
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The statement associated with the CFIR domain of ‘characteristics of individuals’ 
indicates that in relation to ‘self-efficacy’, a high proportion of respondents 
strongly agreed or agreed that they are confident in their abilities in general and 
in working as part of the multidisciplinary team (85.9%, n = 55).  
There was also strong agreement with statements relating to the ‘outer setting’ 
domain of the CFIR with nearly 60% of respondents strongly agreeing or 
agreeing to the ‘peer pressure’ statement “I feel that colleagues in other 
organisations are ahead in implementing the role” (59.4%, n = 38).
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Table 4.5: Development and implementation of clinical pharmacy practice. Responses to items within each of the CFIR 
domains (Median in bold) (N=64) 











    n (%) n (%) n (%) n (%) 
INTERVENTION 
CHARACTERISTICS: 
EVIDENCE STRENGTH  
I feel there is a need for more 
evidence for the benefits of my role  
39 (61) 14(21.9) 9 (14.1) 2 (3.1) 
INTERVENTION 
CHARACTERISTICS: 
QUALITY / COST 
I feel that cost of service provision 
is a deterrent to the development 
of my role 
45 (70.3) 8 (12.5) 10 (15.6) 1 (1.6) 
CHARACTERISTICS OF 
INDIVIDUALS: SELF 
EFFICACY / PERSONAL 
ATTRIBUTES 
I am confident in my abilities 55 (85.9) 6 (9.3) 2 (3.2) 1 (1.6) 
I am confident in my ability as a 
member of the multidisciplinary 
team 
55 (85.9) 5 (7.8) 2 (3.2) 2 (3.2) 
OUTER SETTING: PEER 
PRESSURE 
I feel that colleagues in other 
organisations are ahead in 
implementing the role 
38 (59.4) 16 (25) 8 (12.5) 2 (3.2) 
Advice and guidance from 
professional organisation such as 
UKRPG influence how I practise in 
my role 
50 (78.1) 9 (14.1) 4 (6.3) 1 (1.6)  
INNER SETTING: GOALS / 
FEEDBACK 
I have clear goals for what I want 
to achieve when I practise 
49 (76.5) 12 (18.7) 2 (3.2) 1 (1.6) 
I have clear goals for developing 
clinical pharmacy services 
41 (64.1) 13 (20.3) 8 (12.5) 2 (3.2) 
I have clear goals relating to my 
CPD needs 
46 (71.9) 11 (17.2) 6 (9.3) 1 (1.6) 
INNER SETTING: 
AVAILABLE RESOURCES / 
ACCESS TO KNOWLEDGE & 
INFORMATION 
I feel I have sufficient time to 
practise in my role 




Table 4.5: Development and implementation of clinical pharmacy practice. Responses to items within each of the CFIR 
domains (Median in bold) (N=64) (continued…) 
CFIR Domains and 
constructs 
Statement Strongly 








    n (%) n (%) n (%) n (%) 
INNER SETTING: 
AVAILABLE RESOURCES / 
ACCESS TO KNOWLEDGE & 
INFORMATION 
I feel that I have sufficient cover 
for continuation of the clinical 
services I provide when I am not in 
the department 
14 (21.9) 5 (7.8) 44 (68.8) 1 (1.6) 
I feel that I am burdened with 
having to provide other services 
that take me away from providing 
care for patient with CKD 
42 (65.6) 8 (12.5) 13 (20.4) 1 (1.6) 
I feel I have sufficient 
administrative support to facilitate 
my practice 
10 (15.7) 11 (17.2) 42 (65.6) 1 (1.6) 
I feel I have adequate access to 
patient information (case notes, lab 
data etc) to practise in my role 
59 (92.2) 2 (3.2) 2 (3.2) 1 (1.6) 
I have sufficient support from 
specialists to enable me to practise 
in my role 
53 (82.9) 8 (12.5) 2 (3.2) 1 (1.6) 
I feel I have adequate time to 
attend courses and conferences for 
my development 
17 (26.6) 11 (17.2) 33 (51.1) 1 (1.6) 
I feel I have adequate access to 
funds to allow me to attend courses 
and conferences to help 
development in my role 
13 (20.3) 11 (17.2) 39 (61) 1 (1.6) 
INNER SETTING: 
LEARNING CLIMATE AND 
PROCESS: REFLECTING & 
EVALUATING 
I feel that my clinical knowledge is 
valued and used by the 
multidisciplinary team 
57 (89) 5 (7.8) 1 (1.6) 1 (1.6) 
I am comfortable in my clinical 
pharmacy practice to try out new 
methods of service delivery 




Table 4.5: Development and implementation of clinical pharmacy practice. Responses to items within each of the CFIR 
domains (Median in bold) (N=64) (continued…) 












    n (%) n (%) n (%) n (%) 
 
INNER SETTING: LEARNING 
CLIMATE AND PROCESS: 
REFLECTING & EVALUATING 
 
I feel I have sufficient time to 
reflect and think about my 
clinical pharmacy practice 
13 (20.3) 14(21.9) 36 (56.2) 1 (1.6) 
I have ways of monitoring the 
quality of my clinical pharmacy 
practice caring for patients with 
CKD 
12 (18.7) 17 (26.6) 34 (53.1) 1 (1.6) 
PROCESS: OPINION LEADERS 
(SOCIAL INFLUENCES) 
The actions and views of other 
members of my profession 
influence my practice 
57 (89) 4 (6.3) 2 (3.2) 1 (1.6) 
The actions and views of renal 
specialists influence my practice 
61 (95.3) 2 (3.2) 0 (0) 1 (1.6) 
I feel my role as a clinical 
pharmacist is not fully supported 
by my peers 
16 (25) 11 (17.2) 36 (56.3) 1 (1.6) 
I feel my role as clinical 
pharmacist for patients with CKD 
is not fully supported by my 
multidisciplinary team 
9 (14.1) 6 (9.3) 48 (75) 1 (1.6) 
I feel my role as a clinical 
pharmacist for patients with CKD 
is not fully supported by my 
organisation 
17 (26.6) 13 (20.3) 33 (51.5) 1 (1.6) 
I feel my role as a clinical 
pharmacist for patients with CKD 
is not fully supported by 
specialists 
5 (7.8) 10 (15.6) 48 (75) 1 (1.6) 
PROCESS: OPINION LEADERS 
(SOCIAL INFLUENCES) 
The actions and views of other 
members of the multi-
disciplinary team influence my 
practice 
57 (89) 5 (7.8) 1 (1.6) 1 (1.6) 
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4.4.5. Characteristics of prescribing practice 
Three quarters of the respondents (75.0%, n = 48) were qualified nonmedical 
prescribers and were currently actively prescribing. Most of them were practicing 
independent prescribing (87.5 %, n= 42). More than half of the respondents had 
been registered with the United Kingdom General Pharmaceutical Council (GPhC) 
as prescribers for between one and five years (52.1%, n = 25). The respondents 
were prescribing in various areas related to CKD as shown in figure 4.1. 
 
 


































4.4.6. Development and implementation of prescribing practice  
Table 4.6 provides responses to statements derived from CFIR on the 
development and implementation of prescribing practice relating to CKD. The 
highest level of agreement was reported within the CFIR domain of 
‘characteristics of individual: self-efficacy/personal attributes’. Statements with 
highest levels of agreement were, “I am competent to prescribe within the 
multidisciplinary team” (strongly agree/agree 93.7%, n = 45) and “I am 
competent in continuing the prescribing of medicines initiated by others” 
(strongly agree/agree 91.6% n = 44). In relation to the domain of 
‘characteristics of individuals: other personal attributes’ almost two thirds 
believed that patients would be treated more effectively if a pharmacist 
prescribes for them (66.7%, n = 32), while 73.0% (n = 35) believed prescribing 
is more cost-effective if done by the pharmacist. 
The highest levels of disagreement for statements related to the CFIR domain of 
‘process of implementation: construct of social influences’, specific responses 
were, “My prescribing is not fully supported by my multidisciplinary team” 
(disagree/strongly disagree 83.3%, n = 40) and “My prescribing is not fully 
supported by my organisation” (disagree/strongly disagree 79.1%, n = 38). The 
lowest level of agreement was for, “My prescribing is not fully supported by 
specialists” (strongly agree/agree 4.2%, n = 2). 
Through responses to statements in the CFIR domain ‘intervention 
characteristics: evidence strength and quality’ more than half of respondents 
strongly agreed or agreed that they felt there was a need for more evidence for 
the benefits of pharmacist prescribing for patients with CKD (56.2%, n = 27),  
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There were mixed responses with statements relating to the ‘outer setting’ 
domain of the CFIR in relation to ‘peer pressure’. Responses to the statement “I 
feel that colleagues in other organisations are ahead in implementing pharmacist 
prescribing in their practice” indicated 52% (n = 25) agreed with the statement 
and 29.2% (n = 14) disagreeing. Almost two-third (64.6%, n = 31) of the 
respondents strongly agreed or agreed that ‘other professional organisations 
influence their prescribing practice’. 
Within the CFIR domain ‘inner setting: available resources’ for the statement on 
having ‘sufficient time to prescribe’ there was disparity in the responses among 
respondents. Around a third of the respondents (37.5%, n = 18) strongly agreed 
or agreed, while 39.6% (n = 19) strongly disagreed or disagreed and the 
remainder (18.7%, n = 9) neither agreed nor disagreed with the statement. 
There was a similar response to the statement related to the sufficiency of 
administrative support to facilitate their prescribing’ with (37.5%, n = 18) in 




Table 4.6: Development and implementation of prescribing practice. Responses to items within each of the CFIR 
domains (Median in bold) (N=48) 
CFIR Domains and 
constructs 













& QUALITY / COST 
I feel there is a need for more 
evidence for the benefits of 
pharmacist prescribing for 
patients with CKD 
27(56.2) 12 (25) 7 (14.6) 2 (4.2) 
I feel that cost of service 
provision are a deterrent to the 
development of my prescribing 
practice 
25 (52.1) 9 (18.7) 12 (25) 2 (4.2) 
I feel that the cost of some drugs 
used in CKD are a deterrent to 
my prescribing 
6 (12.5) 10 (20.8) 30 (62.5) 2 (4.2) 
CHARACTERISTICS OF 
INDIVIDUALS: SELF 
EFFICACY / PERSONAL 
ATTRIBUTES 
I am confident in my ability to 
initiate prescribing of medicines 
for my patients 
38 (79.2) 5 (10.4) 3 (6.3) 2 (4.2) 
I lack confidence in switching 
patients from one drug to 
another when I prescribe 
5 (10.4) 12 (25) 29 (60.5) 2 (4.2) 
I am confident in my ability to 
prescribe for patients with CKD 
when they have been initiated on 
medicines by others 
41 (85.4) 3 (6.3) 2 (4.2) 2 (4.2) 
I am confident in my ability to 
prescribe within the 
multidisciplinary team 




Table 4.6: Development and implementation of prescribing practice. Responses to items within each of the CFIR 
domains (Median in bold) (N=48) (continued…) 
CFIR Domains and 
constructs 









    n (%) n (%) n (%) n (%) 
CHARACTERISTICS OF 
INDIVIDUALS: SELF 
EFFICACY / PERSONAL 
ATTRIBUTES 
I lack competency to initiate 
prescribing of medicines for my 
patients 
6 (12.5) 6 (12.5) 34 (70.8) 2 (4.2) 
I am competent in continuing the 
prescribing of medicines initiated 
by others 
44 (91.6) 1 (2.1) 1 (2.1) 2 (4.2) 
I am competent to switch 
treatments (medicines) when I 
prescribe for my patients 
42 (87.5) 1 (2.1) 3 (6.3) 2 (4.2) 
I am competent to prescribe 
within the multidisciplinary team  










Table 4.6: Development and implementation of prescribing practice. Responses to items within each of the CFIR 
domains (Median in bold) (N=48) (continued…) 
CFIR Domains and 
constructs 
Statement Strongly 











I feel anxious when initiating 
medicines for patients with CKD 
12 (25) 12 (25) 22 (45.9) 2 (4.2) 
I feel anxious when prescribing 
medicines which have been 
initiated by others 
5 (10.4) 11 (22.9) 30 (62.5) 2 (4.2) 
I get professional satisfaction 
when initiating the prescribing 
for patients 
36 (75) 8 (16.7) 0 (0) 4 (8.3) 
I get professional satisfaction 
when prescribing medicines 
which have been initiated by 
others 
25 (52.1) 18 (37.5) 3 (6.3) 2 (4.2) 
If I prescribe for patients with 
CKD, I believe that patients will 
be treated more effectively 
32 (66.7) 11 (22.9) 3 (6.3) 2 (4.2) 
If I prescribe for patients with 
CKD, I believe that patients will 
have fewer adverse effects 
18 (37.5) 20 (41.6) 8 (16.7) 2 (4.2) 
If I prescribe for patients with 
CKD, I believe that patients will 
be treated more cost effectively 
35 (73) 9 (18.7) 1 (2.1) 3 (6.3) 
If I do not prescribe for patients 
with CKD, I believe that patients 
may come to harm 
14 (29.2) 11 (22.9) 21 (43.7) 2 (4.2) 
If I have to switch medications in 
stabilised patients, I believe that 
patient care may be 
compromised 




Table 4.6: Development and implementation of prescribing practice. Responses to items within each of the CFIR 
domains (Median in bold) (N=48) (continued…) 
CFIR Domains and 
constructs 









    n (%) n (%) n (%) n (%) 
OUTER SETTING: PEER 
PRESSURE 
I feel that colleagues in other 
organisations are ahead in 
implementing pharmacist 
prescribing in their practice 
25 (52) 7 (14.6) 14 (29.2) 2 (4.2) 
Advice and guidance from 
professional organisation such as 
UKRPG influence my prescribing 
activity 
31 (64.6) 12 (25) 2 (4.2) 3 (6.3) 
INNER SETTING: 
GOALS / FEEDBACK 
I have clear goals for what I 
want to achieve when I prescribe 
for patients with CKD 
40 (83.3) 3 (6.3) 3 (6.3) 2 (4.2) 
I have clear goals for developing 
services for patients with CKD 
using my prescribing skills 
25 (52) 11 (22.9) 9 (18.7) 3 (6.3) 
I have clear goals relating to my 
CPD around prescribing for 
patients with CKD 










Table 4.6: Development and implementation of prescribing practice. Responses to items within each of the CFIR 
domains (Median in bold) (N=48) (continued…) 
CFIR Domains and 
constructs 
Statement Strongly 







    n (%) n (%) n (%) n (%) 
INNER SETTING: 
AVAILABLE 
RESOURCES / ACCESS 
TO KNOWLEDGE & 
INFORMATION 
I feel I have sufficient time to 
prescribe 
18 (37.5) 9 (18.7) 19 (39.6) 2 (4.2) 
I feel that I have sufficient cover 
for continuation of the 
prescribing services I provide 
when I am not in the department 
12 (25) 1 (2.1) 33 (68.7) 2 (4.2) 
I feel that I am burdened with 
having to provide other services 
that take me away from 
prescribing 
31 (64.6) 2 (4.2) 13 (27.1) 2 (4.2) 
Prescribing systems in my 
organisation facilitate me in 
prescribing 
24 (50) 12 (25) 10 (20.8) 2 (4.2) 
I feel I have sufficient 
administrative support to 
facilitate prescribing 
18 (37.5) 8 (16.7) 20 (41.7) 2 (4.2) 
I feel I have adequate access to 
patient information (case notes, 
lab data etc) to prescribe safely 
and effectively 
43 (89.6) 2 (4.2) 1 (2.1) 2 (4.2) 
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Table 4.6: Development and implementation of prescribing practice. Responses to items within each of the CFIR domains (Median in 
bold) (N=48) (continued…) 












    n (%) n (%) n (%) n (%) 
INNER SETTING: 
AVAILABLE 
RESOURCES / ACCESS 
TO KNOWLEDGE & 
INFORMATION 
I have sufficient support from expert advice and specialists to 
enable me to prescribe safely and effectively 
41 (85.4) 4 (8.3) 0 (0) 3 (6.3) 
I feel I have adequate time to attend courses and conferences 
for my development as a prescriber 
16 (33.4) 7 (14.6) 23 (47.9) 2 (4.2) 
I feel I have adequate access to funds to allow me to attend 
courses and conferences for my development as a prescriber 






I feel able to express my own prescribing development needs 
and discuss these with colleagues 
33(68.7) 7 (14.6) 6 (12.5) 2 (4.2) 
I feel that my prescribing knowledge is valued and used by 
the multidisciplinary team 
40 (83.3) 3 (6.3) 3 (6.3) 2 (4.2) 
I am comfortable in my prescribing practice to try out new 
methods of service delivery 
34 (70.8) 8 (16.7) 4 (8.3) 2 (4.2) 
I feel I have sufficient time to reflect and think about my 
prescribing practice 
16 (33.4) 10 (20.8) 19 (39.6) 2 (4.2) 
I have ways of monitoring the quality of my prescribing 
 




Table 4.6: Development and implementation of prescribing practice. Responses to items within each of the CFIR 
domains (Median in bold) (N=48) (continued…) 
















The actions and views of other 
members of the multi-
disciplinary team influence my 
prescribing activity 
40 (83.3) 5 (10.4) 1 (2.1) 2 (4.2) 
The actions and views of other 
members of my profession 
influence my prescribing activity 
36 (75) 8 (16.7) 2 (4.2) 2 (4.2) 
The actions and views of renal 
specialists influence my 
prescribing activity 
43 (89.6) 3 (6.3) 0 (0) 2 (4.2) 
My prescribing is not fully 
supported by my peers 
6 (12.5) 7 (14.6) 33 (68.8) 2 (4.2) 
My prescribing is not fully 
supported by my 
multidisciplinary team 
2 (4.2) 4 (8.3) 40 (83.3) 2 (4.2) 
My prescribing is not fully 
supported by my organisation 
3 (6.3) 4 (8.3) 38 (79.1) 3 (6.3) 
My prescribing is not fully 
supported by specialists 
2 (4.2) 5 (10.4) 37 (77.1) 4 (8.3) 
The structures and processes 
within my organisation influence 
my prescribing activity 
31 (64.6) 8 (16.7) 7 (14.6) 2 (4.2) 
Increased scrutiny of my 
prescribing by my organisation is 
an influence on my prescribing 




4.5.1. Summary of key results 
This study has provided evidence that the vast majority of UKRPG pharmacists 
practicing in CKD are independent prescribers, providing general pharmaceutical 
care to CKD patients in general and specifically to dialysis and kidney transplant 
patients. Respondents reported being confident in their own abilities and feeling 
comfortable in trying new ways of working. In relation to prescribing most were 
confident in their abilities to initiate prescribing for individual patients within their 
areas of competence.  
4.5.2. Interpretation of results 
This work has been underpinned with theoretical approaches throughout its 
planning and execution. The use of CFIR has provided a framework that has 
enabled the researcher to develop a comprehensive understanding of positive 
and negative influences on implementation of clinical and prescribing services, 
including facilitators and barriers, in CKD. Facilitators for the implementation of 
new services such as prescribing practice was reported by the pharmacist 
respondents and included: experience of service provision and confidence in their 
abilities (characteristics of individuals); having support from multidisciplinary 
team members (process); having clear goals to for further development (inner 
setting) and support from professional organisations (outer setting). In terms of 
barriers to implementing new models of practice respondents indicated there was 
a lack of evidence for the benefit of new clinical pharmacy services in CKD, this 
was generally and specifically for prescribing (intervention 
characteristics/evidence and quality). The lack of funding to support clinical 
pharmacy services was considered a hindrance to service development (inner 
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setting/available resources). Many felt burdened by having to provide other 
clinical and non-clinical services (inner setting/available resources).  
Graham-Clarke et al carried out a systematic review and described the 
facilitators and barriers to implementation of nonmedical prescribing. It included 
42 papers and reported on the complex interdependent interplay of themes that 
could act as facilitators or barriers depending on particular circumstances 
(Graham-Clarke 2018). Facilitators identified included trust, understanding and 
confidence of the multidisciplinary team in the nonmedical prescribing role. These 
social influences are also reflected in the results of this present study where 
pharmacist respondents felt that they had the support of the multi-disciplinary 
team, their organisation and specialists. They also expressed high level of self-
efficacy with many indicating that they felt confident and competent in their 
prescribing practice. The systematic review reported that cost and budget 
limitations were among the main barriers to nonmedical prescribing (Graham-
Clarke 2018). However, in this present study resource related responses showed 
a diversity of views in relation to having sufficient time undertake prescribing 
activities but there was a clear desire to have more resources for sufficient cover 
for continuation of the prescribing services during period of absence and lack of 
resource to cover additional roles and activities that respondent felt diverted 
them away from the prescribing role. Disparities perhaps indicate the 
individuality and differential impact of these factors in different organisations 
where the structures and processes of care provision may vary.   
While all respondents were practicing almost exclusively in secondary care, there 
is potential for community pharmacists to contribute to CKD management. A 
study published in 2014 reported that community pharmacists are willing to have 
greater involvement in the care of patients with CKD and that there is a need to 
 157 
increase awareness of clinic patients of the resource available in the community 
(Zhu 2014). A recent study from Scotland reported on the growing pharmacy 
workforce in general medical practice that is delivering clinical and prescribing 
services (Stewart 2019). There is therefore potential for involvement of this 
workforce in the shared care of patients with CKD. Al Hamarneh et al. reported 
that pharmacists in the community setting can contribute in the improvement of 
the care of patient with CKD by providing comprehensive care services such as 
medication management, patient education, and prescribing (Al Hamarneh 
2018). 
The UK National Renal Workforce Planning Group highlighted that pharmacist 
prescribing will impact on the level and quality of pharmacy services through 
initiatives such as medication related harm risk minimization, improvement in 
patient outcomes and support to other healthcare professional (National Renal 
Workforce Planning Group 2002). It is therefore welcomed that many 
respondents were active prescribers in CKD but there is a need for research to be 
conducted and published to evaluate this and add to the evidence base to show 
that it provides safe, effective and cost-effective care (Al Hamarneh 2018, Al 
Raiisi 2019). 
 
In view of this it is of some concern that few of the specialised renal pharmacists 
in this study were involved in any research. Previous studies have reported a 
variety of barriers to engaging in research activities including; lack of time, 
availability of funding, lack of research knowledge and logistic issues (Awaisu 
2015). To enhance pharmacist’s involvement in research, certain strategies have 
been proposed (Armour 2007, Peterson 2009, Krass 2019). Collaboration with 
academics and professional organisations can be an attractive tool to develop a 
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culture, ethos and skill base in pharmacists for research (Armour 2007, Krass 
2019). A UK survey of community pharmacies in London and Essex reported that 
43% of respondents had participated in some form of pharmacy practice 
research, which indicates the willingness to participate in research given support 
(Rosenbloom 2000). A recently published study on the views and experiences of 
practicing pharmacists in research reported that minority of experienced 
secondary care pharmacists are involved in performing research-based activities 
(12.5%, n = 17) however, participants showed an interest in being involved in 
research-based activities (Stewart 2018). 
 
Specific barriers to clinical and prescribing services reported in this study were 
time, resources, training and administrative support. These challenges are not 
unique to this study and have been reported repeatedly in the literature (Salgado 
2012, Al Raiisi 2019). A key facilitator to service development is education and 
training, and indeed, studies suggest that clinical pharmacy education sessions 
had positive impacts on the management of CKD and that the cost expended on 
educational sessions are warranted to improve patient outcomes (Nasution 
2013). 
 
4.5.3. Strengths and limitations 
There are several strengths to this study, including the application of a 
theoretical framework. Using theory within healthcare research is developing at 
pace and is leading to enhanced robustness and rigour (Brazil 2005). The UK 
Medical Research Council Framework for Developing and Evaluating Complex 
Interventions advocates the systematic use of appropriate theory to develop or 
evaluate an intervention or new service (Campbell 2000). The findings of this 
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study offer an original contribution to the evidence base around structures and 
processes related to pharmacy service provision in CKD. Respondents were from 
all geographical areas of the UK and so the results are likely to be representative 
of the breadth of UK practice. Limitations include the fact that the response rate 
of was around 50% and this may compromise the integrity of the finding. It 
should be noted however that such a response rate for a national online survey 
could be considered commendable given the generally poor responses rate for 
such methods when applied to busy healthcare professionals (Cho 2013). Part of 
the reason for a reduced number of responses may relate to the desire to carry 
out a theoretically based, robust and comprehensive study and as such the 
questionnaire may have been considered too long and involved for some 
potential respondents. In addition, the research team aspired to be as 
economically and environmentally efficient through avoidance of a postal survey 
and therefore opted for online dissemination of the questionnaire. Questionnaire 
tool design and method have both been shown to have an impact on response 
rates and this could have been the case in this survey (Nulty 2008). This was a 
self-completion questionnaire and as such it was not possible to confirm or 
triangulate the validity of the responses. These, of course, could have been 
influenced by a number of biases including; non-response, social desirability and 
conformity, acquiescence and prestige bias (Creswell 2017). Furthermore, 
members of a professional network like the UKRPG may not be truly 
representative of a population at large as patients with CKD may also managed 
by non-renal specialist pharmacists and their views on services to these patients 
may have added another dimension to the results. In addition, all participants 
were practicing in secondary care and so the results are obviously viewed in this 
context. As detailed above clinical pharmacy services are developing rapidly in 
 160 
other sectors such as primary care in the UK and as such this may be an 
appropriate are to consider in future studies.  
Despite these limitations, it is evident that UK renal specialist pharmacists are 
highly involved in aspects of care of those with CKD, both in outpatient and 
inpatient settings.  That was both in the areas of general pharmaceutical care 
and more specialised care in those with dialysis and transplantation. The fact 
that a higher proportion of respondents currently provide greater levels of 
inpatient care compared to outpatient care is predictable, given that the role of 
the hospital clinical pharmacist is more established in the ward setting in the UK 
at present. However, there may be scope to extend this to outpatient settings 
and out into primary care with the further development of pharmacist prescribing 
practice and a policy related aspiration for pharmacists to be responsible for their 
own case load of patients (The Scottish Government 2017). Furthermore, 
inpatient care is reflected more in the Competency Framework for Renal 
Pharmacists produced by the UKRPG (Renal Expert Professional Practice 
Curriculum 2014). Activities reported by respondents, including education and 
counselling, discharge planning, medicines reviews and managed introduction of 
new medicines are those which the UK National Renal Workforce Planning Group 
highlight as requiring pharmacist input (The National Renal Workforce Planning 
Group 2002). The statements within the competency framework and the 
standards of practice produced by the UKRPG for the members to assess their 
competency levels and benchmark it against advanced practice (Renal Expert 
Professional Practice Curriculum 2014), may be guiding practice and contributing 
to the high self-reported levels of confidence and competence (The National 
Renal Workforce Planning Group 2002). These frameworks and standards should 
also inform the level of detail to be reported in studies describing care. The 
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recent systematic review of pharmacist input in CKD noted the lack of published 
detail relating to the structures and processes of practice (Al Raiisi 2019). There 
is also a lack of agreement on what constitute appropriate outcome measures for 
studies exploring clinical pharmacy services in patients with CKD and therefore a 
lack of consistency of choice and use of outcomes in studies. This lack of detail 
greatly reduces the usefulness of the evidence generated about the nature and 
extent of the care. The consequence of this is that it cannot be easily replicated 
or the results pooled in synthesis and meta-analysis type analysis.  
This is highly relevant since in this study respondents expressed a desire to 
develop and implement innovative novel services to improve patient outcomes. 
An example of such innovative work includes studies such as Ishani et al’s RCT 
on assessing the role of interprofessional team in CKD management using 
telehealth which concluded that telehealth is a feasible care delivery strategy but 
more detailed information, on particularly, the structures and processes of this 
model of care and clarity on the theoretical basis for the intervention still need to 
be provided (Ishani 2016). A more detailed evidence base for such services that 
is well founded in a theoretical basis and robustly researched and reported will 
enable the connection of evidence to the development of care provision 
(Donabedian 2005, Raleigh 2010). 
There are several potential avenues for further research. In view of the high 
proportion of pharmacist prescribers working CKD evident from this survey and 
the healthcare policy direction in relation to development of this role there is a 
need for qualitative research to allow a more in-depth exploration of pharmacist 
prescribing in CKD from multiple perspectives. Furthermore, outcomes-based 
research is required to support further the evidence base. 
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4.6. Conclusion 
Results of this survey indicate high levels of clinical practice including wide-
spread nonmedical prescribing activity, demonstrating development of practice, 
since the previous systematic reviews (Salgado 2012, Al Raiisi 2019). The survey 
captured detailed information on pharmacists’ behaviour and experiences in the 
care of patients with CKD through robust application of theoretical approaches. 
Despite the high number of independent pharmacist prescribers among the 
respondents, there was a lack of details on the facilitators and barriers to the 
provision of prescribing services for patients with CKD. The results from this 
survey will inform the current models of clinical pharmacy practice for patients 
with CKD in the UK. The results will stimulate further discussion among the 
practitioners on potential ways to overcome the challenges in further developing 
models of practice in response to healthcare policy changes. This in turn will 
facilitate practitioners to provide better care for their patients. An additional 
impact will be that through monitoring and evaluation of the services there will 
also be ongoing improvements in wellbeing and quality of life of patients. The 
use of CFIR enabled the identification of facilitators and barriers for the 
development of clinical pharmacy but lacked details on pharmacist prescribing 
practice. Insufficient time to undertake additional non-core clinical roles and a 
lack of involvement in skills base for research among respondents could be 
considered major barriers to further development of clinical pharmacy practices 
including prescribing. Further work is planned using qualitative methods to 
explore these matters in more depth. 
4.7. Further research 
The findings from the systematic review (Chapter 3) and the results of this 
survey showed lack in details around pharmacist prescribing for patients with 
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CKD. Therefore, the next phase of stage two of this doctoral research was 
focused on the exploration from a professional perspective, on the development, 
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This chapter presents the details of the last phase of this doctoral research: 
semi-structured interviews with pharmacist prescriber members of the UKRPG 
caring for patients with CKD. In chapter four, the key findings of the survey 
showed that the majority of the participants were registered prescribers, 
however, there was lack of depth of information on the structure, processes and 
outcome of prescribing for patients with CKD. The Government policies in the UK 
prioritise the development of the pharmacist prescribing role (Scottish 
government 2013, Department of Health Northern Ireland 2016, Welsh 
government 2017 and General Pharmaceutical Council 2019). The General 
Pharmaceutical Council also highlighted that the changing demands from health 
services and patients across the UK have significantly influenced the use of 
pharmacist prescribers over the last decade (General Pharmaceutical Council 
2019). National pharmacy strategies across the UK appreciate that employing 
pharmacist prescribers in any healthcare settings allow the best utilisation of 
pharmacists’ prescribing knowledge and skills (General Pharmaceutical Council 
2019).  
 A theoretically underpinned interview was deemed to be a rationale method to 
obtain an in-depth understanding of pharmacist prescribing practice for patients 
with CKD in terms of structure, process and outcomes as a part of sequential 
explanatory mixed-method approach. The CFIR was used throughout this 
doctoral research with all constructs considered relevant to this phase of the 
research project (more details are described in Chapter 2).  The layout of the 
chapter includes the objectives followed by methods, findings, discussion and 
finally the conclusion. This Phase aimed to explore from a professional 
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perspective, the development, implementation and evaluation of pharmacist 
prescribing for patients with CKD in the UK. 
5.1. Research objectives 
The specific objectives in relation to pharmacist prescribing in CKD were: 
1. To describe and characterise the models of pharmacist prescribing practice 
2. To describe the plans, actions and parameters used for evaluating prescribing 
practice.  
3. To explore plans to develop pharmacist-prescribing practice further.  
4. To explore the facilitators and barriers relating to implementation of pharmacist 
prescribing.  
5.2. Methods  
5.2.1. Study design 
A constructivist, phenomenological qualitative semi-structured interview 
approach was employed in this phase of the doctoral research. Justifications for 
following this method as a part of mixed-method approach are described in 
details in Chapter 2 of this thesis.  
5.2.2. Setting 
The study was conducted across the UK and was focused on members of the 
UKRPG with representation across healthcare sectors and from the whole of the 
UK. 
5.2.3. Inclusion exclusion criteria 
All pharmacist prescribers registered with the UKRPG and opted to take part in 
further research during previous parts of this doctoral research were included in 
the interviews. Any members of the UKRPG involved in the development and 
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piloting of the tools used for data collection (n = 6) were excluded from the 
study. 
5.2.4. Sampling approach 
The intended sampling frame was all of the 71 pharmacists that completed the 
survey in stage 2, phase 1 and were registered as prescribers in the UK and were 
currently prescribing for patients with CKD. However, only a proportion of these 
(n = 48) pharmacists indicated that they were prescribers but only 29 agreed to 
take part in this further research.  
An email was sent to all of these 29 respondents with a request to take part in 
further research (Appendix 5.1). This included:  
- An information sheet about the study (Appendix 5.2) and  
- A link to a mini-survey designed to gather brief demographic information 
(Appendix 5.3) and  
- A consent form to be signed and sent back to the researcher via email back 
before the scheduled interview (Appendix 5.4).  
The mini survey used Online Surveys, Jisc® (formerly Bristol Online Survey 
Tool®, https://www.jisc.ac.uk/online-surveys) and was used to gather 
demographic information of the participants. The survey also included an 
information sheet for the participants and questions including: 
 Participants name, preferred way of contact, email and contact number 
 Gender: Male, female, prefer not to say 
 Age: <30 years, 31 – 40 years, 41 – 50 years, 51 – 60 years and >60 years. 
 Geographical area of practice: England, Scotland, Wales and Northern Ireland 
 Years qualified as a pharmacist: <1 year, 1 – 5 years, 6 – 10 years, 11 – 15 
years, 16 – 20 years and >20 years.  
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 Years of experience as prescriber:  <1 year, 1 – 5 years, 6 – 10 years, 11 – 15 
years, 16 – 20 years and >20 years.   
 
Two reminder emails were sent to the participants at four weekly intervals. 
Snowball sampling was used to help identify additional appropriate participants 
to interview to enable reaching data saturation. This approach was undertaken 
by asking the interviewees to suggest a prescribing pharmacist for patients with 
CKD who meets the research inclusion criteria. Two further participants were 
identified this way. Figure 5.1 shows the recruitment process for this phase of 
the doctoral research. 
The point of data saturation was identified using the approach of Francis et al. 
(Francis 2010) with an initial sample of 10 and a stopping criterion of three (ie 
data collection ceased if no further themes were identified from the analysis of 
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5.2.5. Data generation tool development 
The doctoral student attended multiple training sessions and short courses 
provided by the graduate school at Robert Gordon University to develop 
qualitative interview skills.  
The development of the semi-structured interview tool (Appendix 5.5) followed a 
rigorous iterative process that initially involved reviewing of the aim / objectives 
of the overall project to ensure that the interview tool was designed to meet 
these. Information from the literature and the previously completed systematic 
review in stage 1 (Al Raiisi 2019) and the results from the survey in stage 2, 
phase 1 (Al Raiisi 2020) was used to generate initial ideas and concepts for 
inclusion.  
The semi-structured interview tool was designed based on the principles of 
implementation theory with constructs and domains of the Consolidated 
Framework for Implementation Research (CFIR) as described in Chapter 2. The 
CFIR was used to frame key sections of the interview schedule with consideration 
of all domains and constructs of the framework (Damschroder 2009). This 
resulted in rigorous structure and content that was relevant to the research’s aim 
and objectives.  
The development of the tool involved discussions and regular weekly meetings 
with the research supervisors and an expert panel throughout the process of the 
tool development. The four expert panels included senior academic staff with 
expert in qualitative research and three of them with prescribing qualification TM, 
KM, ID and AT who reviewed the interview schedule for credibility (Guba 1981). 
Only minor comments were received from the experts and were incorporated into 
a revised copy of the interview schedule. The schedule was tested with two 
 170 
academic members of staff who were also hospital pharmacists and prescribers 
in a face to face trial interview in an office within the academic institute. Both 
pharmacists agreed that the schedule was clear and easy to understand with no 
suggestions to change it leading to the final version of the interview tool. A pilot 
interview was carried out with one of the pharmacist prescribers who had 
completed the recruitment survey and the data were included in the analysis. 
The pilot interview transcript and findings were discussed with the supervisory 
team and the feedback was considered and incorporated in the analysis to 
ensure dependability and credibility. 
The structure of the interview was divided into sections including demographics, 
characteristics of current prescribing practice, questions relating to different 
relevant constructs of the CFIR and additional aspects of the areas of questioning 
explored in more detail through additional probing questions. 
Use of this framework ensured that all aspects of relevance to the research 
objectives for this part of the work were fully and comprehensively covered 
through the constructs and domains of the CFIR.  
The semi-structured interview questions were mapped to the CFIR domains and 







Table 5.1: Interview questions mapped with CFIR constructs. 
Related CFIR 
construct 
Interview questions Probing questions 
Intervention 
characteristics 
What do you feel are the key 
factors that have influenced 
implementation of prescribing 
practice, generally and in 
relation to your own practice? 
How do you feel you have used evidence to develop 
your practice? 
 
How do you feel that your prescribing has changed 
your practice? What about the impact on patients? 
 
Do you feel that your prescribing practice has changed 
or developed since you started?  
 
What is the complexity of your prescribing practice: 
consider clinical complexity and logistics 
 
What about the costs and savings associated with 
providing a prescribing practice? 
 
What do you feel works very 
well and what needs to 






How do you feel your personal 
characteristics have helped 
develop and implement 
prescribing practice for CKD? 
How you feel you complement other in the 
multidisciplinary team in relation to your prescribing? 
 
How confident are you with your prescribing? 
 
Are you considering developing or changing any 
aspects of your prescribing practice?   
 
Any other traits you have that suit your prescribing 
practice?  
 
How you see your prescribing 
practice developing in future? 
 
 
Inner setting What are the barriers or 
facilitators, within your 
organisation, that have helped 
or hindered the development of 
prescribing practice generally 
and in your own practice? 
 
What factors within your organisation do you feel have 
helped or hindered developments? 
 
How communication within your organisation around 
the development of prescribing practice take place? 
 
Do you receive any support for your prescribing role? 
 
What about how nonmedical prescribing is welcomed, 
encouraged, supported? 
 
What happens to cover prescribing practice when a 
colleague is absent? 
 
What advice you would give to 
others who are considering 
setting up a prescribing 
service? Are there any pitfalls 
you should avoid? 
 
Process  How was pharmacist 
prescribing planned for and 
implemented within your 
organisation? 
How were you and colleagues involved with this?  
‘project champions’  
 
Was there any external influence on this? 
 
How do you assess or evaluate your prescribing 
practice in term of safety, effectiveness, cost 
effectiveness? 
 
Outer setting What about external influences 
on the development and 
implementation of pharmacist 
prescribing in your organisation 
generally and in your own 
prescribing practice? 
Do you feel that colleagues in other organisations are 
ahead in implementing pharmacist prescribing in their 
practice?  
 
Does any external body or organisation influence your 
prescribing practise?  
 
Can you tell me about any other external factors 
affecting your prescribing practice? 
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The interview tool was reviewed independently for credibility by an expert panel 
(TM, LK, and AT) selected by the research team. This ensured that each of the 
question was unambiguous and not leading in any way. It also ensured that the 
content covered all topics of relevance to the aims and objectives and general 
area of the research. Think aloud testing of the interview tool was performed by 
two academic members from the Robert Gordon University (MM and CD)  
5.2.6. Data generation 
Once the demographics survey was completed, the researcher started to contact 
the participants via their preferred method of contact to arrange a suitable date 
and time for the telephone interview. If no response was received from the 
participants within four weeks, another email with a gentle reminder was sent. 
As the participants agreed and replied, a date and time was confirmed for the 
telephone interview. The researcher than booked a room with a telephone line 
where the interviews took place. Before the scheduled date for the interview, the 
researcher ensured that a copy of the information sheet, and the consent form 
was sent to the participants. A signed consent form was obtained from the 
participants by a return email prior to commencing the interviews. 
The researcher was granted permission to audio-record the interview by the 
participant at the start of each interview. Interviews lasted between 17 – 47 
minutes, and were recorded using two digital audio-recorders. All interviews 
were transcribed verbatim naturalistically by the student researcher and were 
double checked by an experienced research team member (SC, KM and LK) to 
ensure accuracy of transcription. 
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5.2.7. Data analysis 
The interview data were analysed thematically, as described in Chapter 2. 
Initially the demographics of the interviewees were analysed to inform their 
selection and to ensure participants covered all of the inclusion criteria and the 
sample is adequately represented. This included consideration of; years of 
qualification as prescribers, geographical region of practice and the areas of 
prescribing practice. 
To ensure anonymity of all participants the details gathered and reported here 
were carefully reviewed to ensure that nothing clearly identified individual or 
organisations. 
Once the transcripts were ready for analysis, all interviews were imported to 
NVivo® 11 software (QSR International Pty Ltd. 2017) for data management and 
analysis. NVivo® helped sort the CFIR Domains as ‘nodes’, and the constructs 
and sub-constructs as ‘child nodes’.  
The interview data analysis were guided by the CFIR domains and constructs 
initially. All transcripts were reviewed, coded and discussed by FA and 
independently by at least one of the team members (SC, LK and KM). Further 
key themes were generated and reviewed by FA and SC and any disagreements 
were resolved by discussion among the research team. Findings are presented as 
quotes from the interviewees and reported in accordance with each CFIR 
construct. Quotations were reviewed by the supervisory team to ensure that all 
participants were represented. 
Data saturation is described in great details in Chapter 2 which is expected to 
have been reached once no new themes emerge from the data analysis process 
according to Francis el al. 2010. Using the Francis approach for this work the 
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intention was to carry out the first 10 interviews and then thematically analyse 
these followed by a further 3 interviews. Then if data saturation was not reached, 
further interviews were to be carried-out and analysed to ensure data saturation. 
5.2.8. Data protection 
All research related documents including consent forms, transcripts and any 
analysis reports were stored in secure password protected computers with 
restricted access by the research team only. Any paper-based files were stored 
under lock and key with access by the researcher only. All recordings and data 
were dealt with anonymity of participants to ensure protection of privacy. The 
standard operation procedures of School of Pharmacy and Life Sciences at Robert 
Gordon University were strictly followed to ensure data protection. 
5.2.9. Research governance 
The research was approved by the ethical authority of the Robert Gordon 
University. School of Pharmacy & Life Sciences Research Ethics Committee 
(Approval reference S172) (Appendix 5.6). Signed informed consent was 
obtained from each participant prior to conducting the interviews. 
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5.3. Findings 
5.3.1. Pharmacist recruitment 
Forty-eight out of 71 pharmacists who had completed the survey (as reported in 
Chapter 4) and indicated they were prescribers were invited to participate in the 
interview. Fourteen pharmacists responded and agreed to participate but only 12 
participants responding further. These 12 completed the demographics and 
returned the consent form and so they were all interviewed. The other two did 
not respond to any attempts made to contact them by the researcher. Two more 
pharmacists were recruited through snowball sampling that were suggested by 
two participants. A total of 14 interviews were conducted to reach data 
saturation. Initially 10 interviews were conducted and analysed then a further   
three participants were interviewed and these were analysed. At this point it 
seemed that data saturation was reached with no new themes being identified. 
However, one final participant offered to be interviewed so it was decided to 
include this and from this again no new themes emerged and so this was 
deemed that data saturation was reached. Demographic details of the 
participants are shown in Table 5.2. For anonymity the geographical region has 
been removed from the table. Geographical distribution of the participants was 
as follows: nine participants from England, three from Scotland and one from 







Table 5.2: Participants demographic details. 
Participant Sex Age 
range in 
years 







Pharmacist 1 Male 41 - 50 More than 20 years Secondary care 16 - 20 
Pharmacist 2 Female 41 - 50 More than 20 years Secondary care 11 - 15 
Pharmacist 3 Female 41 - 50 16 - 20 Secondary care 11 - 15 
Pharmacist 4 Female 51 - 60 More than 20 years Secondary care 11 - 15 
Pharmacist 5 Male 31 - 40 11 - 15 Secondary care 11 - 15 
Pharmacist 6 Female 41 - 50 More than 20 years Secondary care 11 - 15 
Pharmacist 7 Female 31 - 40 11 - 15 Secondary care 1 - 5 
Pharmacist 8 Female 31 - 40 11 - 15 Secondary care 1 - 5 
Pharmacist 9 Female 41 - 50 16 - 20 Secondary care 11 - 15 
Pharmacist 10 Male 31 - 40 11 - 15 Secondary care 1 - 5 
Pharmacist 11 Female 31 - 40 6 - 10 Secondary care 1 - 5 
Pharmacist 12 Female 31 - 40 11 - 15 Secondary care 1 - 5 
Pharmacist 13 Female 31 - 40 6 - 10 Secondary care <1 year 
Pharmacist 14 Female 51 - 60 More than 20 years Secondary care 11 - 15 
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5.3.2. Area of prescribing practice 
To ensure anonymity of all participants the details gathered and reported here 
were carefully reviewed to ensure that nothing clearly identified individual or 
organisations. Participants were also asked about the area in which they 
prescribe for patients with CKD.  All participants were practising in secondary 
care with few practising in primacy care and community pharmacy. All 
participants prescribed a full range of renal medicines in inpatient settings. A few 
participants also prescribed specific classes of medication in clinic settings. It was 
noted that specific drug clinics were gaining prevalence as an advanced area of 
prescribing with some participants running clinics related to the drug tolvaptan 
and others expressing an interest to run such clinics in future. Details of their 
areas of prescribing practice are listed in Table 5.3.
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Table 5.3: Participants area of prescribing practice. 
Participant Area of prescribing practice Quotes reflecting pharmacist’s area of practice 
Pharmacist 1 All renal related medicines in 
inpatient setting - secondary care 
"I would go to the ward round, see new patients, if there's anything that we need, maybe 
change like phosphate binders changing of times, etc. I would do that, if there was 
something that was missed off and Initiating new drug" 
Pharmacist 2 All renal related medicines in 
inpatient and outpatient setting - 
secondary care 
"I prescribe of all the renal in and outpatient at clinics like anaemia clinic, tolvaptan clinic 
and prescribe symptomatic relief for the, the dialysis patients. As well as prescribing in 
the ward rounds and doing discharges."   
Pharmacist 3 All renal related medicines in 
inpatient setting and specific drug 
clinic - secondary care 
“I'm working as a prescriber for outpatient tolvaptan clinics” 
“prescribing to inpatients, probably picking up medicines have been incorrectly prescribed 
or admitted during the medicines reconciliation process so correcting errors, and then 
also dose adjustments of medicines to renal function. For example, antibiotic and 
antivirals, so we will adjust those independently, and attempts by transplant protocols of 
our transplant centre” 
Pharmacist 4 All renal related medicines in 
inpatient setting and specific clinic - 
secondary care 
"I do a daily ward round on the transplant unit, So I prescribe immunosuppression and 
stopping old dialysis drug and antibiotics, protocol driven immunosuppression, and also 
surgical pain analgesics, as required anti-emetics and whenever necessary"                      
"I do clinics in one half day a week, when I see acute transplant patients for up to the 
first year just as required and if necessary I will prescribe medicines  they can't get 
through the GP" 
Pharmacist 5 All renal related medicines in 
inpatient and outpatient setting - 
secondary care 
"So currently as a pharmacist independent prescriber I would prescribe for repatriate 
immunosuppression for primary care for transplantation, that’s an entire cohort, ESA and 
iron therapy for all of anaemia CKD patient's, bone mineral management in dialysis 
patients, dialysis reviews, and then, any ad hoc treatment such as when they occur, 
specific programmes for managing anaemia CKD, MBD and transplant." 
Pharmacist 6 All renal related medicines in 
inpatient and outpatient setting - 
secondary care 
"I currently do some of my own prescribing clinics, predominantly working in outpatient 
area, I've got my own clinic work just do some prescribing, looking at renal risk in 
patients so looking at cardiovascular risk, hypertension, proteinuria, statin use, that kind 
of thing” 
“I do a lot of inpatient prescribing because I work on a haemodialysis unit, prescribing to 
them antibiotics, any medications at that time on dialysis, I do lots of transplant 
prescribing as well for our transplant patients "                                                                                  
Pharmacist 7 All renal related medicines in 
inpatient setting and specific drug 
clinic - secondary care 
"as a combination of an inpatient Kardex’s, and, you know, that will be prescribing 
missing medicines or adjusting a dose depending on what they were on before to come in 
and, you know, at the request that say the doctor, the dietitian to add something in, then 
also, I prescribe Aranesp for outpatients where I will review the bloods and then increase 
or decrease the dose as needed." 
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Pharmacist 8 All renal related medicines in 
inpatient setting and specific clinic - 
secondary care 
"I'm working in the transplant outpatient clinic, and every day I have a morning clinic 
where I see renal transplant patients post their transplant. I do prescribe for these 
patients and my prescribing scope of practice includes the immunosuppression’s that we 
use, but also for some of our older existing transplant patients, they are on ciclosporin, 
azathioprine and prednisolone, and I also often prescribe valganciclovir for our patients 
who has got like straight forward CMV, viremia post-transplant, or some of our patients 
are on prophylaxis as well."                                                 
"As an inpatient then I can do prescribing on our med chart" 
Pharmacist 9 All renal related medicines in 
inpatient setting and specific drug 
clinic - secondary care 
"I would prescribe in outpatients and specifically for patients with polycystic kidney 
disease, and I prescribe tolvaptan in that situation, and both initiating tolvaptan to writing 
the initial prescription, and adjusting the dose, so providing ongoing prescriptions of 
tolvaptan and do that independently. For inpatients, I would generally prescribe things 
occasionally to support the doctors”  
Pharmacist 10 All renal related medicines in 
inpatient setting - secondary care 
"So, I do prescribe as part of my role. Unfortunately, most of my prescribing is reactive., 
Most of my prescribing would centre around small scale into hospital inpatient setting and 
making sure medications prescribed correctly or there were omissions or the doses were 
wrong. Occasionally, I will sort of pre-populate, TTO’s (to take out) sort of drug sections 
of discharge summaries" 
Pharmacist 11 All renal related medicines in 
inpatient setting and specific drug 
clinic - secondary care 
“Firstly, it would be when I'm working in my ward role optimising medication, starting and 
stopping of medications, antibiotic review and optimising medicines for new starter on 
dialysis that would be prescribing as part of an MDT discussion during the ward rounds, 
another role would be in the clinic running tolvaptan clinics. I'm reviewing homecare for 
patients so outpatient prescriptions for medicines for home delivery, and that would be 
EPO’s, predominately or if sometimes I review homecare prescriptions for transplant 
patients" 
Pharmacist 12 All renal related medicines in 
inpatient setting - secondary care 
"I'm usually prescribing the dialysis medication. So, epoetin and iron, any dialysis anti-
coagulation, line locks if it got a line, and those types of things" 
Pharmacist 13 All renal related medicines in 
inpatient setting - secondary care 
"Basically, attending the ward round and so, it'll be then when dealing with prescribing 
and also when they come on to the ward, and we do like the medication reconciliation 
process again I will do some prescribing then" 
Pharmacist 14 All renal related medicines in 
outpatient setting - secondary care 
"I'm based in the transplant clinic for the kidney transplant patients, and I prescribe 
immunosuppression for maintenance. I'll prescribe either for the home delivery supply of 
the medication for an outpatient supply and also to go into their dosette boxes. I do a lot 
of prescribing for patients on medication aids, on MTA’s, which I will prescribe just about 
anything as long as it's a continuity of care and it's well documented that what they're on. 
I'll prescribe erythropoietin, cinacalcet and, you know, anything that's registered that we 
have the responsibility to do" 
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5.3.3. Key themes 
The findings presented in Table 5.4 below are derived from the qualitative 
interviews carried out with pharmacists prescribing for patients with CKD in the 
UK. The findings are presented in a structured manner aligned to the CFIR 
domains and constructs in order to allow clear relationships to be made between 
the findings and to the theoretical concepts contained within the CFIR. The 
findings are provided under each of the five CFIR domains, with key themes 
linked to each relevant construct within the domain. Occasionally in the process 
of analysis there was overlap between the themes and the linked constructs, this 










Table 5.4: CFIR domains and constructs matched with identified key themes. 
CFIR Domain CFIR constructs (Theme) Key themes 
INTERVENTION 
CHARACTERISTICS 
Intervention Source Prescribing by pharmacist: arisen from a number of disparate sources. 
Evidence Strength & Quality Lack of evidence of pharmacist prescribing. 
Anecdotal evidence. 
Further research required. 
Relative Advantage Advantages of pharmacist prescribing role. 
Adaptability Prescribing role adapted from clinical role for pharmacists. 
Models of prescribing practice. 
Trialability Trial in small area of practice. 
More advanced skills are required. 
Complexity Conflict with MDT. 
Complexity in process. 
Design Quality & Packaging Prescribing within competencies. 
Replicating exemplar models. 
Prescribing aligned with NHS Trust / Organisation needs. 
Cost Reduced drug costs. 
Cost of pharmacist prescribers versus nurses and consultants.   
OUTER SETTING Patient Needs & Resources Pharmacist prescribing appreciated by and accessibility for patients. 
Learning and development needs. 
Cosmopolitanism Collaboration with external bodies. 
Alliance within NHS Trust units. 
Centralise the service across regions. 
Peer Pressure Challenge to advance prescribing role. 
Competitiveness pressure. 





Table 5.4: CFIR domains and constructs matched with identified key themes 
CFIR Domain CFIR constructs (Theme) Key themes 
INNER SETTING Structural Characteristics Need for more prescribers. 
Potential areas for development. 
Networks & Communications Wide range of communication within trust. 
Good network within organisation. 
Culture Positive culture for pharmacist prescribing. 
Avoidance of blame culture. 
Implementation 
Climate 
Tension for Change Insufficient number of prescribers. 
Lack of administration support. 
Compatibility Pharmacists prescribing can fit in with daily duties. 
Relative Priority Training prioritisations. 
Organizational 
Incentives & Rewards 
Pharmacist prescribing well appreciated. 
Central funding to train prescribers. 
Goals and Feedback Clear goals for development. 
Feedback from stakeholders. 
Learning Climate Continuous learning. 
Learning from errors. 
Readiness for 
Implementation 
Leadership Engagement Support from leaders. 
Available Resources Limited funding.  
Personnel shortage. 
Time to prescribe. 
Training resources needed. 
Need for physical space to practice. 
New technologies needed. 
Access to Knowledge & 
Information 
CPD opportunities. 
Availability of educational materials. 




Table 5.4: CFIR domains and constructs matched with identified key themes 
CFIR Domain CFIR constructs (Theme) Key themes 
CHARACTERISTICS 
OF INDIVIDUALS 
Knowledge & Beliefs about the 
Intervention 
Pharmacists well skilled for prescribing. 
Wide scope for prescribing practice. 
Self-efficacy Awareness of self-competencies. 
Experience.  
Individual Stage of Change Stages of development of pharmacist prescribing. 
Need to progress through stages. 
Individual Identification with Organisation Supported by organisation. 
Other Personal Attributes Awareness of strengths and limitations. 
 
PROCESS Planning Pharmacist prescribing implementation planning. 
Development of prescribing practice. 
Stakeholders engagement importance. 
Engaging Opinion Leaders Support from MDT. 




Champions Doctors engagement and enthusiasm. 
Support from stakeholders. 
External Change Agents Influence from external agents. 
Academic institution support. 
Executing Variation in prescribing models. 
Reflecting & Evaluating Monitoring of prescribing practice. 
Development of patient feedback systems. 




5.3.4. Themes under each CFIR domain and constructs 
The interview findings are presented according to domains and constructs of the 
CFIR to enable easy follow up and produce actionable findings for improving 
implementation. 
A) Interventions characteristics 
This CFIR domain focuses on the key attributes and features of interventions that 
influence the success of implementation (Keith 2017). 
a) Intervention source 
A key theme within this construct was ‘Pharmacist prescribing: arisen from a 
number of disparate sources’.  
The pharmacists believed the intervention was developed with the influence of 
external forces such as changes to general practitioners’ contracts and policies 
relating to preparing pharmacists to prescribe.  
"Generally, probably the changes in the GP contracts that asking to get 
community pharmacist prescribing, in the hospital, it's not really taken off 
as much, and it just depends on where you are." Pharmacist 2 
Pharmacist 5 emphasised that the intervention was developed by the UK 
government allowing development of pharmacist prescribing services as well as a 
need to meet the demands of the service providers like the NHS. 
"The enthusiasm of individuals, the need to make sure that pharmacy is 
not a supply of drugs medicines profession, but actually part of the 
solution to meet the demand in the NHS by being professionally integrated 
into frontline services, the government extending the prescribing roles to 
other healthcare professionals including pharmacists" Pharmacist 5 
 185 
Within the organisation, prescribing was developed through demand for specific 
areas of interest and new initiatives as well as consideration of patient needs. 
"I'm sure with the hepatitis B vaccination sort of coming in house from 
primary to secondary care showed there is a lot more prescribing from 
that point of view" Pharmacist 6 
"We've got a transplant clinic. So predominantly for transplant clinic, on a 
Wednesday Thursday and Friday our busy full day they're always full 
transplant clinics and then on a Monday, we often see there's more a 
nurse led clinics but I also see some of their patients as well, and on a 
Tuesday more kind of my admin day and catching up on other kind of 
guidelines and Directorate work." Pharmacist 8 
There has been a transition from supplementary prescribing to independent 
prescribing within organisations as services developed with involvement of the 
main stakeholders in the organisation internally. 
"Just really, that’s myself and just developed areas where I'd be able to do 
it, and initially it was supplementary, with making sure that the areas that 
the doctor's first happy for us prescribing and now because I've been here 
so long and it's all new doctors that just accepted that I do prescribing as 
much as the doctor are prescribing." Pharmacist 2 
"way before independent prescribing came in I suppose we were first 
doing the sort of, the drug listing as I mentioned earlier, so making sure 
patients were, were getting timely discharge prescriptions by the 
pharmacists starting to list all their discharge medicines in advance" 
Pharmacist 11 
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In a few organisations the development of pharmacist prescribing was policy and 
protocol driven to ensure patient safety and often this was a pharmacy 
department initiative. 
"My department is quite pro in pharmacist prescribing, we have non-
prescriber amendment of prescriptions policy for pharmacists are actively 
encouraged to amend prescriptions in the interest of patient safety, when 
they're not able to get hold of a doctor" Pharmacist 12 
There was appreciation that pharmacist prescribing was progressively developed 
within the organisation to a more independent service. 
"In terms of the clinic setup so we don't have any consultant in clinic with us. 
So, we're completely independent in terms of how we do in the clinics" 
Pharmacist 3 
"When I first got to prescribing, there was only me in the health board to 
prescribe, along the way we had a couple of other people, but in our trust 
that we've got lots of prescribing pharmacists, so I think from those early 
days prescribing has developed a lot" Pharmacist 6 
b) Evidence strength and quality 
Key themes emerged within this construct was ‘Lack of evidence of 
pharmacist pharmacists’ ‘Anecdotal evidence’ and ‘Further research 
required.’.  
There was recognition among the interviewees on the level of evidence to 
support the efficiency of pharmacist prescribing. Interviewed pharmacists 
believed there is sufficient evidence for the benefits of pharmacist prescribing for 
patients with CKD. Most of these data are anecdotal and internally shared within 
the organisation and are not published in peer-reviewed journals. 
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“The volume of pharmacist prescribers is clear, as a national lead 
pharmacist to the renal network, and also, as a practising independent 
prescriber, huge service transformations have been enabled by changing 
an independent new service delivery with pharmacist prescribers, and it’s 
actually been held up within NHS [A Great Britain country] as an exemplar 
of how to make prudent and values-based healthcare happen. So that is 
ample evidence out there to impact these things” Pharmacist 5 
 
“We have had some great, some good outcomes here and we’ve certainly 
found that by adding a pharmacist to our anaemia MDM for example in our 
dialysis clinics, and that we’ve had some really positive improvement in 
outcomes” Pharmacist 11 
 
On the contrary there was a belief that there is little evidence on pharmacist 
prescribing practice in the area of CKD and renal medicine. 
 
"Just really be literature, from reviews and papers, things like that, but 
otherwise there is very little evidence in renal anyway." Pharmacist 2 
 
A few pharmacists suggested that pharmacist prescribing was well received by 
the patients with the quality of service provided by the pharmacists.  
 
"At the moment is gathering evidence and trying to demonstrate all of the 
things that you do on a day to day basis that you see as being really 
important for our patients" Pharmacist 8 
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"I think it's a positive improvement for patients in the clinics, being an 
independent prescriber in the clinics, sometimes we find that patients are 
sort of more willing to perhaps discuss things with pharmacists that they 
wouldn't want to perhaps waste the doctors time with" Pharmacist 11 
 
Additionally, clinicians expressed a preference that a pharmacist prescribes for 
their patients in comparison to junior doctors. 
"Doctors would prefer it, that it was the renal pharmacists that were 
prescribing for their patients rather than FY1 who don’t know anything about 
nephrology" Pharmacist 2 
 
c) Relative advantage 
A key theme within this construct was ‘Advantages of pharmacist prescribing 
role in CKD’.  
Pharmacist prescribing was considered advantageous by the interviewees in 
many different ways. One of the important advantages was to reduce the 
doctor’s workload to allow them deal with more complex cases and share 
prescribing responsibilities. 
 
“It's entirely redesigned the service, [pause] services are being redesigned 
and the ability to have more advanced practice being able to take chronic 
disease management away from physicians including GP’s and allowing 
more time for those physicians to deal with diagnostics and complex 
cases, especially, enable to complete redesign of the services.” Pharmacist 5 
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 “Releasing time to care for the, the doctors, be that, so that they can do 
up things on the wards or in the clinics, and that we are as well great 
problem solvers when it comes to medicines problems, mm, so, definitely 
that's been a driving force in our trust I think in getting pharmacists 
through the prescribing course” Pharmacist 11 
 
Interviewees however, were concerned not to compromise junior doctors’ skills 
by doing all the prescribing on the ward. 
 
“The only thing I found is that no, I think you don’t want to de-skill the 
doctors so, you have to kind of sort of step back with the amount of 
prescribing that I do on the wards, because actually, it's not always that 
helpful for the pharmacist to do all the prescribing on the wards, because 
actually, then it is you would de-skill the doctors then they are learning in 
their sort of junior rotations about renal medicines and what to prescribe 
and when” Pharmacist 11 
 
Patient satisfaction and safety was one of the advantages captured by the 
interviewees in terms of providing prescribing services in timely manner. 
 
“They are [patients] just glad to have somebody prescribing in a timely 
manner for them because the consultant could be a wee bit about of a 
delay before doctors can come down. You can make changes in a timely 
manner” Pharmacist 2 
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“From a patient's point of view as well, because as a pharmacist, I tend to 
write their prescriptions before they come to clinic so that literally, when 
they turn up to clinic, they can walk straight over and pick up that 
prescription rather than having to wait again for that help. I'm sure they 
appreciate that in terms of the amount of time they have to spend in the 
hospital and say, Yeah, this one intervention.” Pharmacist 9 
 
Interviewees mainly agreed that pharmacists are highly knowledgeable about 
medications and can make safer choices for the patients then doctors. 
 
 “I suppose the fact you know the hospitals are busy now, we all have to 
upskill. The fact that a pharmacist can take the more accurate drug history 
and experts in medicines, so we can prescribe more accurately what 
medicines the patient is all before they come in, as well as looking at 
interactions and things with other medicines and will be started during 
their admission.” Pharmacist 7 
 
“I think as pharmacists, we take the pharmacology aspect of the 
independent prescribing course and is a bit for granted but again for the 
nurses, and the other AHPs (Allied Health Professionals) undertaking the 
course, they really struggle with that” Pharmacist 14 
 
Another benefit of the prescribing service highlight by the interviewees was that 
it helps prepare the pharmacy workforce to take new roles and expand the 
service by moving from product-oriented service to more patient focused service. 
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“Because of the efficiency of that rather than spending time with the supply 
function of drugs we actually spend time, improving the health literacy of 
patients, and the digital literacy patients so that they become more active in 
their own treatment titrating drugs in response to their accessing their own 
results, and so patients have a far more robust service mechanism to, to 
understand their own condition the active partners in their own treatment” 
Pharmacist 5 
 
“We keep band 7s but we are interested in staying in the department and 
having new roles and then they are more prepared to become 8A’s, where is 
part of their role anyways, we've taken a decision to do that rather than 
invest in roles like consultant pharmacy post” Pharmacist 6 
 
d) Adaptability 
Two key themes emerged with the construct of adaptability ‘Prescribing role 
adapted from clinical role for pharmacists’ and ‘Progress from basic to 
more complex models’.  
Some of the interviewees felt that prescribing was adapted into their daily clinical 
practice, since they were engaged with many clinical activities that enhances 
prescribing practice. 
 
 “I'm happy to prescribe but the confidence to prescribe well you know, 
say within my ability to prescribe where I feel it could be used better and, 
in the hospital, would be on admission.” Pharmacist 7 
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“I started off by just looking in a kind of MDT fashion, sort of self-
reviewing drug charts, in consultation with the consultant and the anaemia 
nurse, and then changing drug charts in the dialysis units, and optimise 
therapy. It’s a useful tool for reconciliation of medicines, so when drug 
histories have been done on the ward, and when they've been clerked in, 
the prescriber who did their medical clerking has maybe not taking on the 
time to go through the medicines of the patient and maybe they copied it 
for previous admission.” Pharmacist 11 
 
A few interviewees commented that pharmacist prescribing is more fruitful when 
implemented in a focused area of practice where there is a demand for the 
service. 
 
“The pharmacists that work here are trained as blood prescribers. As part 
of the anaemia programme so they are involved as me, four blood 
prescribers in the UK” Pharmacist 5 
 
“In terms of prescribing for the main clinic, the main areas from a resource 
point of view is tolvaptan, so in terms of my learning for that is been a case of 
reading about tolvaptan myself, and utilising the clinic, the practice skills that 
I picked up by shadowing the consultants when I was doing the nonmedical 
prescribing course” Pharmacist 9 
 
e) Trialability 
Key themes within this construct were ‘Trial in small area of practice’, and 
‘More advanced skills needed’.  
 193 
The main concept that arose by the interviewees for this construct was to start 
prescribing in an ad hoc fashion or in a small area of practice before being an 
integral part the clinical service at inpatient or outpatient setting. 
 
“I think if you're really starting off you just need to take a small bit at a 
time so you either do the admissions or do the discharge, I don't know if 
you could do both.” Pharmacist 7 
 
“For us, it's been tolvaptan works very well, because it was a small cohort 
of patients, and we were just looking for somebody to fit the funding for 
about eight hours a month initially, and we were able to get that funding 
back.” Pharmacist 9 
 
One of the aspects of initiating the prescribing service in a niche area and 
developing slowly was to boost the confidence and provide more structured 
service. 
“I encourage people to not, well, to make sure that they're fairly 
comfortable in their area of practice before you have start prescribing 
because there are a lot to do on your own and quickly, and you need to 
know what you don't know basically before you start prescribing.” 
Pharmacist 6 
“I suppose it's good to try, but it's hard because you've got to go in there to 
raise the profile, but at the same time, it's important that, you don't always 
try and be in three places at one time. So, when you move on to a new role 
and you can get reassessed, and have a new scope of practice within your 
own arenas.” Pharmacist 8 
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f) Complexity 
Key themes arose within this construct were ‘Complex process involved’ and 
‘Conflict with MDT’.  
Difficulty in the implementation of prescribing practice was highlighted by few 
interviewees in several aspects. The complex process involved in prescribing and 
becoming a prescriber was brought up by a few interviewees. 
 
“I think a lot of your time is taken up by seeing new patients and 
discharging patient. So, the continuing care patients either have the same 
amount of time, I mean, I've got nine new patients today. So, if you spend 
half an hour in each patient that's four and a half hours, had some 
discharges to do as well, your seven-hour days going, just doing that, it is 
complicated sometimes” Pharmacist 1 
 
“I suppose, what it takes from paperwork is probably a bit too much of 
that if anything. It did take a while to have to often to get your certificate 
to praise, for paperwork to fill out and then you have to get registered on 
the system and it has to get approved, by several different people. I don't 
necessarily think that's a bad thing but I say you could argue if you 
compare that to what the doctors have to do which is nothing, or perhaps 
a mini prescribing test on, on the electronic system just to prove they can 
use it, it is quite a significant amount of more for nonmedical prescriber, 




Having the time to prescribe in addition to the other clinical duties seemed to 
add complexity to the service. 
 “It takes an awful lot of time and sort of prescribing and, that, that's good 
and bad I would say [laughter]. It’s usually just part of your role but it 
does take a lot of time” Pharmacist 6 
 
 “A lot of us have the expertise, but we're not given the time in our day to 
day job to actually focus on prescribing, and you need to make sure that 
you're doing, you don't want to be just doing the repeat prescribing” 
Pharmacist 8 
A few interviewees shared some thoughts about doctors’ negative perceptions of 
the pharmacist prescribing concept with some degree of disagreement or 
resisting pharmacists taking on prescribing responsibilities. 
 
“The barriers initially were, the older doctor’s reluctance to have people 
other than doctors prescribing, but that’s all kind of changed. I think 
you've got to be careful as well that you're not de-skilling the doctors and 
junior doctors, and they also need to be able to prescribe as well” 
Pharmacist 2 
 
“There has been some resistance to that by doctors, because I don't know 
if they are threatened, and actually, if we start doing more and more we 
might downsize the number of the clinicians which I don't think what 
would've happened, but I think that that's part of the wariness.” Pharmacist 
12 
One concern raised by the interviewees was dealing with complex patients and 
the need to prescribe in such situation could be complex. 
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“There is always a team to back you up if you do have a very complex 
patient is always in discussion with the team. It tends to be outpatient 
setting, I guess the challenges are, for us the lack of a consultant in 
clinic.” Pharmacist 3 
 
“So, complexity of the patients I see, they are usually really quite complex 
so they don't often refer to me people who could easily be managed, and 
often people are they tried lots of medications and things won’t work, so 
yes it's definitely difficult from that prospective for that kind of complexity” 
Pharmacist 6 
 
Lack of some clinical assessment and diagnostic skills also were highlighted by 
some interviewees as disruption in providing holistic care for the patients. 
“It's also making sure that there's going to be somebody there to clinically 
check for what we have prescribed as well.” Pharmacist 2 
 
“I don't feel confident, in terms reviewing that patient holistically, in terms 
of listening to their chest, or, you know, listening to the heart, I don't have 
the skills to do that on my own. So that's one of the challenges in the 
clinics, how to deal with patients that need a more holistic review rather 
than just to review their tolvaptan and their kidney function.” Pharmacist 3 
 
Prescribing outside the area of expertise was another issue tackled by the 
interviewees and was perceived as a challenge.  
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“So, on the whole if I am uncomfortable with something, I wouldn’t 
prescribe that honestly, I would probably say someone else I am nae 
happy about this, you go ahead and do it but I am obviously doing that 
every day” Pharmacist 1 
 
“I’d never prescribe anything I wasn’t comfortable prescribing, I still find that 
if I would get the doctors to prescribe with chemotherapy, rather than us 
prescribe it, so we can then check it, clinically check it, and it's also making 
sure that there's going to be somebody there to clinically check for what we 
have prescribed as well.” Pharmacist 2 
 
g) Design quality and packaging 
Key themes within this construct were ‘Prescribing within competencies’, 
‘Replicating exemplar models’ and ‘Prescribing aligned with trust needs’.  
In terms of how the prescribing practice was bundled and implemented, there 
was different approaches undertaken in different regions and Trusts. Obtaining a 
prescribing qualification was an important aspect to start the practice. 
 
“We just have a cohort of prescribers, and bits of prescribing document 
within the trust and says that you can use your prescribing qualification in 
these circumstances.” Pharmacist 10 
 




“As part of the requirements of prescribing tolvaptan, we have to monitor 
liver function tests monthly, we also need to monitor their kidney function, 
and we need to assess their fluid balance, and I guess the clinic's kind of 
gradually I guess evolved, that we're looking more at kind of blood 
pressure control as well as a part of that clinic” Pharmacist 3 
 
 “I think obviously I wanted to develop, to, to work closely with consultant, 
doctors to do the clinics now and probably want to be more clinic focused, 
like tolvaptan and then vasculitis them sorts of things.” Pharmacist 13 
 
Designing a quality prescribing service requires that the pharmacist proves there 
is a need for the service and ensure funding is available to support such services. 
This was one of the points highlighted by the interviewees.  
 
“It is a mind shift from actually using the expertise of what pharmacists 
can deliver and a move away from Central pharmacies to dedicated 
pharmacies for a large regional service employed directly by the renal 
services to, to reshape services” Pharmacist 5 
 
“Make sure you've done the business case to ensure that it is properly funded 
and received, and you've got the support of all the stakeholders, and whether 
you do as a pilot service, because what we found in our trust is we have 






Key themes emerged within the cost construct were ‘Reduced drug costs’, 
‘Pharmacist prescribers more expensive than nurses’ and ‘Pharmacist 
prescribers cheaper than consultants’.  
Providing a pharmacist prescribing service required the organisation to secure 
funding. Many interviewees highlighted that pharmacist prescribers are less 
costly than having a consultant in a clinic setting. 
 
“We would be cheaper pharmacist than a consultant sitting in a transplant 
clinic so, in terms of costing benefits, actually if you had an independent 
pharmacist clinic and you've got considerable waiting time for your 
consultant nephrologist clinic, would it be better for them to recruit 
another consultant to deal with your waiting times would it be better to 
have a pharmacist that was able to run a clinic, and would be in terms of 
consultant in terms specialist knowledge, we would be able to run some of 
the clinics that they do.” Pharmacist 12 
 
“Well there is the health economy cost in terms of pharmacist of course 
are cheaper than doctors so there's that cost saving, I think from the way 
that the pharmacist will practice, we will tend to question medicines more” 
Pharmacist 14 
 
A few interviewees, however, reported that other nonmedical prescribers can be 
less costly in terms of salary but pharmacists are highly knowledgeable about all 
aspects of medications. This is true to a greater extent than other healthcare 
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professionals and this can justify the additional cost of having a pharmacist 
prescriber.  
 
“I think the things that make it difficult, sometimes nursing staff, well, 
some staff more expensive than nursing staff so that could influence these 
different issues in practice.” Pharmacist 6 
 
“The cost save obviously nursing staff costs an hourly rate to the band 
seven nurse is a lot cheaper than a pharmacist” Pharmacist 9 
 
Some of the cost savings associated with pharmacist prescribing were reported 
by interviewees were related to prescribing less costly medications without 
compromising the efficacy and safety of the medication. 
 
“It’s probably kind of making more savings, because you're just giving the 
patient what they are actually needing, and you are speaking to the 
patient first what things like phosphate binders to make sure that it’s 
gonna be something that they are actually going to take, otherwise there 
is no huge difference between us and the doctors prescribing.” Pharmacist 2 
 
“Definitely there is loads of savings in renal there is lots of high cost drugs 
that consultants would like to use. So, you know a very easy example will 
be myfortic. We're always very focused and trying to use the most, 
medicines optimisation and kind of use the best cost-effective medicine for 
that patient, At the moment” Pharmacist 8 
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Although choosing the most cost-effective treatment option for the patients were 
always considered by the pharmacists, some interviewees emphasised the 
importance of engaging the patients in the decision-making process and putting 
the patients at the centre of care. 
 
“I suppose one of the key factors when you are doing cost saving projects 
and in such projects is the most important thing is that you don't kind of 
forget about the patient I think in a lot of our cost saving initiative, making 
sure that they feel engaged as well.” Pharmacist 8 
B) Outer setting 
The outer setting domain includes the features of the external environment or 
background that has an influence on the intervention implementation (Keith 
2017). 
a) Patient needs and resources 
Two key themes emerged within this construct were ‘Pharmacist prescribing 
is appreciated by and accessible for patients’ and ‘Prescribing 
Pharmacists may still have learning / development needs even after IP 
qualifying’.  
Patient needs and the available resources to fulfil theses needs was considered 
by majority of the interviewees as a main driver for providing prescribing 
services. 
 
“I’ve managed to establish a telephone clinic for the tolvaptan clinic as 
well. So, we have some patients that were driving for an hour, an hour 
and a half to come to clinic every month, which was a long time. So, 
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manage to negotiate with the consultants to set up a telephone clinic” 
Pharmacist 3 
 
“In terms of the impact on patients, so for my prescribing on the wards, 
that means that actually doses get changed a lot quicker. The priority has 
always been patients and the supply of medication to patients” Pharmacist 9 
 
One of the barriers to meet patients need in order to provide holistic care by 
pharmacist prescribers was the need to do more clinical training and learn more 
diagnostic and monitoring skills. 
 
“In terms of barriers, I would say, having that, been able to do the clinical 
skills course, which wasn't previously funded for pharmacists, I think had 
that been available when I did the prescriber course in 2012, that would 
have helped building the confidence and allowing you to have an extra skill 
to see patients independently in clinical, where you might need to assess 
them clinically as well as prescribe at the same time” Pharmacist 9 
 
“So, things like the tolvaptan clinics I mentioned, I identified some 
learning needs to go and find out a bit about genetics and polycystic 
kidney disease because for example that sort of questions that my 
patients might ask about sort of genetic testing, and actually you can’t just 
be an independent prescriber and only talks about medicines, if you're 
dealing, you need to look after the patient holistically” Pharmacist 11 
 
The fact that patients need timely healthcare provision to avoid any delay in 
receiving treatment was also highlighted by the interviewees and considered a 
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positive outcome of pharmacists being able to prescribe whether in an inpatient 
setting or in specific clinics. 
 
“I think it's more convenient for patients. The fact that someone I'm 
talking to and they're in agony or constipated, And I can immediately sort 
it.” Pharmacist 4 
 
“Patients now have direct access to specialist services, flexible access to 
secondary care. They have opportunity for more contact with healthcare 
professionals, that is [pause] direct points of contact to decision makers, so 
that’s eliminated treatment delays” Pharmacist 5 
 
b) Cosmopolitanism 
Key themes within this construct were ‘Collaboration with external 
professional bodies’, ‘Alliance with other units within the Trusts’ and 
‘Digitalisation to centralise the service’.  
The majority of the interviewees felt that external independent organisations like 
the RPS and the UKRPG has positive impact on their prescribing practice as well 
as the support their learning and development. 
 
“In terms of what I actually do, obviously I get a lot of good ideas for the 
UK renal pharmacy group and at conference and say that it's always good 
to reach colleagues there, I am on a committee where some people I 
know, our peer to peer review with someone from the renal pharmacy 
group something really useful” Pharmacist 6 
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 “I guess, the renal pharmacy group, I guess you could, if that's an 
external body that would potentially, you know, any discussions in that 
forum would influence my prescribing” Pharmacist 9 
 
Some of the interviewees felt that support in devolved administrations of the UK 
was from the regional organisations such as the NICPLD in Northern Ireland, NES 
in Scotland and Health Education England in the NHS in England. 
“In [A Great Britain country], it’s just part of the, sot of process, I would 
have said as a pharmacist, you go through the system, and I think most 
pharmacists working in clinical jobs expect to be, becoming prescribers, 
And NES funded, to the educators, and we’ve got [a University name], 
very handy for us so it's all quite straightforward” Pharmacist 4 
 
“It is a part of a programme through in [A Great Britain country], the 
[regional organisation], is the organising body. Well that organisation 
[regional organisation], is the overseeing body that you know carries out 
that, that programme.” Pharmacist 7 
 
Collaboration between renal units within organisations or with units from external 
organisations was also perceived as an important network source to improve 
prescribing practice and share experiences.   
 
 “Knowledge of what are other pharmacists doing, at other centres. So, 
being a member of the renal pharmacy group, we find out what's going on 
nationally in other centres, and I think sharing that practice allows you to 
then go back to your hospital and implement things, and the same with 
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going to things like the British Renal Society conference, finding out what's 
going on nationally, and then bringing that back to influence you in 
practice.” Pharmacist 9 
 
“I think that's been the big drive towards independent prescribing for 
pharmacists outside of the hospital. Umm, so some of my colleagues have 
gone in and out of community and hospital and they'll be prescribing in GP 
practices” Pharmacist 11 
  
One of the interviewees shared a view on digitalisation of the service to enable 
networking on a bigger scale. 
 
“By enabling digitalisation of the service. Actually, as a central hub with a 
large region, means that we can deliver the service to almost half 
geographical massive areas from a single centre, as well as having digital 
programmes, we also encourage patients to access that programme digitally” 
Pharmacist 5 
 
c) Peer pressure 
Key themes arose from this construct were ‘Challenge to consider the 
advancing role and collaborative approaches with other in NMP e.g. 
nurses.’ and ‘Medical staff pressures of capacity and need to focus on 
diagnosis skills – gap for NMP pharmacists to fill’.  
Many of the interviewees felt that their peers from other units or organisations 
were practising prescribing in more established and advanced ways. 
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“We have got a number of prescribers across our Trust, but people who 
work in London for example it's gonna be two or three renal pharmacists, 
in a particular area and so they've got more scope so get into areas.” 
Pharmacist 6 
 
 “We do take that into consideration what other Trusts do. I think they are 
ahead, in terms of my Trust definitely they ahead, they are ahead in 
implementing it, because obviously we are smaller, and I think obviously, 
there's not enough of us to be able to do everything. So, don't be peer 
pressured, don’t prescribe something if you are not confident to do it.” 
Pharmacist 13 
 
Some of the interviewees, however, highlighted that they practice in an 
exemplary way, felt they are at the leading edge of prescribing practice and 
setting a good example for others. 
 
“Some of our colleagues work in community, and there's certainly a pitch 
for that with sort of pharmacist in general practice, and I think yeah, as a 
Trust we probably are one of the ones that are ahead” Pharmacist 11 
 
“I see, we get in to transplant clinic and actually running my own clinic in 
my own right is probably be a big step.” Pharmacist 12 
 
Few interviewees felt they were pressured by the skill’s other medical 
professional such as doctors and nurses have and that they need to be more 
involved in direct patient care activity and learn such skills. 
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“You probably are competing with other people as well. There are nurses, 
and the other nonmedical prescribers, sure other professions will, and I 
suppose pharmacists got to be careful, it's not left behind” Pharmacist 1 
 
“If we done our IP course but actually we haven't had the years of training 
that the doctors have had to kind of got more of that background 
knowledge, so, that would be as good at physiology, certainly, not as good 
as in a diagnosis and patient assessment and a that sort of things. I think 
nurses have a lot of unique skills that we don't so we've probably still got 
a lot more to learn about that, they do a lot more on patient assessment 
and care as well.” Pharmacist 11 
 
d) External policy and incentives 
A key theme within this construct was ‘Prescribing align with local and 
national guidelines and policies’.  
Majority of the interviewees agreed that the governmental and regulatory 
policies and guidelines are considered for the implementation of prescribing 
services.  
 
“The externals policies we received mostly that’s coming from the (A Great 
Britain country) government and changing the GP contracts and getting 
more prescriber” Pharmacist 2 
 
“I'm aware there is a guidance out for consultation at the moment for 




“We have an independent pharmacist prescribing policy and staff 
arrangements, which governs what we can do and we can prescribe in 
accordance with that, and obviously the national drivers to sort of get 
pharmacists upskilled and prescribe” Pharmacist 10 
 
C) Inner setting  
This domain involves the main features and structures of the organisation that 
may influence implementation of the intervention of interest (Keith 2017). 
a) Structural characteristics 
The two key themes emerged within this construct were ‘Need for more 
pharmacist prescribers’ and ‘Potential areas for development’.  
There were mixed views about the maturity and the structural size of the 
organisation where prescribing services were in place.  
 
“The renal unit is expanding all the time, more dialysis patients coming on 
and more transplant patients coming back so at the minute I would really 
only be prescribing for inpatients, and let’s say the outpatients, possibly 
down into the dialysis patients and transplant patients, which is something 
I don't have access to at the moment.” Pharmacist 7 
 
“I think when you work at a big organisation where you have like 16 
consultants who are nephrologists, we have another, like maybe 16 
surgeons, we do see lots of doctors practice in slightly different ways so 




A few interviewees highlighted that within the organisation they have a 
designated independent prescribing clinic to perform prescribing practice and see 
patients and take responsibility to prescribe for them in an inpatient setting. 
 
“The clinic is independent, and we do have a designated consultant or two 
nominally responsible for the clinic. So, if we have a clinical query we will 
spoke out to them” Pharmacist 3 
 
“At the moment I'm predominantly in an outpatient role, but from time to 
time with annual leave, and with cross covering and colleagues on my 
ward and things, and that weekend, I still do weekends I cover the 
wards.” Pharmacist 8 
 
b) Network and communications 
Key themes within this construct were ‘Wide range of communication within 
trust’ and ‘Good network within organisation’.  
Within the organisation there were various forms of formal and informal 
communication related to prescribing practice information or updates. Verbal 
communication between healthcare professionals whether one-on-one or in 
meetings were well described in a positive way by the interviewees. 
“We have regular medical prescribing meetings within the renal 
directorate, and actually what we've done as a result of that is we've 
brought examples of our clinic notes and our clinic letters to that meeting 
and reviewed, and peer reviewed it. We do have regular discussions with 
either the consultants or the lead for their clinic and sort of get him to 
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check when we are not sure on a blood result. In terms of renal we have 
certainly had clinical medical prescribing meetings, everybody that could 
attend that meeting is working in a slightly different role.” Pharmacist 3 
 
“I think obviously because I’ve built a rapport with the team, and then, 
you know, I can ask them questions and, you know, they ask me question 
the thing that helped me develop the practice because you know you can 
learn from each other.” Pharmacist 13 
 
A few of the interviewees emphasised on the circulation of written 
communications in the form of emails or bulletins to share prescribing related 
information. 
 
“Communication bulletins come up via email and on the website in terms 
of prescribing errors that we think would have an impact across the 
organisation so shared learning for errors” Pharmacist 12 
 
“We have a global email, that is sent every day, like prescribing, and we 
have a newsletter every week as well.” Pharmacist 13 
 
Some interviewees felt that communication with colleagues in local and regional 
conferences enhanced their prescribing practice 
 
“Going to the annual renal pharmacy group meetings, reading journals, 
talking to other pharmacy colleagues, and talking to other medical 
colleagues” Pharmacist 9 
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“When looking at renal as a practice and looking at the UK RPG in 
attendance at that conference and how forward thinking as one is and how 
many pharmacists we have in clinics across the country” Pharmacist 12 
 
Interestingly, one respondent suggested that working in collaboration to 
generate local data is a useful tool to communicate outcomes. 
 
“It would be nice to actually collaborate with lots of other renal pharmacists in 
the same area and all look at the same thing and maybe put a paper together 
which is a bit more meaningful” Pharmacist 8 
 
c) Culture 
Two key themes generated within this construct were ‘Positive culture for 
NMP’ and ‘Avoidance of blame culture’.  
Most of the interviewees reported that the norms, basic values and assumptions 
of the organisation towards pharmacist prescribing practice were positive. 
“I think what they [organisation] wanted us to do was, you had the experience 
go and do your independent prescribing, this is going to be beneficial for you, for 
the ward, for the patient. There is no culture to stop you from prescribing 
around, everybody is supportive.” Pharmacist 1 
 
 “I think the organisation definitely values the role and encourages people 
to kind of undergo the qualification. So, I think it's highly thought of and 
encouraged” Pharmacist 3 
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One respondent felt that there is still a negative culture within an organisation 
towards pharmacist prescribing. 
 
“Sometimes the medics or the nurses can be a little bit, or the cultures 
that is a bit more of a kind of held account, there's a bit more of a blame 
culture sometimes and that we're trying to try and roll out.” Pharmacist 8 
 
Whereas, another respondent highlighted that within their organisation there are 
restricted processes before being able to prescribe. 
“At [a city name] hospital it is quite unusual, you have to do sort of 
comprehensive validation before you're allowed to prescribe” Pharmacist 10 
 
d) Implementation climate 
i. Tension for change 
Key themes within this sub construct were ‘insufficient number of pharmacist 
prescribers’ and ’Lack of administration support’.  
The majority of the interviewees perceived a few aspects that they felt need to 
be changed to enable them perform their prescribing duties more efficiently. One 
of the most reported issues was lack of sufficient prescribers. 
 
“I think obviously it’s, reduction in availability of medical staff so there is a 
need to have other people so take on the role. Yes, free up, doctors times 
for doing other roles.” Pharmacist 6 
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“Certainly, where there’s been a shortage we’ve had a particular problem 
with a shortage of more junior doctors on the wards, and we’ve seen some 
posts that have been converted to pharmacists’ posts” Pharmacist 11 
 
Another issue highlighted by the interviewees was lack of support to carry out 
non-clinical duties within the organisation. 
 
“Kind of secretarial or admin support, cause just now we are relying quite 
heavily on nurse, pharmacy technology and pharmacy technician, but 




A key theme within this sub-construct was ‘NMP by pharmacists can fit in 
with daily duties’.  
Most of the prescribing responsibilities fitted well with pharmacists daily clinical 
duties in a hospital setting as highlighted by some interviewees. 
 
“When you're in the clinic setting where the doctors are running their 
clinics and the nurses are running their clinics because there's lots of 
valuable referrals that you get when they have a patient in front of them” 
Pharmacist 8 
 
“We can kind of come up with the process and get that sorted out quicker, 
so that helps with medicines reconciliation, there’s that not often linked in 
with the trust sequence in terms of, you know, you’ve got to get your 
medicines reconciliation sorted out within the first 24 hours” Pharmacist 10 
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Appreciating the role and responsibilities of each member of the multidisciplinary 
team was another aspect that fitted well with existing workloads and this was 
highlighted by the interviewees. 
 
“I don't feel it’s the pharmacist’s place to [pause] be assessing patients 
physically, I think there’s a reason doctors go to university first, six years 
for that, rather than pharmacists doing a course on it.  That’s, I don’t feel 
that’s something that we should be doing” Pharmacist 2 
 
 “I think for the trust that I work in and certainly within the renal service, 
you know, we have been encouraged to sort of do an Independent 
prescribing, and we do also have nurses who do the independent 
prescribing but actually, as a group of pharmacists we would probably do 
more than most within our service, we do a lot” Pharmacist 14 
 
iii. Relative priority 
A key theme within this sub-construct was ‘Training prioritisations’. 
Pharmacists believed that implementation of a pharmacist prescribing service for 
patients with CKD was a priority for all healthcare providers within an 
organisation in order to ensure advancement of practice.  
 
“Prescribing is essential, and the vast majority of drugs prescribed in the 
unit of a chronic basis are done by independent prescribing pharmacists, 
so, it enabled work programmes to be transformed, dedicated for those 
renal disease areas, and the repatriation from primary care” Pharmacist 5 
 
 215 
“Well, we're lucky in renal and it's quite a specialised area. There are lots 
of different prescribing models within that, so as I said before anaemia, 
hypertension, do all the different things. Mineral bone disease, a lot with 
plenty of areas. So that's what works well as a prescriber it in renal.” 
Pharmacist 6 
 
iv. Organisational incentives and rewards 
Two key themes within this sub-construct were ‘NMP well appreciated’ and 
‘Central funding to train prescribers’.  
Although it was felt that there were no significant incentives for the development 
of prescribing practice by pharmacists there were views that there were some 
rewards in form of appreciation and acknowledgements of the benefits of the 
service by patients and the organisation as a whole.  
 
“I suppose, by sort of prescribing, it makes them [the organisation] more 
thoughtful about my practice and obviously, additional level of 
responsibility shows off” Pharmacist 10 
 
“I think, yeah, just to get a lot of acknowledgments seems growing over 
last few years as the value that we can add I think. my Trust definitely saw 
the value of pharmacists in clinics, I think oncology was probably one of 
the first areas that had two independent pharmacists prescribing in clinics, 
so we learned from them a little bit, and now we've got pharmacist 




v. Goals and feedback 
Key themes emerged from this sub-construct were ‘Clear goals for 
development’ and ‘Feedback from mentors, doctors and patients’. 
Interviewees highlighted that whether it is organisations goals or personal goals, 
it is important to focus on specific goals and try to work towards achieving them. 
 
“I think it depends on your organisation really, and you in particular 
department and the goals of the pharmacy department there, I think you 
need, you need the support of the Clinician's that you're working with to 
get it off the ground” Pharmacist 3 
 
“As a pharmacist you become a prescriber and then you start doing things 
because, the doctors are unavailable and before you know it becomes your 
responsibility and it's never been your responsibility, it's not your duty and 
yet it's fallen to you, and so, trying and avoid, trying and avoid service 
creep and make sure you've got your business case for your service, if you 
plan to expand and make sure that funding is there” Pharmacist 12 
 
On the other hand, one of the interviewees emphasised the importance of having 
a clear vision to develop prescribing practice and try and act upon it in order to 
persuade the organisation to support the implementation of new services. 
 
“I think it was if we did have a sort of clear vision of what potentially we 
could offer as prescribers, that might bit make it easier to sell to trust 




A number of interviewees reported that there was a process of feedback relating 
to the service outcomes or related issues to the stakeholders or staff whenever 
required. 
 
“I feed my views back to my line manager and that goes into senior 
leadership team within the pharmacy department and they will feed that 
back to expertise within the trust.” Pharmacist 10 
 
“I certainly, encouraging other prescribers as well so, reflecting on each 
other’s prescribing and make you leave some feedback that you would do 
to a doctor perhaps you've identified a prescribing error making sure that 
we do that with our pharmacist colleagues as well.” Pharmacist 11 
 
There was a suggestion by an interviewee that consideration of feedback from 
the patients was important to enable improvement of the service and tailor it to 
patient needs. 
 
“I think you've got to put the work into, to audit your prescribing and get 
feedback from your patients as well. So, that's really important because 
without that feedback you don't really know how your consultation is 
gone.” Pharmacist 8 
 
vi. Learning climate 
Two key themes within this sub-construct were ‘Continuous learning to 
improve prescribing practice’ and ‘Learning from errors’.  
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There were similar views among interviewees on the importance of a positive 
learning climate. This included whether it was identifying own learning needs 
associated with prescribing practice or learning relevant to sharing development 
across a team. 
 
“We have done that as a kind of way of sharing knowledge and skills to 
see what's out there, and what has been useful. And it's given us an idea 
of how other people have approached it made us realise that our practice 
is very different to other people's practice” Pharmacist 3 
 
“I learned a lot, because I was actually still quite new in my role, not with 
a lot of renal knowledge in my background so it was quite a steep learning 
curve, and actually it was a really good opportunity to make sure that I 
actually did know the evidence between, behind those treatments and 
things like that. I recently had my appraisal and I identified lots of learning 
needs that I don't think I would have thought of previously, if I wasn't sort 
of acting more independently with my prescribing and patient review” 
Pharmacist 11 
 
There was a sense of the importance of each team member having a positive 
environment to share learning and it was considered this was essential in the 
process of change towards a better service.  
 
“When I've come across problems then gone away and spoken to the 
consultants about that, and that's helped my learning to understand more 
about tolvaptan or more about that clinical condition that patients presented 
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with and that helped with all of my practice. From a ward point of view, 
building up that rapport with the consultants and a trust to be able to write a 
scope of practice that says essentially that we can adjust doses and we can 
prescribe things, that we feel confident to do, and that they're happy for us to 
prescribe for their patients as part of the team.” Pharmacist 9 
 
e) Readiness for implementation 
i. Leadership engagement 
A key theme within this construct was ‘Support from management and 
leaders.’.  
The interviewees commented on the positive engagement and commitment of 
the leaders within the organisation from different levels such as pharmacy 
managers, directorates, clinical leaders and consultants. 
 
“You need the will of the people to help them, whether the managers in 
the pharmacy, the consultants. I don't think anybody really wants to block 
you, I think they'd be willing for you to do things, but you need back fill to 
do your jobs so that you can go and do another job” Pharmacist 1 
 
“I think it is very much encouraged both at a clinical level and in the wards, 
but the pharmacy management are very much proactive about it, and 
wanting 8A pharmacists to be at clinics prescribing, managing a caseload. 
The main impact is if you can take on a clinic and have a key fold of 
patients, and that it's always good to be attracted to pharmacy management 
and the medical staff as well.” Pharmacist 4 
 
 220 
ii. Available resources 
A number of key themes were emerged within this sub-construct ‘Limited 
fund’, ‘Personnel shortage’, ‘Time to prescribe’, ‘Training resources 
needed’, ‘Need for physical space to practice’ and ‘New technologies 
needed’.  
The main hindrance in terms of resources was the availability of funds, time and 
personnel to enable the expansion of the prescribing service. This was expressed 
broadly by the interviewees. 
“If you get resources it will help you if you don't get resources they are 
hindrance, so money, time, personnel, if they want to expand things, they 
have got to give you time and money for resources” Pharmacist 1 
 
“There's not the central funding anymore, so it's not as easy to get the 
funding to do the course. I think it's you know it's harder and harder to 
get study leave and the support to do that, so, I think that would be the 
main barriers.” Pharmacist 14 
 
However, in relation to a key theme on ‘Training resources needed’ there was 
an agreement across the interviewees on the fact that the independent 
prescribing course was supported widely by the organisation and helped in 
developing more prescribers. There were also other prescribing related courses 
that were available to the pharmacists to undertake and advance their 
prescribing skills. 
 
“There's a course at [a hospital name], where you can do an advanced 
clinical practitioner skill. So, I think because you see your patients, and, 
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you know, you do a small bit on physical assessment but I wouldn't be an 
expert” Pharmacist 8 
 
“Doing the prescribing course, gives you, this gives you a different way of 
looking at the way drugs that are prescribed really, if you're different 
compared to the pharmacist” Pharmacist 9 
 
Some interviewees shared more positive responses about the availability of 
personnel resources (‘Personnel shortage’) to implement and further develop 
the prescribing practice. 
“We've managed to train nearly all the 8A pharmacist, and that working in 
specialties as nonmedical prescribers. So, we've got a large number of our 
more senior pharmacists that are trained. And we're currently looking at 
where they're going to be training our specialist sevens as well.” Pharmacist 
3 
 
“Because we've got lots of independent prescribers, a lot more than other 
hospitals and I think it is just because we've got a lot more pharmacists so 
there's a lot more capability to cross cover, to support people getting in 
courses, and we probably as a trust got more money than other trust so 
we can afford to send people on these courses” Pharmacist 11 
 
Some of the available resources highlighted by the interviewees were the 
availability of electronic prescribing (‘New technologies needed’), attending 
conferences and having access to books in their area of practice which were all 
considered of great value to enhance the service. 
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“The renal drug handbook is great, you know, get some advice based on 
evidence on practice and custom. Really the best evidence to back it up.” 
Pharmacist 3 
 
“I go to conferences, to British renal society conference, and that's kind of 
influence what I do in practice as well.” Pharmacist 6 
 
“The fact that the I think the prescribing role has changed over time as 
well and fact that with resources, with electronic prescribing coming in, a 
lot of pharmacists now, you get trained up in this specialty you have a 
good practice for your particular job that you're doing at that time, but it's 
very much more flexible” Pharmacist 8 
 
iii. Access to knowledge and information 
Key themes within this sub-construct were ‘CPD opportunities’, ‘Availability 
of educational materials’ and ‘Lack of CKD related prescribing courses’. 
There were various sources of knowledge about prescribing practice reported by 
the interviewees. Ease of access patients’ medical records was deemed an 
important source. 
 
“I would have the emergency care summary, I'd have clinical vision file, 
which the renal system, and I have the patient, so obviously the patients 
would be fit to speak to me, I use them as a big source of, of the 
medicines.” Pharmacist 1 
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“At that time, having access to all the right blood results, having access to, 
umm, having access to kind of a proper history” Pharmacist 8 
 
A few interviewees felt that better information from the drug companies could 
help improve prescribing of certain medications in CKD. 
 
“The requirement that we could have better information from drug 
companies around use of their medications and patients with CKD” 
Pharmacist 3 
 
Other aspects related to access knowledge about prescribing and the ability to 
incorporate it into prescribing practice highlighted by the interviewees include the 
need for safety alerts, prescribing related bulletins, recording CPDs and attending 
renal courses and conferences. 
 
 “Obviously we did our own CPD we have to make sure we include some 
prescribing; it should be easy to get CPD cases from our own prescribing 
practice.” Pharmacist 6 
 
“A lot of our prescribing, bulletins, and med safety alerts, come from the 
med safety team so we have like a designated team in pharmacy who 
produce a monthly bulletin and they help, they actually feed in with the 
experts in different areas, and then often ask us in renal, is there anything 
new or developing or a new prescribing, is there any new prescribing 
advice that you'd like to publish this month” Pharmacist 8 
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D) Characteristics of individuals 
This domain comprises of the main characteristics of the individuals involved in 
the intervention implementation (Keith 2017). 
a) Knowledge and beliefs about the intervention 
Two key themes within this construct were ‘Pharmacists well skilled for NMP’ 
and ‘Wide scope for prescribing practice’.  
The majority of the interviewees believed that pharmacists are knowledgeable 
about the drugs and related issues such as safety, effectiveness and 
pharmacokinetics. It was considered that these unique skills put pharmacists at 
the best position to implement prescribing services. 
 
 “I think our knowledge of drugs has been good so yeah, and different 
types of medical staff are always focusing on, on the drug aspects kind of 
things so that we are passed what they are doing, so as a pharmacy 
perspective, we're focusing much more on drugs.” Pharmacist 6 
 
“Our abilities to prescribe that, our knowledge of the interactions, our 
ability to counsel patients, and the fact that we would be cheaper than the 




Key themes within this construct were ‘Awareness of self-competencies’, 
‘Experience’ and ‘Willingness to prescribe’.  
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Interviewees were aware of their own abilities to be able to provide prescribing 
services and there was clear evidence that pharmacists only tend to prescribe in 
their area of competency where they feel comfortable to initiate prescribing. 
 
“Unless it was fairly simple stuff, I don't tend to get too involved in 
complicated stuff, I would leave that up to the medical staff. I'm not really 
too keen on prescribing for patients that I don’t really know that well and 
maybe at another unit. So, I wouldn’t tend to get terribly involved with 
that” Pharmacist 1 
 
“I am an 8A hospital pharmacist now specialised in chronic kidney disease, 
trying to work with my strengths of optimising anaemia and bone health 
management, and on the ward when I was reviewing patients 
independently” Pharmacist 11 
 
Some interviewees highlighted that they were aware on the need to develop 
some skills to allow them to perform better in relation to prescribing practice, 
especially for patients with CKD. 
 
 “We've got these pharmacological skills so we can develop interactions 
and things, I think, actually that's the benefit. So, having those, that 
clinical knowledge means that our patients who are prescribed tolvaptan 
are kept safe, so something doesn’t interact with it, we, we've picked that 
up” Pharmacist 9 
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“I think of all the options. Whereas, before I used to just think about what 
the option that I wanted and that could give, you can give more weight to 
alternative options, and I think I'm more cautious because it's me, it's 
making a decision, so, I feel the weight of it is more, I feel up-skilled in 
terms of my knowledge base in doing the prescribing qualification so, sort 
of additional learning considerable additional learning that I developed 
myself, so I have greater understanding” Pharmacist 12 
 
c) Individual stage of change 
Two key themes within this construct were ‘Stages of development of NMP’ 
and ‘Need to progress through stages’.  
Interviewees demonstrated that there were discrete stages of development from 
a non-prescriber to a skilled and competent independent prescriber. 
 
“I have started my prescribing as a supplementary prescriber in (a city), 
and then moved through to [a city] where I did the conversion to 
independent prescribing. My experience with working with the renal 
patients I feel confident prescribing for them, and then because I'm 
getting older I am probably more forceful than I used to be and confident 
in what I am prescribing and advising the doctors to do [pause] as well” 
Pharmacist 2 
 
“I became an independent describer in nephrology about 10 years ago, 
and just trained a consultant nephrologist. I then worked for the university 
actually had enough long medical prescribing training programmes, so 
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involved in academia from that point of view. All pharmacists, who work 
on my renal unit trained as nonmedical prescribers” Pharmacist 5 
 
A few interviewees felt that they need to further develop their prescribing roles 
into more clinic settings and to more specialised areas of practice.  
 
“I think definitely will be clinic, I think what [colleagues name] doing 
there, heart failure, I think that will be the future. Umm, I think, you want 
specialist pharmacist doing specialist clinics.” Pharmacist 1 
 
Interviewees highlighted that there was a need to consider a change in the 
profession from product oriented to more patient focused services. 
 
“I feel like pharmacy is a profession that really does need to raise its game 
and you know we are enumerated well as a professional and therefore we 
need to take responsibility of actually doing moving out to the traditional 
habits of traditional pharmacies to supply function and actually doing what 




A comment by one of the respondents highlighted the difference between 




“It is interesting how the kind of younger generations of pharmacists seem 
to be a lot more keen to do it then perhaps the slightly older generation, 
that maybe always have a more traditional pharmacist roles perhaps” 
Pharmacist 11 
 
d) Individual identification with organisation 
A key theme within this construct was ‘Supported by organisation’. 
Interviewees’ demonstrated positive perception towards their organisation and 
their relationship and level of commitment with the organisation or the NHS 
Trust they practice in.  
 
“I think my Trust have been really supportive from the outset really, 
allocated slot on the prescribing courses been oversubscribed with 
applications of every year since it came out really.” Pharmacist 11 
 
“I was fully supported by the department, everybody was very keen for 
me to do it, and yeah, I have not looked back, it's been great.” Pharmacist 
14 
 
e) Other personal attributes  
Key themes within this construct were ‘Consultation and social skills 
essential’, ‘Awareness of strengths and limitations’ and ‘Willingness to 
learn and develop’.  
Some interviewees felt that their experience as a pharmacist had a great impact 
on advancing their practice to become prescribers. 
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“I think experiences important, maturity, knowing when to say NO, 
because when you're younger, sometimes you're doing, you'll be bullied 
into doing things. So, I think you've got to have the social skills as well, as 
well as knowing, when to draw a line under something and saying no this, 
I shouldn't be doing this and know knowing your own attributes and your 
capabilities as well.” Pharmacist 1 
 
“It very much depends on the competencies of the pharmacist, and I'm 
lucky that I've been in my area a long time and feel competent, most of 
the time, and if I don't, then I would always have a discussion with 
medical staff.” Pharmacist 4 
 
Many of the interviewees believed that being confident in what you do is the key 
to success, and being motivated as well as cautious with approaches help deliver 
better patient care services.  
 
“I'm usually quite chatty, quite open person, so done little bit of work 
around consultation skills as well, just to sort of try to, to make sure that 
I'm appropriate when I'm in the clinic setting with patients, have a really 
good rapport with our patients. I'm really confident that we can make a 
positive impact on the patients.” Pharmacist 3 
 
"I definitely started of, I would say quite cautiously, and in a kind of 
supportive, supported situation" Pharmacist 11     
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Some also noted that listening to patients concerns during the consultation and 
being calm and approachable are some important traits of a good prescriber. 
 
“I think my characteristics of sort of being calm and listening to my 
patients and sort of, I want to learn as well, I have got lots of CPD" 
Pharmacist 11 
 
“It's given me more confidence to act as an independent practitioner. As a 
person I'm quite approachable. So, patients ask me more than they would 
necessarily ask a doctor so, they never been informed sort of shouting me 
over when I walk on the ward, and they see me as being more approachable 
then necessarily interrupting the doctor” Pharmacist 12 
 
E) Process 
The implementation process domain of the CFIR is related to the approaches and 
plans that can influence the implementation of an intervention (Keith 2017).  
a) Planning 
Key themes within this construct were ‘NMP implementation planning’, 
‘Advancement planning’, ‘Development of prescribing practice’ and 
‘Stakeholders engagement importance’.  
Although, prescribing practice in the UK was generally developed since 2004, 
however, none of the interviewees were particularly aware of the early planning 
process. However, some interviewees highlighted that there is a Trust wide plan 
to further develop prescribing practice part of which is to increase capacity by 
supporting the qualification and development of more prescribers. 
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“It is within the [a regional Trust], all the pharmacists are pushed to do 
their prescribing qualifications, so there has been a push from the top, for 
the pharmacists to go, and get the prescribing qualification as opposed to 
what other trust locally, whereas, it hasn’t been such a big push and of 
course there’s not many of them [pause] they actually have any of the 
prescribing qualification” Pharmacist 2 
 
“There has been a Trust drive within our department, to get prescribers, 
probably about two years ago, we probably had five to ten prescribers, but 
over the last three years, there has been some different drive where they 
need to kind of boost prescriber numbers, so was all building upon 
numbers” Pharmacist 10 
 
Some interviewees believed that the plan was according to the needs identified 
in each Trust. 
 
“I guess when tolvaptan was released, we identified that actually, it was 
basically quite well designed for the prescriber, because a lot of its around 
monitoring, seen a lot of diagnosing and you're kind of monitoring the 
patient and assessing fluid status and actually we felt we were able to do 
that quite well and the patient has to come back monthly, so again, it's a 
big clinic burden to put like a registrar or consultant in” Pharmacist 3 
 
“It looks at the needs for the department so if we need more like help, you 
know, surgical admissions obviously the surgical pharmacist would take 
priority, and the admissions pharmacist because that's when we have 
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more of the clerking in issues, and then it is funnelled down in case of 
priority and need.” Pharmacist 13 
 
Interviewees suggested that pharmacists should not seek to do their prescribing 
qualification immediately after completion of the undergraduate degree, noting 
that having some hands-on practical experience would be preferable prior to 
starting. 
 
“The moment I think as one pharmacist come out as independent 
prescribers, I don't agree with that. I think they should practice as 
pharmacists for a while, for two, three years, and then go on and become 
prescribers, I need to get a good foundation, as a pharmacist when your 
trade and then you have taken that extra step to becoming an 
independent prescriber.” Pharmacist 1 
 
“I know that there's quite a lot of consideration decision making going into 
that. I mean, I do think it's sensible that you should wait at least for two 
years after qualification, before you start thinking about taking that step, 
but it does seem some certainty to enter formal diploma course, because 
then you've sort of looking at all the different aspects of your potential 
role, and other external influences.” Pharmacist 11 
 
b) Engaging 
i. Opinion leaders 
A key theme within this sub-construct was ‘Support from MDT’.  
 233 
Most of the interviewees reported that consultants and other senior healthcare 
professionals within the multidisciplinary team in the organisation had a positive 
influence and attitude towards the prescribing role of the pharmacist and this 
was important. 
 
“The consultant I worked with was really supportive of me doing the 
prescribing course, and again, as a result of me doing the course actually 
met few nurses through it as well, because they recognise the value that 
we could free up consultant time, and allow them to, again, concentrate 
on the more complicated patients, and I guess that's pretty good situation 
here as well.” Pharmacist 3 
 
“It's about deciding what the consultants are happy for the pharmacist to 
do in terms of them, stepping away from certain things. In terms of 
support, and I guess it's having the consultants that when you go to them 
and say, actually I think the pharmacist could run the tolvaptan clinic and 
the clinical director saying actually Yes, I agree with that” Pharmacist 9 
 
Conversely, some interviewees shared the opposite view that individuals within 
some organisations had a negative influence on pharmacist prescribing role. 
 
“The head of service at the time basically just blocked it, his view of 
pharmacy and pharmacists, do the different role of it should be advising 
about drugs and screening drug charts. I would certainly say that some 
medical staff within the trust has a fixed view for pharmacist prescribing and 
that is certainly, definitely a barrier for me” Pharmacist 10 
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ii. Formally appointed internal implementation leaders 
Two key themes within this sub-construct were ‘Mentors support’ and 
‘Administrative support’. The interviewees reported that there were formally 
appointed leaders mainly in the pharmacy department who were support for the 
implementation of prescribing practice. 
 
“I think we're quite lucky that [name] our clinical lead is very pro, 
encourage us all to becoming independent prescribers and developing that 
aspect over our role and that he's always pushing us to do a lot more of 
doctors roles in particularly and working alongside them and working 
within kind of more embedded role in the MDT team” Pharmacist 8 
 
“I'm sure there's senior management team within my department do 




Key themes within this sub-construct were ‘Doctors engagement and 
enthusiasm’, ‘Nursing support’, ‘Pharmacy staff support’ and ‘Patients 
support’.  
The interviewees emphasised that the success of prescribing service within an 
organisation was because of the support from individuals within the organisation 
who dedicated themselves to overcome any obstacles in the implementation 
process. The main champions recognised were the physicians and consultants 
within the renal units. 
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“It was a renal physician that was my [pause] tutor, and wanted to see 
exactly what I was going through, but he was more than convinced and 
then I presented to the rest of the renal unit, and I was, gradually just 
expanded over the years” Pharmacist 4 
 
“Definitely the consultant nephrologist who work here. So, one of them is 
very proactive towards MDT and separate lots of different roles, helped me 
develop lots of different roles in terms of prescribing. I have another 
nephrologist who had the idea of doing this pharmacist led admission 
clinic. From my point of view, it's mainly been nephrology consultant 
colleagues who have helped me reinforce my prescribing. On a personal 
basis I definitely say my nephrologist who’s a mentor, who I can discuss 
with him the cases, and we do meet regularly discussing this. He has been 
the biggest influence.” Pharmacist 6 
 
Some interviewees recognised the pharmacy management as champions in the 
implementation and support of prescribing services whether it was director of 
pharmacy, head of the service within pharmacy or even other pharmacists within 
the team. 
 
“When we had a new head of service and sort of, they were supportive of 
prescribing” Pharmacist 10 
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“I'm really lucky that I've got another pharmacist in the team who would 
look at my prescriptions with me for me, having a director of pharmacy that 
wants and drives for prescribing agenda is really helpful and finds the 
funding. Having a director pharmacist backs you, backs the department and 
the prescribing it's really, really helpful.” Pharmacist 12, 
 
iv. External change agents 
Two key themes within this sub-construct were ‘Influence from external 
agents’ and ‘Academic institution support’.  
Interviewees expressed their thoughts about any individual who was affiliated 
with another organisation and helped in the advancement of the prescribing 
practice. 
 
“Probably UK renal pharmacy group is the one that, cause obviously, it's 
quite specialised, they put in questions, that could influence your 
prescribing and seeing what other people are doing, and, that's probably, 
the UK Clinical Pharmacy Association doesn't really have a renal group. 
It's, it's more the UK renal pharmacy group itself. So, that that's probably 
the biggest influence on it” Pharmacist 1 
 
“We do have like learning at lunches, where we have external speakers 
that come in and talk about, new drugs etc which again obviously will 
influence prescribing” Pharmacist 13 
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Although interviewees were positive about the external agents who influence 
their prescribing there was some concern about being aware of the influence 
from certain external individuals such as medical representatives. 
 
“When the drug company comes to me that's not gonna influence my 
decision on prescribing, I tend not to see drug reps that often anyway.” 
Pharmacist 1 
 
“We all can be influenced by drug reps and drug companies. So, you just 
need to try and always be aware of that, and always do your own kind of 
individual literature search and to always have a look at the actual 
evidence that they're trying to present.” Pharmacist 8 
 
c) Executing 
 A key theme within this construct was ‘Variation in prescribing models’. The 
majority of the interviewees were engaged in a defined and planned role as a 
prescriber. One of the well-defined roles was prescribing in an inpatient setting 
where the pharmacist spends most of their time providing clinical care for 
patients with CKD. 
 
“I do a daily ward round on the transplant unit, So, I see transplant 
patient prescribing immunosuppression and stopping old dialysis drug and 
antibiotics, protocol really driven immunosuppression, and also surgical 




“In terms of my prescribing activity is quite varied. So, it would be when 
I'm working in my ward role and I attend a daily ward round in the 
morning, optimising medication and starting and stopping of medications, 
and antibiotic review and optimising medicines for new starter on dialysis 
for example and all sort of things like that, and so, that would be 
prescribing as part of an MDT discussion during the ward rounds” Pharmacist 
11 
 
Another model of prescribing described by the interviewees was running specific 
outpatient clinics within the organisation and prescribing for defined groups of 
patients or a defined group of medication. 
 
“I'm working as a prescriber for outpatient tolvaptan clinics, and so in that 
situation, there's myself and my colleague, the other 8A renal pharmacist, 
and we run a pharmacist lead clinic which happens every fortnight.” 
Pharmacist 3 
 
“In terms of my prescribing practice, I would prescribe in outpatients and 
specifically for patients with polycystic kidney disease, and I prescribe 
tolvaptan in that situation, and both initiating tolvaptan to writing the 
initial prescription, and adjusting the dose of tolvaptan” Pharmacist 9 
 
Some interviewees highlighted a combined model of prescribing in an inpatient 
setting and outpatient setting. 
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“I prescribe of all the renal in and outpatient, at clinics like anaemia clinic, 
tolvaptan clinic and prescribe symptomatic relief for the dialysis patients. 
As well as prescribing in the ward rounds and doing discharges” Pharmacist 2 
 
“As a combination of an inpatient Kardex’s, and, you know, that will be 
prescribing missing medicines or adjusting a dose depending on what they 
were on before to come in and at the request that say the doctor, the 
dietitian to add something in. Then also, I prescribe Aranesp for 
outpatients, as an outpatient where I will review the bloods and then 
increase or decrease the dose as needed.” Pharmacist 7 
 
Another model of prescribing described by an interviewee was the homecare 
prescribing model where the pharmacist prescriber can prescribe for homecare 
patients and arrange delivery to the patients without the need for the patient to 
visit the healthcare facility. 
“I'm reviewing homecare for patients so outpatient prescriptions for 
medicines for home delivery, and that would be EPO’s, epoetin, mircera 
predominately or if sometimes I review homecare prescriptions for transplant 
patients” Pharmacist 11 
 
d) Reflecting and evaluating 
Key themes within this construct were ‘Regular monitoring of prescribing 
practice’, ‘Internal / external processes’, ‘Need to develop patient 
feedback systems’ and ‘CPD / reflection and work-based appraisal 
systems in place’.  
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Many of the interviewees were engaged in various types of activities to reflect 
and assess their prescribing practice and to improve the service and enable 
delivery of best patient centred care. Mostly the interviewees relied on peer 
review process to assess prescribing efficiencies or identify any errors. 
 
“Well we do a peer review every so often, I haven’t done one for a couple 
of years, but (a colleague) peer reviewed me, she came through, and I 
showed her three Kardex’s. I did the same for her and we evaluated each 
other.” Pharmacist 1 
 
 “I can only really be peer reviewed, and we have tried setting up peer 
reviewed groups of pharmacists prescribing in the hospital and the 
problem is we are not successful at all getting together for regular 
meetings.” Pharmacist 4 
 
Another group of interviewees reported that they depend on the electronic 
prescribing system within their organisation to generate timely reports and 
identify any issues related to prescribing. 
 
“It’s something we have not really done unfortunately, but it's something 
that we keep thinking of doing, of course we do electronic prescribing, we 
can be monitored via the electronic prescribing and also through the Datix 





“We have an electronic prescribing system, so we can see a log of what we 
have prescribed and what changes we have amended, literally I press the 
button it goes through the IT we can audit our work.” Pharmacist 12 
 
Furthermore, some interviewees used a medication error reporting system as a 
tool to identify any prescribing related errors within a Trust. 
 
“The Datix, it’s the error reporting system in the hospital. So that's what 
they use in [a hospital name], they probably use it in other hospitals as 
well. So basically, they look at the data access every month, so the error 
which are under reported.” Pharmacist 1 
 
“I know they regularly meet and analyse data and record for example how 
long it took to do it or how many errors were, you know, picked up 
whenever the junior doctor did as compared to when the pharmacist do it 
was it often all the data goes on in that regard but that's not something 
I'm directly involved in.” Pharmacist 7 
 
“In terms of safety, we have an incident reporting system so pharmacist 
prescribers are reported to the same way as the medical prescribers are 
reported, and if it is an error, and it's sent back to the drug prescriber and 
reflection takes place.” Pharmacist 12 
 
A group of interviewees also emphasised the importance of the auditing process 
to assess prescribing efficiencies in the Trust and sharing these data within the 
Trust or at other national platforms.  
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“We have all the data and what's been issued, what doses patients are on, 
and some of the quick, easy audits I've done have been kind of easy with 
the raising of our profile so things like I've audited prescribing. I kind of 
highlighted things like 30% of our prescribing was the dose was incorrect 
based on the patient's current renal function. I think that's quite powerful 
to present back to the MDT that actually you know, even within the renal 
team. I haven't published it yet [laughter]. So, I do have, so I do plan to 
put the audits that I have done into sub tasks which is at the end of the 
year.” Pharmacist 8 
 
“I guess maybe it would be more useful to have a more formal method of 
audit and reporting. I must say, I have, have a look at my own prescribing 
myself using the electronic system but it probably would be helpful if we 
had a formal way of making sure that everybody did that, and that we 
shared all the learning formally.” Pharmacist 11 
 
There were a few interviewees who felt that carrying out presentations to 
highlight any issues related to prescribing and presenting it to all stakeholders is 
a beneficial way of reflecting on prescribing practice.  
 
“I've started doing a sort of six-monthly sort of lunch time presentation to 
sort of the junior doctors flagging up some of that sort of prescribing 
errors that potentially I'm rectifying just simply to try and sort of make 
sure that the learnings of experiences are shared” Pharmacist 10 
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The results of these qualitative semi-structured interviews are grounded in 
theory through the use of the CFIR. Clinical pharmacist members of the UKRPG 
who are prescribing for patients with CKD shared their experiences and views on 
the structures and processes for the development and implementation as well as 
evaluation of outcomes of pharmacist prescribing for patients with CKD in the 
UK. In addition, the findings provide data on their views of the key facilitators 
and barriers to further implementation and development of pharmacist 
prescribing for patients with CKD.
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5.4. Discussion 
This section will cover the key findings of the research followed by interpretation 
of these findings in wider context. It will also highlight the main strengths and 
limitations of the research and will end with an overall conclusion. 
5.4.1. Summary of key findings 
The aim of this phase of the doctoral research was to explore from a professional 
perspective, the development, implementation and evaluation of pharmacist 
prescribing for patients with CKD in the UK. The interview schedule was 
underpinned by CFIR as a theoretical basis and 14 interviews were carried out 
with experienced pharmacist prescribers until data saturation was achieved. The 
interviewees were generally very supportive of the development and 
implementation of prescribing practice and this practice was prevalent in a 
variety of settings. In term of the characteristics of the development and 
implementation of prescribing practice many were practising in secondary care 
with only a few working in primary care settings. They used a variety of models 
of prescribing including within different settings and in different specialist 
contexts. These models included independent prescribing in both inpatient and/or 
outpatient settings, prescribing in a clinic setting either for specific conditions 
such as CKD associated anaemia or a specific drug clinic such as epoetin clinics. 
One of the drug specific clinics highlighted frequently by the interviewees was the 
tolvaptan clinic which seemed to be a new clinic managed by some pharmacists 
and planned for implementation by others. The use of CFIR helped identify the 
key facilitators and barriers to implementing and advancing their prescribing 
practice. The interviewees reported a wide range of facilitators in terms of 
support and resources compared to a limited number of barriers that included 
the need for more funding, lack of sufficient number of personnel, no CKD or 
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renal specific training and lack of time to fit in prescribing practice within daily 
clinical duties. Interviewees also highlighted that there was insufficient coverage 
for their prescribing duties when they are away on holiday.  The majority of the 
pharmacists were aware of the plans for the future development of their 
prescribing practice with many planning to establish clinics within their 
competence and the future strategic demands of the organisation.  The 
interviewees stated that they were continuously assessing and evaluating their 
prescribing by various methods and using different parameters to assess their 
prescribing efficiency.     
5.4.2. Interpretation 
This research was underpinned by the CFIR framework throughout the research 
process from setting aim and objectives to completion of the data analysis. All 
the findings were aligned with the research aim, objectives and the CFIR 
domains and constructs. 
From the themes identified in relation to the first objective of the research 
namely ‘describe and characterise the models of pharmacist prescribing practice’ 
it was evident that there is significant variation in activities related to pharmacist 
engagement in prescribing practice. Progress has been made for the 
advancement and development of pharmacist prescribing in the UK with the 
specialist area of caring for patients with CKD from supplementary prescribing to 
completely independent prescribing within their competence. Pharmacist were 
mainly prescribing independently in different care settings. Some pharmacists 
were prescribing in both inpatient and outpatient clinic settings while, others 
were either prescribing for inpatients or only in clinic settings. There was clear 
evidence from the interviewees that prescribing has evolved significantly in terms 
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of models but also the volume of activity since it started in 2004 from a 
supplementary or collaborative model to more independent model (Tonna 2007). 
The interviewees indicated they felt that they met a wide range of competencies 
in relation to prescribing, with resultant versatility in engaging with different 
models of prescribing practice. This helps the development of pharmacists 
working in clinical setting for patients with CKD and makes a difference through 
the sharing of prescribing responsibilities with other healthcare practitioners. 
However, literature showed that one of the key challenges to the implementation 
of pharmacist prescribing is a need for sustainability in these models and it was 
evident that they felt that this still needs to be addressed (Stewart 2017).  
The Royal Pharmaceutical Society published a competency framework for all 
prescribers stating that ‘the patient must be at the centre of care when 
prescribing a medication, to ensure patients are managed safely and effectively’ 
(Royal Pharmaceutical Society 2016). The interviewees emphasised the 
importance of building a rapport with the patients and involving them in the 
decision-making process of prescribing. This exemplifies the construct of ‘patient 
needs and resources’ of the CFIR. The framework also helped highlight the key 
competencies required by the prescribers which were captured in the findings of 
this research phase.  ‘Applying professionalism’ was reported to be an essential 
competency which requires using professional codes of conduct when prescribing 
for patients (Royal Pharmaceutical Society 2016). The interviewees highlighted 
some important steps to ensure professional practice. This included ensuring that 
patient needs and safety are always a key priority, adapting consultations to 
meet patient needs, reflecting on their own practice and learning from it, 
recognising when support is required and making use of it when required and 
lastly knowing their own limitations and extent of competencies.  
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The findings derived in relation to the fourth objective (exploration of the 
facilitators and barriers relating to implementation of pharmacist prescribing) 
identified facilitators and barriers related to implementing pharmacist prescribing 
for patients with CKD with a wide range of facilitators and only a limited number 
of barriers highlighted by the participants. These facilitators and barriers were 
reflected in the five domains of the CFIR:  
A) Intervention characteristics 
Within the ‘intervention characteristics’ domain the interviewees believed that 
prescribing within their competency for their patients led to positive outcomes. It 
is resource efficient since it releases doctors to see more complex patients and 
offer a more holistic approach to care for patients. Despite these facilitators, the 
interviewees also highlighted some barriers such as the complex steps required 
to become a prescriber, no specific courses for CKD or renal related conditions 
and a few believed that their prescribing creates some conflict with other 
healthcare professionals since there is some resistance from a few senior doctors 
to have healthcare professions other than a doctor prescribing. However, work 
by McCann et al. aimed to look at pharmacist prescribing practice in Northern 
Ireland reported that pharmacist prescribing provided more continuity of care for 
patients in a timely manner as well as providing improved patient outcomes 
(McCann 2011).  
B) Outer setting 
Facilitators to develop and implement prescribing practice in relation to the ‘outer 
setting’ domain were reported and included the benefits of; consideration of 
patient needs when planning any continuous professional development, 
collaboration and support from external organisations such as the RPS and the 
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UKRPG and the benefits of alignment of prescribing practice with the national 
policies and guidelines. The only barrier reported by interviewees within the 
‘outer setting’ domain of CFIR was the perception of peer pressure by 
interviewees due to other pharmacists having more advanced practice for 
patients with complex needs such as running independent prescribing clinics for 
specific CKD related conditions or a tailored CKD drug related clinic. A study by 
Bourne et al. has suggested that a national strategy and standards are needed 
for such complex and specialist practice that go beyond the general specifications 
of core standards of prescribing (Bourne 2016). The need for this is evident from 
this research where interviewees were clear that such an approach would enable 
assurance that their prescribing complies with the national policies and standards 
within their area of practice and enable them to more confidently progress to 
advanced practice involving complex patients. 
C) Inner setting 
In this research aspects of the ‘inner setting’ domain was evident from findings 
that show that pharmacist prescribing is a well-recognised role within the 
organisation with a wide range of communication and networking within 
professionals in the healthcare facilities. This included involvement in initiatives 
such as prescribing group meetings, prescribing related bulletins and newsletter 
communication via internal email, promoting a positive culture to support 
pharmacist prescribing and clear messages of support from senior managers and 
clinical leaders. Within the inner setting participants felt there is more need for 
administrative support, a need for more training opportunities specifically related 
to CKD and the need to boost the number of prescribers within an organisation 
by allocating specific funding for prescribing courses and allowing time to take 
the courses. George et al. reported the challenges in the implementation of 
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prescribing practice that included inadequate funding as a huge challenge 
followed by not being recognised by the organisation. This paper, therefore, 
concluded that it is important to identify the need to build an infrastructure to 
support prescribing practice (George 2007). Funding is an ongoing challenge 
when it comes to implementation of innovative services in healthcare systems. 
Pharmacist prescribing, however, is well established and respected and indeed 
actively encouraged by the hierarchy of management within organisations (Cross 
2018). This includes support and funding in some organisations for pharmacists 
to undertake the prescribing course and so develop capacity to delivery higher 
quality patient services through greater availability of prescribers within the 
organisation.   
D) Characteristics of individuals 
The findings related to CFIR domain on ‘characteristics of individuals’ emphasised 
that pharmacists were appropriately skilled to perform prescribing duties and 
that they were aware about their area of competence and knew their limitations. 
They were also confident in their abilities to prescribe for their patients and they 
were aware of the view that they were considered an asset by the organisation 
within which they practise. Two study based in the UK published in 2006 and 
2007, when nonmedical prescribing was at its infancy, showed that pharmacists 
were keen to take the role of supplementary prescribing and believed that a 
more independent prescribing role would be a more appropriate model for 
secondary care setting (Hobson 2006, Tonna 2007). This current work shows 
that there have been significant advances in pharmacist prescribing practice 
across sectors with many different models of prescribing practice and highly 
qualified and confident practitioners with range of clearly defined competencies 
(Royal Pharmaceutical Society 2016).  
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E) Process 
Lastly, the process of development of a model of pharmacist prescribing practice 
as reported by the interviewees always started with completing a GPhC 
accredited prescribing course which is a mandatory requirement to become an 
independent pharmacist prescriber. Thereafter, they recognised the need for 
stakeholder’s engagement in the implementation process, then need for support 
from the multidisciplinary team members and the need for regular monitoring of 
the prescribing service by peer review process, regular multidisciplinary team 
meetings or conducting audits. This appears to be supported by the findings of 
McIntosh and Stewart who reported that participants in their work were in favour 
of pharmacist prescribing but only after gaining some experience as a 
pharmacist. They also reported that engaging with the multidisciplinary team is 
one of the important facilitators to pharmacist prescribing (McIntosh and Stewart 
2016).  
To date there is no other theoretically based study on pharmacist prescribing for 
patients with CKD, therefore it was only possible to compare the findings with 
literature focusing on general nonmedical prescribing or prescribing in other 
areas such as cardiology and mental health. A paper published in 2013 
highlighted some of the challenges faced by a pharmacist prescriber for patients 
with heart failure and included; the fact that they could be practising out of their 
comfort zone, the need to learn more clinical skills, insufficiency of time available 
for practice, complexity of patients and the support needed from other members 
of the healthcare team (Bateman 2013). Jones et al. found that pharmacist 
prescribing was appreciated by patients with mental illness due to the continuity 
of care and scope to build positive relationship with the patients. On the other 
hand, pharmacists also felt they involved the patients in the decision-making 
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process and they believed they have the knowledge and experience to prescribe 
for these patients (Jones 2007). 
The themes generated relevant to the last two objectives (the plans, actions and 
parameters used for evaluating prescribing practice and the plans to develop 
pharmacist-prescribing practice further) indicate that prescribing was evaluated 
by various methods to ensure high standards of prescribing practice. These 
methods included peer review of the prescriptions among pharmacists, feedback 
from other healthcare professionals and patients, learning from errors, regular 
meetings related to prescribing and recognition by the organisation. A study by 
Physick et al. reported that reviewing error reports, clinical audits and patient 
feedback are of great value to achieve reduction in prescribing errors, ensure 
accurate data transfer from one point of care to another and improve patient 
experience and ensure patient safety. The study reported significant reduction in 
prescribing errors between medic prescribing compared to pharmacist prescribing 
from 22% to 0.7% respectively (Physick 2016).  
The future plans to further develop prescribing practice as reported by the 
participants included initiation of independent clinics, digitalisation of prescribing 
service, securing more funds to qualify more pharmacists as prescribers and 
alliance with more advanced prescribing service providers to enable replicating 
exemplar models.  
In 2016 a review was published that aimed to summarise the evidence on the 
impact of electronic prescribing on patient safety in a secondary care setting in 
the UK. It reported that there are future opportunities for digitalisation of the 
healthcare services in the UK including the integration of the services to improve 
access to clinical information and so enhance prescribing and improve efficiency. 
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In addition, the integration of the service interoperability was also highlighted in 
the review and reported to help improve information exchange between 
secondary care and primary care (Ahmed 2016). These advancements are in line 
with the future plans reported by the interviewees in this research. However, it 
depends on the size of the organisation, the number of pharmacist prescribers 
and the allocated budget to implement such services. There were few 
participants already running these advanced services but some articulated a 
desire to plan for further implementation of such services in the future. 
Although, the participants were confident that their prescribing practice had 
positive impacts on the patients and facilitated an increase pharmacists’ 
confidence in their abilities they mostly agreed that there is a lack of published 
evidence on their role as prescribers for patients with CKD. This was evident in 
the recently published systematic review as a part of this doctoral project (Al 
Raiisi 2019). The systematic review included 47 papers on the clinical pharmacy 
services for patients with CKD and identified only one paper from the UK (Al 
Raiisi 2019). Despite the fact that the UKRPG organises annual conference to 
share the advancement in practice in relation to patients with renal diseases, 
where a number of pharmacists’ present research undertaken in their practice, 
there is still lack of published evidence in this area. There could be potential 
reasons for the scarcity of the literature such as busy work environment, lack of 
time and lack of confidence in writing a research paper as reported by the 
participants. One of the solutions to this problem could be the potential 
collaboration between the practitioners and academic researchers to enable 
teamwork and undertake high quality research.      
It is well recognised that underpinning qualitative research with theory results in 
high quality research that provides comprehensive conceptual understanding of a 
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phenomenon (Giacomini 2010).  It is noticeable that none of the literature was 
based on a theoretical framework such as the CFIR which was used in this 
qualitative research. In view of this, there was lack of reporting all aspects of the 
implementation of prescribing practice in these studies. The use of CFIR was of 
great advantage to enable in depth evaluation of implementing pharmacist 
prescribing services for patients with CKD.   
5.4.3. Strengths and limitations 
A) Strengths 
There are several strengths to this qualitative research. Employing a qualitative 
method is of merit in allowing in-depth understanding of the implementation of 
pharmacist prescribing service for patients with CKD and enables the generation 
of rich data related to the topic. The doctoral student received programme of 
training to develop qualitative research skills with a focus on performing 
interviews. 
A1) Trustworthiness 
Trustworthiness is a tool to assess the quality of qualitative research. However, 
there are certain steps that should be followed to ensure the research is 
trustworthy. The doctoral student undertook many steps to warrant 
trustworthiness of this research considering all the elements such as credibility, 
transferability, dependability, confirmability and Reflexivity (Guba 1981, 
Korstjens and Moser 2018). These steps included: 
Credibility was ensured throughout the research process from selection of the 
research design, to development of the interview schedule and through extensive 
literature search. All of this was theoretically underpinned by the CFIR and peer 
reviewed by an expert team of academics and clinical practitioners (TM, LK, AT, 
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MM and CD). A rigorous process of independent checks was employed 
throughout the research process. Analysis was performed by more than one 
researcher (FA, SC, LK and KM) and verbatim quotes were reported to illustrate 
the themes generated to enhance credibility. 
Transferability of research findings is a challenging aspect of research, since it is 
difficult to have a similar way of practice among practitioners. However, it is 
researcher’s responsibility to provide detailed information of interviewees, the 
research process and findings to allow others to consider if the findings of this 
research are transferable to their setting (Elo 2014). The doctoral student 
believed that there were aspects of the findings that may be transferable to other 
care settings with sufficient details provided to ensure transferability was 
possible to consider.  
Dependability can be maintained through transparent description of the research 
method with clear path from the start with aims and objectives that help outline 
the required research steps to the final report of the findings (Korstjens and 
Moser 2018). The doctoral student ensured sufficient details are provided 
throughout the research process to enhance dependability. 
Confirmability is the degree of findings being agreed by other researchers 
(Korstjens and Moser 2018). Confirmability can also be ensured by providing 
detailed information about the whole research process and ensuring 
interpretation of findings that are truly derived from the data and are not 
impacted by researchers own views and beliefs (Korstjens and Moser 2018). The 
doctoral researcher ensured that all details and clearly stated and that analysis 
findings were mapped to CFIR constructs to ensure confirmability of findings. 
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Reflexivity as described in Chapter 2 is the process of self-reflection as a 
researcher in a critical manner to consider the potential impact on the stages of 
the research process of the researchers own believes, biases and perceptions 
about the research topic. It also considers the researcher’s relation with the 
participants and how this relationship can impact the responses of the 
interviewees. The doctoral student considered carefully this topic and reflected 
on her own background as a non-UK registered pharmacist. She also discussed 
this and its potential impact on the research with the supervisory team. 
However, it was felt that a salient issue was that the doctoral student carrying 
out the work was not a prescriber. Given the focus of this stage of the research 
on prescribing practice this means that the lack of prescribing qualification and 
experience would minimise its impact in execution of the research work. Being a 
pharmacist and being a member of the UKRPG allowed the doctoral student to 
build a rapport with the interviewees throughout the research process.  
A2) Theoretical underpinning 
Underpinning a research with a theoretical framework is an important part of any 
research as detailed in Chapter 2 to allow detailed and systematic consideration 
of all aspects including facilitators and barriers to implementing prescribing 
practice and to enable meaningful contextualised analysis of the findings. This 
qualitative research followed theoretical underpinning with CFIR (Damschroder 
2009) throughout the research process from the development of the interview 
schedule to data analysis and interpretation.    
A3) Recruitment of experienced prescribers 
The participants were practising pharmacists in the UK and were registered and 
experienced prescribers mainly in secondary care. Recruitment involved sending 
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an invitation to the pharmacists who had completed the survey phase of this 
research and had agreed to be involved in further phases of the work. Initially 14 
of these pharmacists agreed to be interviewed but in the end it was only possible 
to interview 12 but a further two were identified through snowball sampling 
strategy and subsequently included. Generating data from an experienced cohort 
of pharmacist prescribers for all range of different groups of patients with CKD 
has enabled a significant addition to the evidence base since there was no 
published literature to date about pharmacist prescribing experiences for patients 
with CKD. The participants were committed to provided information and sharing 
their views and this was evident from the length of interviews and richness of the 
data obtained.  
A4) Participants from across the UK 
Participants were recruited from across the UK mainly from England, with smaller 
numbers from Scotland and one from each Wales and Northern Ireland. 
Generalisability is not the intention of qualitative research. However, the fact that 
this work included 14 participants in an area of specialised area of practice with 
quite a small number of practitioners and also since it was geographically well 
distributed it may be that the findings offer a view of the current scope and 
extent of prescribing practice in CKD that does indeed offer a generalised view of 
the current situation.   
A5) Data saturation 
Data saturation was achieved by using the process suggested by Francis with an 
initial number of five to ten interviews to be conducted followed by at least three 
once data saturation is achieved (Francis 2010). Agreement by the pharmacists 
to take part in the survey to be involved in further research and through 
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snowball sampling resulted in interviewing 14 participants and ensured data 
saturation was achieved as suggested by Francis (Francis 2010).  
B) Limitations  
With any research it is recognised that there are always limitations which must 
be acknowledged and mitigated if at all possible. It is acknowledged that this 
research has some limitations and it is therefore necessary to interpret the 
findings in the context of these limitations.  
B1) Number of participants 
The low number of participants is not necessarily a limitation in a qualitative 
research, only 14 participants from 71 who completed the survey agreed to 
participant in the interviews. There is a chance that participants who agreed to 
be interviewed had different views and experiences from those who did not agree 
to be interviewed. However, having participants geographically distributed 
throughout the UK may have added value to overcome the low number of 
participants as well as data saturation was achieved with this number.  
B2) Biases 
The nature of qualitative data makes it potentially challenging to separate the 
researcher completely from the participants or from the data making it difficult to 
maintain objectivity and avoid biases (Galdas 2017). There are two main types of 
biases in qualitative research; participants bias and researcher bias (Pannucci 
and Wilkins 2010), detailed in Chapter 2 of this thesis. The doctoral student was 
aware of these biases and was aware that being a pharmacist might have some 
influence on the research, therefore all attempts were made to bracket the 
researcher from the data (Tufford and Newman 2010) as well as consider 
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reflexivity which was described in Chapter 2. Participants were aware of 
researcher’s background and this might have influenced the interview flow and 
the responses and social desirability bias was considered. To avoid such bias, the 
researcher ensured that the format of the questions allowed the participants to 
feel comfortable in responding with no judgmental comments or responses from 
the researcher and try and maintain neutrality throughout the interview. The 
researcher was not a qualified prescriber and this should help eliminate any 
researcher biases such as confirmation bias and leading question bias. The 
analysis of the data was carried out by two members of the research team 
independently, with any disagreement discussed among the researcher team and 
resolved to avoid analysis and reporting biases (Thirsk and Clark 2017). All data 
were entered in NVivo® to allow data storage and analysis of the data to provide 
rigorous findings.     
5.5. Conclusion  
Overall, the key findings demonstrated positive views on the development and 
implementation of prescribing practice models for patients with CKD among the 
pharmacists interviewed. The majority were prescribing in an inpatient setting 
with some having specialised clinics. The pharmacists were prescribing within 
various prescribing models. Key facilitators reported by the interviewees included 
having different models of prescribing practice, administrative support and 
undertaking the independent prescribing training. The main barriers reported 
were the need for more funding, lack of sufficient number of personnel, no 
specific training in CKD and lack of time. Given the complex nature of patients 
with CKD and the relative risk of medication errors and adverse effects, the 
pharmacists highlighted the importance of their input in a prescribing role but 
also the importance of having specific prescribing training for patients with CKD. 
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The findings for this phase of the doctoral research will inform the current 
practice models adopted by pharmacists across the UK for prescribing in patients 
with CKD. The findings will stimulate discussion at local and national levels 
among pharmacy professional organisations, NHS organisations and individual 
prescribers on the main barriers to implement such services and ways to 
































This final chapter of this doctoral research will consider again the overall research 
aim and the aim of each phase of the research and explore the relationship of 
the key findings from each phase. The chapter will also recap the overall 
interpretation of the findings of each stage, recently published relevant literature 
and the main strengths and limitations associated with each phase of the 
doctoral research. Potential impact, originality and implications of the findings in 
practice are considered along with potential for further research. Finally, overall 
conclusions of the research programme are presented.     
6.1. Overall aim of this doctoral research 
The overall aim of the doctoral programme was to scope structures, processes 
and related outcomes of clinical pharmacy practice in the care of patients with 
CKD. The research was conducted in 2 stages with stage 1 focused on identifying 
the gap in knowledge through a systematic review and stage 2 in 2 phases. The 
first phase of data generation was a quantitative survey whereas, phase 2 
focused on prescribing by interviewing the participants. This doctoral research 
was underpinned with a theoretical framework (CFIR) to enable the collection 
and generation of robust and rigorous data.  
6.2. Specific aims and key findings of each stage 
6.2.1. Stage 1: Systematic review (Al Raiisi 2017, Al Raiisi 2019) 
The aim of the systematic review was to appraise, synthesise and present the 
available evidence for the structures, processes and related outcomes of clinical 




Key findings from the systematic review: 
The systematic review identified 47 studies from a variety of countries, with 31 
based in a hospital setting. Resources available for service provision were poorly 
reported in all papers. Positive impact on clinical outcomes included significant 
improvement in parathyroid hormone, blood pressure, haemoglobin and 
creatinine clearance. most of the included studies focused on processes such as 
the process of reviewing drug charts and identifying drug related problems in 
patients with CKD. Pharmacists’ interventions had an acceptance rate of up to 
95%. Impact on humanistic outcomes was shown through improvement in 
health-related quality of life and patient satisfaction. Economic benefits arose 
from significant cost savings through pharmaceutical care provision. This 
systematic review showed that there is some evidence of positive impact on 
clinical, humanistic and economic outcomes, however, high quality studies are 
still warranted. A detailed interpretation of the review findings was discussed in 
Chapter 3. 
Since the publication of this systematic review several studies have been 
published which meet the inclusion criteria. The key findings of these studies are 
as follows.  
Hawley et al. explored the clinical services provided by pharmacy residents in a 
nephrology clinic to patients with nondialysis kidney disease. The pharmacists 
were able to tackle medication related issues such as polypharmacy, medication 
discrepancies and drug related problems. The study concluded that involvement 
of pharmacist in nephrology clinic resulted in identifying medication related 
problems and recommending changes in therapy which lead to improved care 
process (Hawley 2019). 
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A study by Yamamoto et al. assessed the impact of pharmacists’ participation in 
the CKD network on the rate of a patient’s hospitalisation as a result of 
medication related kidney injury. The contribution of pharmacists was included 
review and where necessary modification of the prescribing and administration of 
drugs that can cause kidney insult in high risk patients. This included reduced 
NSAID prescriptions and encouragement of paracetamol prescribing instead as a 
safer alternative in more than 14000 hospitalised patients. The results of the 
study showed significant reduction in hospitalisation and concluded that 
pharmacist participation was of value to the CKD network (Yamamoto 2019).  
Yang and colleagues assessed the impact of pharmacist-led post kidney 
transplant medication therapy management. Pharmacist participation impact was 
measured by outcomes including cost‐saving effect, immunosuppression 
therapeutic drug monitoring, safety, and blood pressure and plasma glucose 
levels. The study reported reduction in average medication cost, maintained 
tacrolimus levels, and better blood pressure control compared to the pre-
intervention group (Yang 2019).  
Falconer et al aimed to determine the key criteria employed by pharmacists for 
patient prioritisation for potential medication harm during admission. Although 
this study did not focus on patients with CKD, the results from this qualitative 
research reported that the main prioritisation criteria used by pharmacists for 
determining medication harm was renal impairment, list of high-risk medication 
and the drugs that need therapeutic drug monitoring (Falconer 2019). 
A study in Malaysia explored pharmacists’ knowledge, attitude and practice 
towards medication dose adjustment for patients with CKD. A survey was sent to 
more than 1500 pharmacists with a poor response rate of 14.7%. The study 
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results showed that more than 85% of the pharmacists were practising dose 
adjustment based on patients’ renal functions and that younger pharmacists 
working in secondary care had better knowledge of dose adjustments. 
Conversely, the main obstacles reported by the pharmacists who were not 
practising dose adjustment were lack of knowledge of patient’s latest kidney 
function and no access to patient’s medical history. Therefore, the study 
suggested that more training should be provided to pharmacists to improve their 
knowledge as well as to ensure patients have an alert card with the recent 
kidney functions to enable better communication between hospitals and primary 
care (Teh and Lee 2019).  
It is noticed that most of these studies were focused on the process of care with 
only the study by Yang et al. measuring outcomes of pharmacists’ contribution in 
patients care (Yang 2019). Additionally, it should be highlighted that the 
systematic review findings and the findings from these additionally identified 
studies were derived from studies with varying methodological quality and none 
of the studies utilised a mixed-method approach. The key limitations of these 
studies includes a lack of consistency in the reporting of outcomes of the services 
provided and the fact that there is no theoretical underpinning of the research. 
These studies (Hawley 2019, Yamamoto 2019, Yang 2019, Falconer 2019 and 
Teh and Lee 2019) have therefore added little new evidence to the studies 
included in the systematic review. Overall, there remains a need for high quality 
studies with more emphasis on consideration of the structures and processes for 
clinical pharmacy practice and a critical need for consideration of consensus on a 
core outcome set for clinical pharmacy services for patients with CKD. This would 
greatly enhance the quality and usefulness of the available literature. 
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6.2.2. Stage 2, Phase 1: Quantitative survey (Al Raiisi 2020) 
It was evident from the findings of the systematic review and the literature that 
there is still gap in knowledge of detailed exploration of structure, process and 
outcomes of clinical pharmacist caring for patients with CKD. Hence, there is a 
need for a comprehensive primary research in this area. The aim of phase 1 of 
this doctoral research was to determine pharmacists’ behaviours and experiences 
and the barriers and facilitators to the implementation of models of care in 
patients with CKD.  
The specific research questions for this phase included: 
 What are the characteristics of clinical pharmacy practice and how have these 
models been developed, implemented and evaluated? 
 What are the facilitators and barriers related to the implementation of 
pharmacist prescribing practice? 
 What are the key areas for future practice development and what are the 
recommendations for implementing these developments? 
This phase was theoretically underpinned with the CFIR domains and constructs 
throughout the research process as described in details in Chapter 4. Key 
findings from this phase of the research showed that the vast majority of UKRPG 
pharmacists practising in CKD are independent prescribers, providing general 
pharmaceutical care to CKD patients in general and specifically to dialysis and 
kidney transplant patients in secondary care setting. Respondents reported being 
confident in their own abilities and feeling comfortable in trying new ways of 
working. In relation to prescribing most were confident in their abilities to initiate 
prescribing for individual patients within their areas of competence. The 
implementation of clinical and prescribing practice was captured by all the 
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domains and constructs of the CFIR which has provided a framework that has 
enabled the research team to develop a comprehensive understanding of positive 
and negative influences on implementation of clinical and prescribing services, 
including facilitators and barriers, in CKD. Despite the development of pharmacist 
prescribing services among pharmacists caring for patients with CKD there was 
lack of detail on the facilitators and barriers to pharmacist prescribing for 
patients with CKD and details of the models of prescribing practice. It was clear 
that there was a need to evaluate in depth the pharmacist prescribing practice 
specifically for such complex group of patients. Details on interpretations of 
findings of the survey are described in Chapter 4.  
6.2.3. Stage 2, Phase 2: Qualitative interviews 
The preceding phase of this stage reported that a large proportion of clinical 
pharmacists caring for patients with CKD were also prescribers. This phase of the 
research was developed to explore pharmacist prescribing practice for patients 
with CKD.  The aim for stage 2 Phase 2 of this research was to explore the 
development, implementation and evaluation of pharmacist prescribing for 
patients with Chronic Kidney Disease in the UK. 
The specific objectives in relation to pharmacists prescribing in CKD were to: 
 Describe and characterise the models of pharmacist prescribing practice. 
 Explore the facilitators and barriers relating to implementation of pharmacist 
prescribing.  
 Describe the plans, actions and parameters used for evaluating prescribing 
practice.  
 Explore plans to develop pharmacist-prescribing practice further. 
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Data saturation was achieved after completion of 14 interviews with pharmacist 
prescribers’ members of the UKRPG. Key findings of the qualitative semi-
structured interviews with pharmacists prescribing for patients with CKD 
demonstrated that there were variety of prescribing models adopted by 
pharmacists in variety of settings and these models were well appreciated by the 
different stakeholders. Pharmacists demonstrated overall organisational support 
for their prescribing role and the underpinning with CFIR domains highlighted 
main facilitators and barriers to the implementation of prescribing practice which 
was reported comprehensively in Chapter 5.  
6.3. Interpretation of findings 
The systematic review conducted at stage 1 of this doctoral research project and 
the previous systematic review by Salgado et al. (Salgado 2012) provide some 
evidence for the outcomes of pharmacists’ intervention in patients with CKD. 
Again it is worthy to note that there was clear lack of evidence on the structures 
needed to practice and on the core outcomes of care in patients with CKD with 
most of the studies focused on the process of care. Despite the wide practice of 
pharmacist prescribing in some developed countries, none of the included papers 
captured pharmacist prescribing. There has been a recent statement by the GPhC 
and the four UK Chief Pharmaceutical Officers to potentially replace the 
preregistration year post qualification with a foundation programme to allow 
newly qualified pharmacists to become independent prescribers. This could be 
implemented as soon as 2021 and has generated much debate and a diversity of 
opinions among different stakeholders (Burns 2020). Currently, to become an 
independent prescriber those registered with the GPhC as pharmacists must have 
at least two years of relevant clinical practice after completion of the 
preregistration year.  Allowing newly graduated pharmacists to become 
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independent prescribers is a significant change in the current situation. However, 
for prescribing within very specialised areas such as CKD it is likely that this will 
still require advanced level of practice and experience to deal with such complex 
groups of patients. According to the RPS Advanced Pharmacy Framework, 
pharmacist must demonstrate advanced stages of practice in the six clusters of 
expert professional practice, collaborative working relationship, leadership, 
management, education, training and development and research and evaluation 
(Royal Pharmaceutical Society 2013). Experienced pharmacists with mastery 
level of expertise may transfer more advanced skills to newly qualified 
pharmacists and mentor them to enhance their practice in highly specialised 
areas of practice. In addition, the RPS have developed a framework for approval 
of consultant level posts within the NHS and also a system for credentialing 
individual pharmacists at consultant level (Royal Pharmaceutical Society 2020). 
Those credentialed will then be able to apply for the approved consultant posts. 
This is a further progression of advanced practice and prescribing will be an 
integral part of these roles and it is highly likely that the approved posts will be 
in specialist areas such as CKD. 
The quantitative survey in stage 2, phase 1 of this doctoral research with the 
clinical pharmacist members of the UKRPG who were clinically practising in the 
care for patients with CKD demonstrated high standards of clinical and 
prescribing practice in the UK. There is still limited literature on the structure 
required and the outcomes of such practices. However, many studies focus only 
on the process of providing care to patients with CKD. A study by Khokhar et al. 
published in 2020 aimed to assess the effectiveness of pharmacist intervention 
model in non-dialysis CKD patients in terms of improving disease knowledge and 
medication adherence (Khokhar 2020). The study included 120 patients and 
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were assigned equally to intervention and control group, where the intervention 
group will receive an extra care as pharmacist intervention model whereas, the 
control group will only receive the routine management. The study reported that 
pharmacist intervention model was effective in improving patient’s knowledge of 
CKD hence, better adherence to medication. The study lacked details on the 
delivery of the intervention and the duration of the research was insufficient to 
draw firm conclusions (Khokhar 2020). Another recent study focusing on 
economic outcome reported that dose adjustments by clinical pharmacists for 
patients with CKD was cost saving to the health organisation (Sukkha 2020). 
Role of the clinical pharmacist in managing CKD complications such as anaemia 
was appreciated in literature. A Canadian model of pharmacist involvement in the 
management of CKD associated anaemia was evaluated by El Nekidy et al. 
(2020) and the study reported favourable outcomes in terms of dosage 
optimisations, cost saving and achieving therapeutic targets (El Nekidy 2020). 
The primary research of this doctoral project was underpinned with a theoretical 
framework (CFIR) to allow comprehensive evaluation of the clinical and 
prescribing services provided by the pharmacists in the care for patients with 
CKD. However, none of the studies included the systematic review were 
reinforced by the use of any theoretical frameworks. Grounding the primary 
research of this doctoral research with CFIR enabled assessing the facilitators 
and barriers for the implementation of clinical pharmacy services for patients 
with CKD. Facilitators included: support from the healthcare team and 
administration, pharmacists’ experiences and having clear goals to further 
advance the practice. Whereas, the main barriers to implementation of clinical 
pharmacy services for patients with CKD included: lack of evidence, lack of 
funding and being loaded with non-clinical duties. 
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The findings from stage 2, phase 2 interviews identified the variation in the 
models of prescribing practice among pharmacists providing the service for 
patients with CKD. The research findings also highlighted the main facilitators 
and barriers to the implementation of prescribing services as reported in details 
in Chapter 5. Despite the advanced prescribing practice in general and in patients 
with CKD in particular in the UK with different prescribing models, there is lack in 
available published evidence. A paper published in 2019 by Scuderi et al. 
described a model of prescribing practice for patients with CKD which included a 
physician, renal nurse, renal clinical pharmacist and a renal social worker 
(Scuderi 2019). Involvement of the pharmacist was valued by the other team 
members but the role of the pharmacist was only limited to detection and 
prevention of drug-related problems with no prescribing role (Scuderi 2019, 
Mongaret 2020). There is still long way to go in many countries to allow 
pharmacists to become prescribers despite the growing evidence that supports 
and shows the benefits of pharmacist prescribing.  
6.4. Strengths and limitations of this doctoral research 
6.4.1. Coherency of study design 
The research was carried out in a coherent way throughout the doctoral 
programme with stage 1 of literature review followed by a sequential explanatory 
mixed-method design. The systematic review identified the gap in knowledge and 
helped develop the need for primary research in this area. 
In stage 2 of this doctoral research a sequential explanatory mixed-method 
approach was appropriate given the aim of both phases in stage 2 of primary 
research.  
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Stage 1 phase 1 employed a theory driven (CFIR) quantitative survey method 
aiming to determine pharmacists’ behaviours and experiences and the barriers 
and facilitators to the implementation of models of care in patients with CKD. The 
last phase was a qualitative semi-structured interview with a sample from the 
participants of the survey who indicated being prescribers, to enable generate in-
depth knowledge to fulfil the aim of this phase which was to explore the 
development, implementation and evaluation of pharmacist prescribing for 
patients with CKD in the UK. 
The use of theoretical framework (CFIR) was of added value to the whole process 
of research from generated data collection tools to analysing the data and 
interpreting the findings.  
6.4.2. Trustworthiness 
Various steps were taken to improve the quality of the research as detailed in the 
previous chapters of this thesis, enhancing the validity and reliability of the 
quantitative research and trustworthiness of the qualitative research. Credibility 
was enhanced by ensuring the process of choosing the appropriate 
methodological approach, suitable methods were considered and reflexivity 
applied throughout the research process. The research student ensured 
transferability of findings was maintained throughout the research by providing 
background information, detailed description of the research procedures and 
involvement of experts in the study design selection and experts in the field of 
clinical and prescribing practice for patients with CKD. 
6.4.3. Biases 
To ensure high standard research, it is important to be aware of potential biases 
and it is researchers’ responsibility to undertake all possible actions to minimise 
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the biases that might occur throughout the research process and may impact the 
trustworthiness of the research (Barry 1999, Šimundić 2013, Bradbury-Jones, 
Taylor and Herber 2014). Details of all potential biases and the steps taken to 
minimise the risk of bias are discussed in Chapter 2.  
As a researcher, it is also important to be aware of self-background knowledge 
and experience in the area of research. Hence, the doctoral student considered a 
reflexivity approach throughout the research programme which is covered in 
details in Chapter 2. 
6.5. Originality 
6.5.1. Novel research design 
To the knowledge of the research team the design of this doctoral research is 
original and novel since no published studies of structure, process and related 
outcomes of clinical pharmacy practice in the care of patients with CKD have 
reported a similar approach. The findings of each phase informed the design of 
the subsequent phases of this doctoral research. 
The systematic review of stage 1 of this doctoral research was registered with 
Prospero (registration number, Al Raiisi 2017) and the completed review was 
published in 2019 (Al Raiisi 2019) which included a significant amount of 
published evidence that needed scrutiny with only one study from the UK. The 
review identified new evidence related to the global practice of clinical pharmacy 
services for patients with CKD building on the findings of a previous systematic 
review (Salgado 2012).   
The 2 phases of this research in stage 2 which was a mixed-method approach 
are the first to the knowledge of the research team to employ theoretical 
underpinning in this area of research. The stage 2, phase 1 survey was published 
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in 2020 (Al Raiisi 2020). Stage 2, phase 2 of this doctoral research was the 
qualitative part of the mixed-method approach and focused on depth information 
of prescribing models and the development and implementation of pharmacist 
prescribing practice for patients with CKD. The research team are not aware of 
any similar theory based qualitative research published in the area of this 
research ensuring an original contribution to knowledge and evidence base.  The 
qualitative phase is under the process and consideration for publication in a peer-
reviewed journal. 
Overall, the three phases of this doctoral research generated original findings to 
enable extend the evidence base around the structure, process and outcomes of 
clinical pharmacy practice in the care of patients with CKD with in-depth focus on 
elements of prescribing.  
6.5.2. Dissemination of research findings  
One of the important outcomes of a research is to disseminate the original 
findings to a broad range of audience and stakeholders whom are concerned with 
the outcomes of the research. The doctoral research team had a clear plan for 
disseminating the original findings of this research. A list of disseminated work is 
highlighted in the foreword to this doctoral thesis which includes all national and 
international conference abstracts for oral and poster presentations as well as 
publications in peer-reviewed journals. A list of potential future publications is 
also highlighted at the start of this thesis. The findings of the doctoral research 
will also be shared with the main stakeholders the UKRPG members in an effort 





Impact has been defined by many scholars, Reed 2018 defined impact as “a 
direct or indirect, immediate or long-term benefit of a research or prevention of 
harm as a result of a research to the public and it must be demonstrable” (Reed 
2018).  
The UK research and innovative (UKRI) introduced pathways to impact to 
enhance and motivate researchers to think in depth about the impact of the 
research work and how a research can make an impact to different stakeholders 
(Kearnes 2011, UKRI 2018, UKRI 2020). The UKRI defined impact and 
categorised it into two major streams: 
1. Academic impact: Which focuses on the demonstrable contribution that 
excellent research makes to academic advancement across and within disciplines 
in terms of theories, methodologies and application of these theories, Figure 6.1 
(Kearnes 2011). 
2. Economical and societal impacts: The demonstrable contribution that excellent 
research makes to society and the economy. Economic and societal impacts are 
the major domains to achieve value added impact of any research to benefit 
individuals, organisations and communities by: developing global economic 
performance, increasing the efficiency of infrastructure and policies and 
improving quality of life, health and creative outcomes, Figure 6.1 (Kearnes 
2011). 
The pathways to impact with potential academic impacts and economic and 
societal impacts are summarised in Figure 6.1. 
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Figure 6.1: Pathways to impact by UKRI (Kearnes 2011). 
 
The impact of this doctoral research based on the pathways on different 
stakeholders is discussed below. 
1. Impact on the pharmacy profession by identifying the core elements of 
pharmaceutical care and prescribing practice in patients with CKD. The 
findings of this research identified the facilitators and barriers to providing 
pharmacist care and prescribing for patients with CKD and addressing such 
them to potentially overcome the barriers. The findings also highlighted the 
skills required for prescribing in such complex population and the outcomes of 
nonmedical prescribing on the patient care. The research findings also 
provided opportunity for professional development in such a highly specialised 
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clinical area. The findings will also inform the participants and at a broader 
level the practitioners’ member of the UKRPG to improve prescribing practice 
by following some exemplar models highlighted in the findings of stage 2 
phase 2 of this doctoral research. The research findings may also inform the 
educational needs as well as other models of practice to support prescribers 
to prescribe safely and effectively for patients with CKD. 
2. The impact on the researcher as a PhD student: this project helped the 
student to develop her research skills in applying different methodological 
approaches and helped her understand research philosophies in-depth. 
Additionally, it helped the student develop her knowledge and skills on the 
use of theories and building research network. 
3. Impact on the organisation (RGU), recognition as a high standard institution 
and opportunities for training skilled researchers, improving teaching and 
learning throughout the University. Dissemination of the results of the project 
at different phases (phase 1 was presented as poster at the UKRPG annual 
conference) and publishing in peer-reviewed journals will have a positive 
impact on the organisation. 
4. Impact on patients and patient care by improving the quality of care provided 
to patients with CKD through identifying and addressing the gap in current 
practice. Developing further models of practice for pharmacists prescribing in 
CKD will facilitate further develop of the models of care and the contribution 
pharmacists make along with other healthcare professionals to enhance the 
quality and efficiency of patient care.  
6.7. Implications of the findings in practice 
The research showed the practice of clinical pharmacy in the care for patients 
with CKD and the standards at which pharmacists in the UK practise. Pharmacists 
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that participated in stage 2 of this doctoral research demonstrated high levels of 
practice in a very complex and specialised area in the care for patients with CKD. 
Given the nature of this complexity, pharmacists were providing their services in 
a variety of settings including clinics focussing on specific renal conditions or 
providing services in a broader context in inpatient settings. The most 
challenging barrier for advancing practice was lack of resources. Interviewees 
expressed concerns that due to insufficient funding of services there is a lack of 
capacity in terms of other similarly qualified pharmacists for service continuity to 
cover periods of leave or absence. This could lead to interruption of the services 
and a reduction in the quality of patient care and safety. Unfortunately, there 
was no standard way of evaluating the services to demonstrate the importance 
of the role. Pharmacist always reported lack of time to be able to participate in 
conducting academic research which is one of the important ways to research the 
quality of services and provide high quality evidence to the stakeholders. The 
advanced prescribing practice was evident among the clinical pharmacist caring 
for patients with CKD with different models of prescribing in line with the RPS 
Advanced Pharmacy Framework (Royal Pharmaceutical Society 2013). However, 
there was no documented framework for pharmacist prescribing for patients with 
CKD. The UKRPG competency framework was published in 2009 with no focus on 
prescribing. A further work to update the framework with an emphasis on 
prescribing is warranted. Furthermore, there is a potential to develop a 
pharmacist prescribing for patients with CKD framework. As mentioned above, 
recently published guidance on consultant pharmacist practice has outlined the 
requirements and expectations of consultant level pharmacists providing care in 
the NHS organisations demonstrated that this level of practice needs expertise in 
the field of practice at a senior level (NHS 2020). NHS consultant pharmacists 
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posts have been getting approved through a new system run by the RPS since 
January 2020 and the tandem process of credentialing individual pharmacists at 
consultant level will commence in October 2020 (Royal Pharmaceutical Society 
2020). Given the growing importance of pharmacist prescribing in policy and 
practice (Royal Pharmaceutical Society 2016) and the development of consultant 
level pharmacist practice, it is important to consider the need to advance 
prescribing practice to be able to prescribe in complex groups of patients such as 
patients with CKD.  
In stage 2, phase 2 interview, pharmacists demonstrated skills and experience to 
enable them prescribe for patients with CKD nevertheless, they highlighted that 
there is a need for more resources to enable them perform better and on wider 
scale. They also emphasised on the need for specific renal and CKD focused 
prescribing courses.   
6.8. Further research 
The results and findings of this doctoral research will potentially highlight further 
research in the development of pharmacy practice and prescribing practice in the 
UK. The UKRPG developed a competency framework for renal pharmacists in 
2009 with no focus on prescribing practice (Bradley 2009). Proposal 1 will focus 
on the potential to update the framework based on the findings of this doctoral 
research in collaboration with the UKRPG board members. Furthermore, the 
research student was funded from the Omani government to develop research 
skills and support and advance research practice in Oman. Hence, proposal 2 and 
3 will focus on research opportunities in relation to advancement of clinical 
pharmacy services and the potential to develop prescribing services in Oman.  
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6.8.1. Proposal 1: A study to review the UKRPG competency framework 
through a Delphi consensus approach to update the requirements 
for pharmacists providing care to renal patients with a focus on 
prescribing practice. 
Aim:  
To review the UKRPG competency framework through a Delphi consensus 
approach with key stakeholders to update the requirements for pharmacists 
providing care to renal patients with a focus on prescribing. 
Philosophy:  
A positivist approach deemed most suitable for this study, which assumes that 
the phenomena of interest can be observed and measured (Creswell 2018).   
Methodology and methods:  
A quantitative consensus approach will be followed for this study based on the 
findings of this doctoral thesis. All findings of the previous phases will be used to 
collate key statements for this study. A Delphi technique in the form of iterative 
anonymous questionnaire with experts will be employed to reach agreement 
around the statements related to competencies to allow update the competency 
framework and incorporate prescribing practice in the new version of the 
framework.  
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6.8.2. Proposal 2: A study, in Oman, to explore the views and 
experiences of stakeholders on aspects of clinical pharmacy 
services for patients with CKD with the view to develop a 
competency framework. 
Aim:  
To explore the views and experiences of stakeholders on aspects of clinical 
pharmacy services for patients with CKD with the view to develop a competency 
framework for Oman. 
Philosophy:  
The research will follow a phenomenological qualitative approach with an 
exploratory focus (Creswell 2018). 
Methodology and methods: 
The study will be grounded in the CFIR (Damschroder 2009), involving semi-
structured qualitative interviews with key stakeholders including leaders and 
nephrology consultants who have influence and are decision makers in the 
Ministry of Health in Oman. The interview questions will be guided by the CFIR 
and the findings of previous studies in addition to literature. In order to generate 
representing data, participants will be selected purposively from range of expert 
stakeholders at the Ministry of Health in Oman. The targeted key stakeholders 
will include nephrology consultants, pharmacy directors, administrative leaders 
(Hospital and Ministry level), heads of clinical pharmacy services and policy 
makers. Interviews will be conducted face-to-face and will be audio recorded and 
transcribed verbatim. Thematic analysis following Howitt’s steps will be 
employed. 
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6.8.3. Proposal 3: An exploration of views and perceptions of 
stakeholders in Oman on the potential of development of 
pharmacist prescribing services in Oman; a mixed-methods 
approach. 
Aim:  
To explore the perceptions of stakeholders in Oman on the potential of 
development of pharmacist prescribing services in Oman. 
Philosophy:  
This study is suggested to follow a pragmatic approach (Creswell 2018) to enable 
the exploration to examine a phenomenon (pharmacist prescribing) in a wide 
context.  
Methodology and methods: 
The proposed methodology suggested for this research is an explanatory 
sequential mixed-method approach (Creswell 2018). Starting with a quantitative 
survey to explore stakeholder’s perception towards developing pharmacist 
prescribing services in Oman. The survey tool will be developed from an 
extensive literature search of relevant databases and will be checked for face and 
content validity by experienced researchers’ team. The data collection tool will be 
piloted and any modifications will be considered by the research team. The 
sampling frame will be key stakeholders in the ministry of health involved in 
providing care to patients with CKD including nephology consultants and clinical 
pharmacists. The participants will be randomly selected from the sampling frame. 
The study will focus on gathering data on participants demographics, 
stakeholders’ knowledge and views on pharmacist prescribing, their opinion on 
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developing such service in Oman in terms of logistics and legal aspects. The data 
will be considered for descriptive and inferential analysis.  
The results from the survey will guide the development of the second phase, the 
qualitative semi-structured interviews with the stakeholders to further explore in 
details their views and perceptions on the development of pharmacist prescribing 
services in Oman. The participants from the survey would be contacted and 
asked if they would be interested to take part in the face-to-face interviews. 
Once agreed, the participants will be sent an email with all related information 
about the research, provide demographic information, contact details and a 
consent form to be signed and sent back in a reply email. 
Interview schedule will be will be designed underpinned with CFIR and guided by 
the findings of the survey and checked and tested for face and content. Data 
analysis will follow a Framework approach (Ritchie 2014). 
6.9. Conclusion 
Despite the available literature on clinical pharmacy services for patients with 
CKD prior to conducting this doctoral research there was lack of literature for the 
UK. Clinical pharmacy and prescribing practice are well developed in the UK but 
there have been few studies published in relation to the UK practice. Given the 
advancement of clinical pharmacy practice in the UK and the establishment of 
the UKRPG for pharmacists caring for patients with CKD, exploration of clinical 
pharmacy and prescribing practice for patients with CKD was needed. 
This doctoral research presents an original contribution to knowledge and the 
findings were rigorous, robust and underpinned with implementation theory to 
support further development of the services provided by the clinical pharmacists 
for patients with CKD. 
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Over two stages of research, where the first stage was focused on systematic 
literature review to provide evidence on the existing literature related to this 
doctoral research topic. The review reported positive impact of clinical 
pharmacists in the care for patients with CKD but there was lack of high-quality 
research in this area and there is lack of published evidence for the UK practice 
and none of the studies was grounded with implementation theory. The findings 
of the systematic review led to the next stage of this doctoral research. The 
second stage was carried out in two phases with phase one surveying the clinical 
pharmacists’ members of the UKRPG and practising in the care for patients with 
CKD. Findings showed that pharmacists were positive and enthusiastic about 
their experiences in clinical practice with majority being independent prescribers. 
These findings were incorporated into the next phase of this doctoral research of 
qualitative interviews with pharmacists’ prescribers for patients with CKD. 
Findings from the interviews demonstrated that pharmacist prescribing services 
were widely incorporated in their daily work routine. The interviewees were 
competent and focused on their prescribing duties for their patients and their 
prescribing mostly was well supported and appreciated by their organisation and 
the stakeholders. The use of CFIR ensured that all aspects of the prescribing 
service development, implementation and evaluation were captured.     
In view of the overall findings from this doctoral research and the advancement 
in pharmacist prescribing policies (Burns 2020) it is hoped that the findings will 
contribute in the advancement of the clinical pharmacy and prescribing services 
in general and in particular for patients with CKD. So, leading to better patient 
care through transferability of evidence-based models of practice and so 
comprehensive, high quality service provision by the clinical pharmacist members 
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Appendix 4.2: Pilot Launching e-mail 
Pilot Launching email 
Dear UKRPG members 
It gives me pleasure to invite you to participate in the piloting of a survey. This 
survey is part of my PhD and is being done collaboratively between UKRPG and 
Robert Gordon University. 
The aim of this survey is to in determine the behaviours and experiences of 
pharmacist members of the UK Renal Pharmacy Group on provision of 
multidisciplinary care of patients with Chronic Kidney Disease. 
It will take approximately 20 minutes to complete the survey and we will 
appreciate a response before 20th of August 2018.  
By way of thanks, you will be able to opt in to a Prize draw for a £50 Amazon 
voucher at the end of the survey. 
Your response is very important to us in order to further improve the content and 
the layout before launching the actual survey to the members of the UKRPG. 
Please click the link below to access the survey: 
ACCESS SURVEY 
Thank you very much for your support and help. 




























Appendix 4.4: Survey launching e-mail 
Survey launching email 
Dear UKRPG members 
It gives me pleasure to give you advance information of an upcoming online 
survey that will be sent to all member of the UKRPG. This survey is part of my 
PhD and is being done collaboratively between UKRPG and Robert Gordon 
University. 
The aim is to in determine the behaviours and experiences of pharmacist 
members of the UK Renal Pharmacy Group on provision of 
multidisciplinary care of patients with Chronic Kidney Disease. 
Your input will be very valuable to us. It will help us understand what services 
are being provided and how we can plan to improve things further in the future.  
We will be sending out invitation emails with a direct link to the survey in the 
next few weeks. Please look out for it. 
By way of thanks, you will be able to opt in to a Prize draw for a £50 Amazon 
voucher at the end of the survey. 
Please do consider completing the survey once it is launched. 
Thank you very much for your support. 
Fatma Al Raiisi 
Research Team 
Fatma Al Raiisi, Ass. Professor Caroline Ashley, Dr Scott Cunningham, Professor 
Derek Stewart and Professor Moustafa Fahmy. 
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Appendix 4.5: First reminder e-mail 
Gentle reminder 
Dear UKRPG members, it was great seeing some of you at the conference last 
weekend and thanks for everyone who have completed the survey so far. Please 
accept my apologies for receiving this reminder again but unfortunately for the 
sake for data protection we cannot separate the names of those who completed 
from those who did not yet. So please ignore this email if you have completed 
the questionnaire. 
Dear members please do consider completing the questionnaire for mutual 
benefit to the renal services in the UK and globally. It will take approximately 20 
minutes to complete the survey and we will appreciate a response before 31st 
October 2018.  
By way of thanks, you will be able to opt in to a Prize draw for a £50 Amazon 
voucher at the end of the survey. 
We value your response and participation towards the best of renal pharmacy 
services within the UK and globally. 
Please click the link below to access the survey: 
ACCESS SURVEY 
Thank you very much for your support and help.  
Fatma Al Raiisi 
Research Team 
Fatma Al Raiisi, Ass. Professor Caroline Ashley, Dr Scott Cunningham, Professor 
Derek Stewart and Professor Moustafa Fahmy. 
 
338  
Appendix 4.6: Second reminder e-mail 
Gentle second reminder 
Please could I encourage you, if you haven’t already, to complete the on-line 
research questionnaire which is part of an RPG members PhD, looking at 
behaviours and experiences of pharmacist members of the UK Renal Pharmacy 
Group on provision of multidisciplinary care of patients with Chronic Kidney 
Disease.  RPG member input is imperative to this research and which could 
ultimately benefit the renal pharmacy workforce.  Many thanks for your support. 
Andrea Devaney 
RPG Chair 
Dear UKRPG members, Thank you for all who completed the questionnaire so far, 
we received 45 responses corresponding to 32% of the members. This is an 
important study to allow full description and understanding of pharmacist input 
to the care of renal patients. To be able to generate meaningful data we are 
aiming for a response rate of 50% or more. Please if you didn’t already 
completed the questionnaire, do spare 20 minutes for the sake of this important 
research with mutual benefit to all members and the profession. 
Please accept my apologies for receiving this reminder again but unfortunately 
for the sake for data protection we cannot separate the names of those who 
completed from those who did not yet. So please ignore this email if you have 
completed the questionnaire. 
We will appreciate a response before 31st October 2018.  
By way of thanks, you will be able to opt in to SIX Prize draw for a £50 Amazon 
voucher at the end of the survey. 
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We value your response and participation towards the best of renal pharmacy 
services within the UK and globally. 
Please click the link below to access the survey: 
ACCESS SURVEY 
Thank you very much for your support and help.  
Fatma Al Raiisi 
Research Team 
Fatma Al Raiisi 
Ass. Professor Caroline Ashley 
Dr Scott Cunningham 
Professor Derek Stewart 
















Appendix 5.1: Interview recruitment e-mail 
Interview email  
Dear UKRPG member, 
 Thank you very much for responding previously to a survey on the behaviours 
and experiences of pharmacist members of the UK Renal Pharmacy Group on 
provision of multidisciplinary care of patients with Chronic Kidney Disease at the 
end last year. 
 You kindly agreed, at the end of the survey, to consider helping with further 
research to allow us to explore some aspects in more detail.  That is why I am 
contacting you again now. 
The final part of this doctoral research will be interviews focused on prescribing 
practice care of patients with Chronic Kidney Disease. 
I would like to carry out and interview with you – over the phone – towards the 
end of June /start of July 2019. 
Please find below a link to a mini survey (It will take only 1 minute to complete 
it). This is simply complete some demographic and contact information of the 
participants to enable us to prepare for the interviews. 
Mini survey link 
Thank you, 





Appendix 5.2: Information leaflet 
A qualitative service evaluation of pharmacist prescribing for patients with 
Chronic Kidney Disease in the UK 
Research Team 
Robert Gordon University Dr Scott Cunningham, Professor Derek Stewart, Mrs Fatma 
Al Raiisi | UK Renal Pharmacy Group Ass. Professor Caroline Ashley| Oman 
Pharmacy College Professor Moustafa Fahmy Mohamed 
You are invited to take part in a research study being conducted by Robert Gordon 
University. We want to explore the service evaluation of pharmacist prescribing for 
patients with Chronic Kidney Disease in the UK. Please take the time to read the 
following information carefully. It is important that you understand why the research is 
being done and what it will involve. Please ask if there is anything that is not clear or if 
you would like more information. Take your time to decide whether or not you wish to 
take part. 
What is the purpose of the study? 
We are interested to explore the development, implementation and evaluation of 
pharmacist prescribing for patients with Chronic Kidney Disease (CKD) in the UK. 
Why have I been chosen? 
This invitation has been sent to all pharmacists members of the UK Renal Pharmacy 
Group who opted in for further research in the previous phase of this doctoral research. 
Do I have to take part? 
No. Participation in this study is voluntary; you may withdraw at any. To withdraw from 
the study, please contact the researchers via the contact details below. All data, audio 
recording and consent forms will be destroyed if you decide you no longer wish to be a 
part of the study. Your relationship with the research team will not be affected by your 
decision to take part or if you withdraw. 
What will happen to me if I take part? 
We will ask for your name, e-mail address and phone number and brief demographic 
details so that we may contact you about your participation. We will then send you an 
invitation for the interview and will ask for suitable date, time and place for the interview 
to be carried out (the interview will take no longer than 45 minutes). Please note, that if 
you agree, steps will be undertaken to ensure that your confidentiality is protected. 
What are the possible benefits of taking part? 
There is no direct benefit to you from participating in this study. However, it is possible 
that findings will help to clarify aspects of developments and implementation of 
pharmacist prescribing for patients with CKD. 
Will my contribution to this study be kept confidential? 
All information which is collected about you during the course of the study will be kept 




What will happen to the results of the research study? 
A short report of the findings will be made available. The full findings of the study will 
form part of a PhD and may be published in a health care journal and presented at a 
conference. 
Who is organising and funding the research? 
This project is organised by a Robert Gordon University led research team. 
Who has reviewed the study? 
The study has been reviewed and approved by the School of Pharmacy and Life Sciences 
Ethics Review Panel. 
What next? 
Please keep this information sheet for future reference. If you decide you would like to 
participate in the study, we will contact you on the telephone number you have provided 
to arrange an interview date and time. We are hoping to conduct the interviews in the 
coming months and will be in contact in the next few weeks. 
What if something goes wrong? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions. If you remain unhappy and 
wish to complain formally, you can do this by contacting Dr Scott Cunningham from 
School of Pharmacy and Life Sciences at RGU, by telephone (01224 262533) or via email 
(s.cunningham@rgu.ac.uk). 
On behalf of the research team, thank you for your time and consideration in 
reading this information sheet. If you have further questions about this study 
please contact either: 
 
 
Dr Scott Cunningham 
School of Pharmacy and Life Sciences 
Sir Ian Wood Building 





















Appendix 5.4: Interview consent/copyright forms 
Interview consent form 
Title of the project: A qualitative service evaluation of pharmacist prescribing for 
patients with Chronic Kidney Disease in the UK. 
Name of the principal investigator: Fatma Al Raiisi, school of Pharmacy & Life 
Sciences, The 
Robert Gordon University, Aberdeen 
Statements of agreement Tick the 
box 
1.  I confirm that I have read and understand the information sheet 
dated  
 /    /2019 for the above study. 
 
2.  I understand that my participation includes an interview session 
lasting 45 minutes. 
 
3.  I agree that the interview will be audio recorded and transcribed 
into a paper document. 
 
4.  I understand that my name will not be included anywhere in the 
report of the findings. 
 
5. I understand that my participation in this study is entirely 
voluntary and I am free to withdraw at any time without giving a 
reason. 
 
6.  I agree to take part in the above study.   
 
Name of participant                       Date                                          Signature 
 
___________________       ___________________                   ____________ 
 
Name of Person taking consent       Date                                          Signature 
(if different from researcher) 
 
_____________________     ______________                          ____________ 
 
Researcher                                    Date                                            Signature 
 





Interview copyright clearance form 
Research Project: A qualitative service evaluation of pharmacist prescribing for 
patients with Chronic Kidney Disease in the UK. 
Date:  /  /2019 
Location: 
The purpose of this agreement is to ensure that your contribution is used 
according to best 
practice and in strict accordance with your wishes. All material will be preserved 
for the life 
of the research project and may be used in publication, education, lectures, 
broadcasting 
and on the internet. 
All contributions will be anonymised and all identifying materials will be stored 
separately 
to preserve anonymity and confidentiality. 
I hereby assign the copyright in my contribution to The Robert Gordon University 
School of 













Appendix 5.5: Semi-structured interview schedule 
 
Dr Scott Cunningham  Prof Derek Stewart 





Prof Moustafa Fahmy 
 
A qualitative service evaluation of pharmacist 
prescribing for patients with Chronic Kidney Disease in 
the UK 




SEMI-STRUCTURED INTERVIEW SCHEDULE for UK Renal Pharmacy Group members  
 
 
***SWITCH ON THE AUDIO RECORDER*** 
Put the phone on ‘Speaker phone’ (loud speaker  button at 
bottom right on the CISCO RGU phones).  
Check volume is sufficient for recording. 
 
Phone the pharmacist: dial ‘9’ for outside line and then the 
pharmacists phone number.  
 







Hello, can I speak to [pharmacist name], please? 
 
IF NO:  OK, I had arranged to call at this time.  Should I call again 
in ten minutes or email them to re-schedule? 
 
Write the outcome in your diary chart and take the appropriate 
action (call back, email) 
 
Hello, [pharmacist name].  I’m [Fatma Alraisi], the doctoral research student from Robert Gordon University ringing / visiting to interview 
you about your prescribing practice for patients with Chronic Kidney Disease.  
Please, can I check you have read the participant information sheet. 
The main purpose of this interview is to explore the development, implementation and evaluation of pharmacist prescribing for patients 
with Chronic Kidney Disease (CKD) in the UK. 
Your participation is voluntary and you may withdraw at any point. 
If you do not want to answer a specific question, then please let me know. 
There are no right or wrong answers and I am interested in your personal opinion. 
The identities of all participants will remain strictly confidential and it will not be possible to identify individuals from the study results.  
Are you okay to do the interview now?  It will take around 30-40 minutes. 
 
 
IF NO: That’s okay.  When would you like me to call back?   
(offer to email if pharmacist is not sure) 




Write the new day/date/time here and in diary chart: 
 
IF YES continue:  That’s great, thank you. 
 
B. Housekeeping 
As you are aware from the information sheet and consent form, this conversation is being audio recorded to make sure that I don’t miss 
important points by relying on my memory or notes but I would emphasise that it is confidential.  Are you still OK with that?   
 
 
IF NO:  
That’s fine.  I won’t use the audio recorder but I’ll need a bit more 
time to write down notes as we go through the sections and I may 
ask you to repeat some answers. 
 
Reminders: 
 Make sure the audio recording is activated 
 Take time to write detailed notes 
 If in doubt, ask the pharmacist for clarification before you move on 





If you decide after the interview you no longer wish to be a part of the research, please let us know within the next seven days.  The contact 
details are on the information sheet. *** IF YES, CHECK THAT AUDIO RECORDING IS ACTIVATED***  Technical problem? Keep 






To explore the development, implementation and evaluation of pharmacist prescribing for patients with Chronic Kidney Disease 
(CKD) in the UK 
 
Objectives 
The specific objectives in relation to pharmacists prescribing in CKD: 
1. To describe and characterise the models of pharmacist prescribing practice. 
2. To explore the facilitators and barriers relating to implementation of pharmacist prescribing.  
3. To describe the plans, actions and parameters used for evaluating prescribing practice.  
4. To explore plans to develop pharmacist-prescribing practice further. 
 
SECTION 1. Your current prescribing practice 
 
1. Could you please describe your current involvement in prescribing for your patients?  
 
 Can you elaborate more on aspects of that – it may be useful for you to describe a typical week… 
o Resources / Facilities / Funding; who else is involved, where this takes place, length of consultations, pharmacist 
consultations or team consultations, number of days per week. 
o Processes: sources of information, regular follow-up of patients, documentation, communication channels  
 What is your area / areas of prescribing practice; e.g. haemodialysis, transplant 
 Which settings – inpatient / outpatient? 
 Supplementary / independent prescribing? 




2. We are interested to know more about the background and development of your practice as a prescriber -where 
have you worked/trained, who has influenced you along the way: 
 
• After you qualified as a prescriber - Can you outline the steps in your development to your current level of practice – Initially: 
which areas, how much time, and any supervision / ongoing: how did things develop /change over time?  
• How do you feel prescribing fits within other aspects of your clinical practice in CKD? e.g. meds rec / review, patient 
counselling, education / training of others. 
• What help did you get – if any – to develop your prescribing practice? From whom: e.g. line manager, colleagues, nurses, 
doctors. Nature of help: extra staff, mentorship, shadowing / observation of others, suggestions for reading, support at 
meetings etc ) 
 
SECTION 2. CFIR Constructs  
 
CFIR: intervention characteristics 
 
3. We are interested to understand what you feel are the key things/factors that have influenced 
implementation of prescribing practice, generally and in relation to your own practice. 
 
 In our survey – that you completed - 56% of the pharmacists who responded felt there is need for more evidence for the 
benefits of pharmacist prescribing for patients with CKD, how does this relate to you? What do you think of this response? 
How do you feel you have used evidence to develop your practice? 
 How do you feel that your prescribing has changed your practice? What about the impact on patients? 
Do you feel that your prescribing practice has changed or developed since you started? If so – why, in what way, and how 
easy was this? 
 What are your views on the complexity of your prescribing practice: consider clinical (complex patients) and non-clinical 
(complexity in logistics) 
 What about the costs and savings associated with providing a prescribing practice for patients with CKD – do you feel the 
health service get ‘value for money’? 
 





4. Prescribing practice is based on the actions and behaviours of individuals within a multidisciplinary team. 
How do you feel your personal characteristics have helped develop and implement prescribing practice for 
CKD.  
 
 Outline how you feel you complement other in the multidisciplinary team in relation to your prescribing in CKD; what 
knowledge, beliefs and skills do you have 
 
 How confident are you that your clinical knowledge and prescribing skills can make a difference. Why is this? 
 
 Are you considering developing or changing any aspects of your prescribing practice?  Why is this? How supportive do you 
feel your workplace is to your prescribing practice? 
 
 Can you tell me about any other traits or personal characteristics you have that suit you to prescribing practice? Things like 




5. We are interested in the actual steps taken in the development and implementation of pharmacist prescribing 
for CKD in your organisation generally and your own practice.  
 
 How was pharmacist prescribing planned for and implemented within your organisation? 
 How were you and colleagues involved with this? What about multidisciplinary team members? 
 Were there any particular ‘project champions’ allocated at all? If so, who were they? 
 Was there any external influence on this? 
 How do you assess or evaluate your prescribing practice in term of safety, effectiveness, cost effectiveness? 
 Prompt; peer review, analysis of prescribing data, audits …. any formal, informal, how select, any research etc 





6. What about external influences on the development and implementation of pharmacist prescribing in your 
organisation generally and in your own prescribing practice? 
 
 More than half the respondents felt that colleagues in other organisations are ahead in implementing pharmacist 
prescribing in their practice, what do you think about that? Why do you think it is right? What do you think they do better 
then you? 
 
 Does any external body or organisation influence your prescribing practise? How this supports the advancement of your 
practice – if at all? e.g RPS, UKRPG, BRA, NES, CPPE, NPC, GPhC etc 
 
 Can you tell me about any other external factors affecting your prescribing practice?  
 
CFIR: inner setting 
 
7. We are keen to explore the barriers or facilitators, within your organisation, that have helped or hindered the 
development of prescribing practice generally and in your own practice. 
 
 What factors within your organisation do you feel have helped or hindered developments?  
o MDT team make-up, expertise, experience 
o maturity of nonmedical prescribing practice in organisation  
o identified need / strong drivers for change 
o Lack of ‘fit’ of your prescribing practice with others e.g. junior doctors? 
o Pharmacy and other management support 
 
 Thinking about communication within your organisation around the development of prescribing practice, do you think 
that; had any impact. e.g. bulletins, email circulars, meetings, informal networks.  
 Do you receive any support for your prescribing role? 
o Prompt: colleagues, peers, administration 
 What more could your organisation / employer do to help enhance your practice? 
 
 How do you feel the ‘culture’ helps or hinders development of prescribing practice - within the organisation? 
 




 One of the main issues raised in the questionnaire study phase of this work was what happens to cover prescribing practice 
when a colleague is absent / away.  Can you outline what happens in your organisation? 
 
General final questions 
 
8. What do you feel works very well and what needs to improve regarding your prescribing practice? 
 
9. What advice you would give to others who are considering setting up a prescribing service? Are there any pitfalls you 
should avoid? 
 
10. How you see your prescribing practice developing in future? 
   




Appendix 5.6: School of Pharmacy and Life Sciences ethics approval for 
the interviews 
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